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ABSTRACT
The effect of the exposure of male BALB/c mice to sensory stimuli from male 
Brown Norway rats was assessed using plasma corticosterone (CORT) concentrations and 
glucocorticoid receptor (GR) binding in the cortex, and a number of behavioural measures 
(sucrose preference, food intake and elevated plus-maze tests). Following 8 weeks of 
exposure, stressed mice showed a 97% increase in plasma CORT concentrations but GR 
binding, sucrose preference, food intake, and the elevated plus maze (EPM) measurements 
were unaltered. In conclusion, this study suggests that chronic exposure of mice to sensory 
stimuli from rats increases stress hormones and may provide a natural predator model of 
stress.
The effects of acute and chronic restraint stress with the administration of 
paroxetine (10 mg/kg p.o.), a selective serotonin reuptake inhibitor (SSRI), on the 
hypothalamic-pituitary-adrenocortical (HPA) axis were studied in adult male Wistar rats. 
Three weeks of restraint stress induced a 700% increase in plasma CORT and a 100% 
increase in adrenocorticotrophin (ACTH) concentration, whilst decreasing GR binding in 
the cortex by 34% and hippocampus by 30%, and a 24% decrease in food intake. 
Administration of paroxetine induced a 166% increase in plasma CORT concentration, 
whilst decreasing GR mRNA levels by 45% in the cortex and food intake by 25%. 
Paroxetine administration decreased the stress-induced plasma CORT by 80% but 
enhanced ACTH concentration by 78%, partially reversing the stress-induced 
downregulation of GR in the cortex by 34%, increasing GR mRNA in the cortex by 58%, 
reducing BDNF mRNA in the cortex by 30%, and reversed the stress-induced decrease in 
food intake by 22%. Taken together, these results suggest that restraint stress provoked a 
stress response, which remained elevated after three weeks, and feedback inhibition on the 
HPA axis following stress was facilitated by treatment with paroxetine.
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CHAPTER 1. INTRODUCTION
1.1. Depression
LLLCharacteristics and origins
The aetiology of depressive illness is complex and variable. The origin of 
depression may include social, developmental, and genetic factors as well as aberrations in 
brain biochemistry and possibly in anatomy. A genetic vulnerability has been identified as 
a predisposing factor in some cases of bipolar depression -  with a 43% concordance 
among monozygotic twins (Wells & Hayes, 1989; Weissman et al, 1984). However, it is 
most likely to be an interaction of social stressors, genetics, and possibly age that causes a 
depressive episode at a given point.
In the United States, the DSM-IV (1994) represents the most widely used system 
of psychiatric diagnosis for research purposes. The manual’s criteria reflect the view that 
major depression is a syndromal illness with both psychological and biological 
components - depressed mood, withdrawal of interest, feelings of worthlessness, changes 
in patterns of eating and sleeping.
1. Types
Major affective disorders can be subdivided into unipolar and bipolar illness, 
whereby the bipolar type is manifested by mania or by both mania and depression, and 
unipolar illnesses are manifested only by depression. An exception to this is melancholic 
depression, a highly consistent association of symptoms that includes hyposomnia, 
anorexia, and diurnal variation in mood (DSM-IV, 1994), of which the hallmark is an 
intensely painful arousal and an obsessional preoccupation with personal inadequacy and 
the inevitability of loss. This syndrome therefore crosses the boundaries of unipolar and 
bipolar illness.
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i) Unipolar disorder {major depression). A  positive diagnosis is made if an 
individual has five or more of the symptoms of depression during the same two-Aveek 
period - persistent sad, anxious, or "empty" mood; feelings of hopelessness, pessimism; 
feelings of guilt, worthlessness, helplessness; loss of interest or pleasure in hobbies and 
activities that were once enjoyed, including sex; decreased energy, fatigue, being "slowed 
down"; difficulty concentrating, remembering, making decisions; insomnia, early-morning 
awakening, or oversleeping; appetite and/or weight loss or overeating and weight gain; 
thoughts of death or suicide; suicide attempts; restlessness, irritability; persistent physical 
symptoms that do not respond to treatment, such as headaches, digestive disorders, and 
chronic pain. Unipolar major depression typically presents in discrete episodes that recur 
during a person’s lifetime.
ii) Bipolar disorder {manic-depressive illness) is characterized by cycling mood 
changes: severe highs (mania) and lows (depression). Sometimes the mood switches are 
dramatic and rapid, but most olften they are gradual. There is abnormally and persistently 
elevated mood or irritability accompanied by at least three of the following symptoms: 
overly-inflated self-esteem; decreased need for sleep; increased talkativeness; racing 
thoughts; distractibility; increased goal-directed activity or physical agitation; and 
excessive involvement in pleasurable activities with potential for negative consequences.
2. Factors
Evidence firom neuroscience, genetics, and clinical investigations demonstrate that 
depression is a disorder of the brain. Modem brain imaging technologies are revealing that 
in depression, regulatory neural circuits responsible for mood, thinking, sleep, appetite, and 
behaviour fail to function properly, and that critical neurotransmitters are out of balance. 
Genetic research indicates that vulnerability to depression results fi*om the influence of 
multiple genes acting in combination with environmental factors.
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There is much knowledge still to be gained about the aetiology of depression, more 
specifically, the various pathways to depression. There is evidence that a number of amine 
transmitter systems are involved in the development of some depressions. Biochemical and 
neurohormonal data indicate that several neurotransmitter systems may be acting either 
alone or in combination to produce depressive symptoms.
LL2. Treatments
One of the principal treatments of depression is the use of antidepressants. 
Numerous randomised clinical trials have demonstrated the efficacy of somatic 
antidepressant therapy for major depressive disorder (Cohn et al, 1990; Bech et al, 2000).
Research has shown that certain types of psychotherapy, particularly cognitive 
behavioural therapy (CBT) and interpersonal therapy (IPT), can help relieve depression. 
CBT helps patients change the negative styles of thinking and behaving often associated 
with depression. IPT focuses on working through disturbed personal relationships that may 
contribute to depression.
Research on children and adolescents with depression supports CBT as a useful 
initial treatment, but antidepressant medication is indicated for those with severe, recurrent, 
or psychotic symptoms in depression. Studies of adults have shown that while 
psychotherapy alone is rarely sufficient to treat moderate to severe depression, it may 
provide additional relief in combination with antidepressant medication 
(Kombluh et al, 2001; Brown, 2001). For mild depression, however, a recent analysis of 
multiple studies indicated that combination treatment is not significantly more effective 
than CBT or IPT alone.
Electroconvulsive therapy (ECT) remains one of the most effective yet most 
stigmatised treatments for depression. Eighty to ninety percent of people with severe 
depression improve dramatically with ECT, which involves producing a seizure under 
general anaesthesia by applying electrical stimulation to the brain through electrodes
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placed on the scalp. Repeated treatments are necessary to achieve the most complete 
antidepressant response. Memory loss and other cognitive problems are common, yet 
typically short-lived side effects of ECT. Although some people report lasting difficulties, 
modem advances in ECT technique have greatly reduced the side effects of this treatment 
compared to earlier decades. Research on ECT has found that the dose of electricity 
apphed and the placement of electrodes (unilateral or bilateral) can influence the degree of 
clinical improvement and severity of side effects (Flint & Gagnon, 2002; Kombluh et al, 
2001).
Recently there has been an enormous growth in public interest in herbal remedies 
for various medical conditions including depression. For example, St. John's wort 
{Hypericum perforatum L.) is a widely used remedy for the treatment of mild to moderate 
depressions (for a review see Schultz, 2002). However, the nature of its active principles 
and the exact mode of antidepressant action are stiU unknown. It has been suggested 
repeatedly in preclinical and clinical studies that the content of the acylphloroglucinol 
hyperforin decisively contributes to the antidepressant efficacy of St. John's wort extracts 
(MüËer et al, 2001; Buchholzer et al, 2002). Experimental studies in vivo also indicate that 
the naphthodianthrone hypericin may reduce the activity of the HPA axis (Butterweck et 
al, 2002).
Neurochemistry
Many of the biological theories of depression, have been closely associated with 
the chemical effects of clinically effective first generation antidepressant dmgs; - 
monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs), discovered 
in the late 1950s. The biological theories of depression centred largely on the ability of 
MAOIs and TCAs to alter the release or uptake of monoamines into nerve terminals. The 
monoamine neurotransmitters include the catecholamines - noradrenaline 
(Schildkraut, 1965; Bedawy & Evans, 1981) and dopamine (Willner, 1983), and the
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indolamine serotonin, or 5-HT (Glassman, 1969; Curzon, 1988). TCAs inhibit the reuptake 
of amines released from the nerve, and MAOIs act via inhibition of monoamine 
degradation, and therefore potentiate the effect of these neurotransmitters. The discovery 
of the antidepressant activity of imipramine and of the MAOI iproniazid (Crane, 1957) 
intensely stimulated biochemical-pharmacological research on the pathophysiology of 
depressive illnesses and the mechanism of action of the antidepressants.
Other theories suggest that an interaction of amine systems may cause depression 
or that amine-specific subtypes of depression may exist. Mendels et al (1975) proposed 
that affective disorders might result from a complex interaction between cholinergic and 
adrenergic neurotransmitter activity. Depression appears to occur when cholinergic activity 
is elevated in comparison to adrenergic activity.
Lesioning the serotonergic system with a serotonin neurotoxin results in the failure 
of TCAs to down-regulate p-adrenergic receptors or to decrease the sensitivity of the p- 
adrenergic coupled adenylate cyclase (Janowsky et al, 1982). Therefore, the discovery of 
the down-regulation of certain monoamine receptors by antidepressants prompted a 
different hypothesis, the neurotransmitter receptor hypothesis (Chamey et al, 1981; Stahl, 
1984). It postulated monoaminergic hyperfimction mediates the clinical effects of 
depression and held that antidepressants work by down-regulating postsynaptic 
monoamine receptors, especially adrenergic and/or serotonergic receptors. In parallel with 
the molecular changes in p-adrenergic receptors, following prolonged administration of 
antidepressant drugs to rats, 5HT-2 receptors are also down-regulated 
(Peroutka & Snyder, 1980). Evidence from neuroendocrine research suggests that some 
antidepressants may exert effects on 5-HT pathways through intimate connections with 
noradrenaline pathways (Chamey et al, 1984). Others have proposed that acetylcholine 
pathways may have complex connections with other transmitter systems and the sum of 
events leads to depression.
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According to Stahl and Palazidou (1986) a number of problems exist with these 
hypotheses, which relate antidepressants or depressive illness to neurotransmitter 
receptors. Firstly, they are predominantly based on biochemical observations in normal rat 
brain. Secondly, numerous difficulties arise because there are limitations with the 
techniques available for assessing central nervous system (CNS) receptors in humans. 
Thirdly, psychopharmacologists must not assume that "correlations" infer "causation", 
since receptor changes observed after antidepressant drug treatment could be well-timed 
epiphenomena rather than the causative molecular mechanism of antidepressant action.
LL4. Clinical Studies
Studies of the amine hypotheses have been conducted using a variety of different 
experimental approaches. For example, (i) Changes in biogenic amine neurotransmitters in 
post-mortem brains from suicide victims and depressive patients who died from natural 
causes (Lloyd et al, 1974; Coppen & Doogan, 1988); (ii) Changes in cerebrospinal fluid 
(CSF) and urine concentrations of monoamine metabolites from patients suffering from 
depression (reviewed by Kapur & Mann, 1992); (iii) Changes in neurotransmitter receptor 
ftinction and density on platelets and lymphocytes from patients before and following 
effective treatment (Sneddon, 1973; Paul et al, 1982); (iv) The dexamethasone suppression 
test (DST) is used to determine the sensitivity of the HPA axis to negative feedback. HPA 
activity is abnormally high in some melancholic patients: cortisol concentrations are 
elevated in plasma (Carroll, 1978) and CSF (Carroll et al, 1976; Traskman et al, 1980). 
The cause of this abnormality is a failure of the brain to inhibit the release of ACTH 
(Carroll & Mendels, 1976). Dexamethasone is a synthetic corticosteroid, which suppresses 
ACTH release.
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LL5. Animal models and Behavioural Tests
A model is defined as any experimental preparation developed for the purpose of 
studying a condition in the same or different species. Typically, models are animal 
preparations that attempt to mimic a human condition. In developing and assessing an 
animal model, it is critical to consider the explicit purpose intended for the model, because 
the intended purpose determines the criteria that the model must satisfy to establish its 
validity.
Responsiveness to antidepressant drugs is usually taken to be a basic requirement 
for an animal model of depression. Yet some depressed patients fail to respond to 
antidepressants, and in addition to their antidepressant effects, TCAs appear to be highly 
effective anxiolytics (Deakin & Lader, 1991) and after chronic treatment appear to be 
effective in at least one animal model of anxiety (Bodnoff et al, 1988).
It is widely believed that because the pharmacotherapy of depression requires 
continuous drug treatment, for a period of weeks, the validity of an animal model is called 
into question by an acute antidepressant response only. Therefore the real test for a 
simulation of depression is that tolerance must not develop to the antidepressant response: 
irrespective of how it responds to acute antidepressant treatment, the model must respond 
to chronic treatment.
The major group of models of depression are based on responses to stressors of 
various kinds. The theoretical rationale underlying these models is usually derived from 
the well-established finding that the risk of depression is increased substantially by a 
stressful life event (Paykel et al, 1969).
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1. Predator Stress
Most studies on stress are based on the use of physical stressors such as electric 
shocks or restraint. However, animals do no confront these kinds of stimuli in their natural 
environments. As a consequence, other procedures involving natural contexts such as using 
predatory stimuli have been developed (Hendrie & Neill, 1991; Blanchard et al, 1998). 
Predatory stimuli are ecologically relevant for an animal’s survival and, consequently, 
induce responses quite similar to those shown in natural contexts. It is claimed that the 
recognition of such stimuli depends on innate mechanisms (Kavaliers, 1988; Zangrossi & 
File, 1992b).
While not assessed to a comparable extent, psychogenic stressors, such as predator 
exposure or cues associated with a predator, lead to behavioural and neuroendocrine 
variations (Adamec & Shallow, 1993; Blanchard et al, 1995a).
2. Elevated Plus-Maze (EPM)
The elevated plus-maze (EPM) test is based on the aversion of rodents for open 
spaces (Treit et al, 1993) and uses a plus-shaped maze elevated above the floor, consisting 
of two open and two enclosed arms (Figure.1.1.). This test of anxiety developed from the 
work of Montgomery (1955) and of Handley and Mithani (1984), was vahdated in rats by 
Pellow et al (1985), and in mice by Lister (1987).
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Figure.1.1.
/
A photograph of an elevated plus-maze.
The test involves placing the animal in the centre of the apparatus and allowing it to 
explore for a short period (usually 5 min). From the beginning, the primary indices of 
anxiety in the plus-maze have been spatiotemporal in nature (i.e., the proportion of entries 
that are made on to the open arms of the maze, and the time spent on the open arms of the 
maze expressed as a percentage of the total time spent on both the open and closed arms) 
and are highly correlated, while the total number of arm entries has frequently been 
employed as a measure of general activity. Plus-maze paradigms involve the study of 
spontaneous exploratory patterns in individual animals exposed to unfamiliar 
environments, which invariably include areas of relative safety. In this paradigm, the 
animal is initially placed not in the most aversive area (i.e., the open arm) but at a choice 
point, the central platform. Although a small proportion of animals may freeze on 
introduction and an even smaller proportion may display rapid escape, the vast majority
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initially engage in high levels of risk assessment from the centre platform towards the 
arms. Such behaviour dominates the first few minutes of the test, with most time spent on 
the centre platform and roughly equal time spent exploring the open and closed arms. 
Thereafter, risk assessment levels decline rapidly, coincident with the emergence of a 
spatiotemporal preference for the enclosed arms (thigmotactic cues). Therefore, ranges of 
defensive behaviours are observed (freezing, risk assessment) and these are usually ignored 
in favour of a relatively simple spatiotemporal measure.
The elevated plus-maze paradigm is currently one of the most widely used animal 
models in behavioural pharmacology (Handley & McBlane, 1993; Hogg, 1996) and is 
routinely used for studying the effects of putative anxiolytic drugs, as well as the 
neurobiological mechanisms of anxiety (Cruz et al, 1994; Pellow & File, 1986). It has 
proven to be bi-directionally sensitive to manipulations of anxiety (Cruz et al, 1994; 
Pellow & File, 1986).
3. Restraint Stress
An animal model of depression based on the biochemical and behavioural effects of 
a two-hour immobilisation stress in the rat was developed by Curzon (1988). These effects 
were (a) increased plasma concentrations of corticosterone during the stress, (b) decreased 
locomotion and increased defecation on placement 24 h later in an open field, and (c) loss 
of appetite or anorexia. On repeating the stress each day, adaptation occurred 
(Kennett et al, 1985a). Therefore, failure or delay in adaptation was a rational model for 
depression (Katz et al, 1982). Adaptation was associated with increased postsynaptic 
serotonin fimction, since some components of the serotonin behavioural syndrome, 
induced by the serotonin agonist 5-methoxy-N, N-dimethyltryptamine (5-Me-ODMT), 
were increased when the drug was given 24 h after repeated stress (Kennet et al, 1985b), in 
particular, reciprocal forepaw treading and tremor that are thought to be mediated by 
postsynaptic 5HT-1A receptors (Trickelbank et al, 1985), were increased. These findings
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lead to a depression model with high corticoid response to stress and low serotonin 
functional activity opposing adaptation and therefore predisposing to the illness. This is 
interesting, since (a) high corticoid production and defective cortisol feedback control are 
characteristic of depression (Carroll, 1985), (b) there are numerous indications of a 
serotonin abnormality in depression, and (c) familial studies suggest that defects of both 
cortisol feedback control (Coryell & Zimmerman, 1987) and of serotonin synthesis 
(Sedvall et al, 1980) may be associated with vulnerability to affective illness.
Behavioural changes following acute uncontrollable stress have been used as 
animal models of depression (Willner, 1984). Previous results strongly indicate that failure 
to adapt to repeat restraint may be a valid model of depression since elevated 
glucocorticoids (Carroll, 1972) and reduced central 5-hydroxyindoleacetic acid (5-HlAA) 
concentrations (Van Praag, 1982) are recognised features of depression.
4. Sucrose Preference
One of the most significant effects of stress, observed in a number of models, is a 
reduction in the performance of rewarded behaviour. The hypothesis that depression results 
from a reduction in the activity of reward systems is central to a number of theories of 
depression (Ferster, 1973). The influence of stressors upon sucrose or saccharin preference, 
and self-stimulation phenomena are of particular interest because these processes are 
believed to reflect changes in motivational and emotional functions of the brain. It is 
noteworthy that both behaviours are closely interrelated; it was found that rats genetically 
selected for high self-stimulation rates consumed the most, whilst the genetically low self- 
stimulators drank the least of a saccharin solution in a two-bottle preference test 
(Ganchrow et al, 1984). This further underlines the similarity of central nervous functions 
involved in both experimental procedures. The fact that saccharin and sucrose preference is 
a hedonic-like effect is also demonstrated by its antagonism by small doses, not interfering 
with motor activity and total fluid consumption, of pimozide (Bailey et al, 1986; To well et
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al, 1987). This selective D2 receptor antagonist exerts a potent central influence decreasing 
the rewarding properties of opiates and psychostimulants (Wise, 1978).
Several animal models of depression, such as the learned helplessness model of 
Seligman and Maier (1967) and Katz’ chronic stress model (1982), attempt to parallel the 
putative role of stress in producing depressive states. Willner and colleagues (1987) have 
reflned the latter model with the development of the chronic mild unpredictable stress 
(CMUS) model of depression. Exposure of rats to chronic, unpredictable, and diverse 
stressors was found to reduce preference for saccharin and sucrose for more than 2 weeks 
after termination of the stress regime (Katz, 1982; Willner et al, 1987). The CUMS model 
aims to mimic the reduced sensitivity to reward, termed anhedonia, which is a key 
symptom of many depressive states (Nelson & Chamey, 1981), and a core feature of the 
DSM-IV subtype of melancholia (DSM-IV-R, 1994). The relevance of this model to 
depression is ftirther supported by the evidence that the decreases in sensitivity to reward 
are reversed by chronic administration of all the major classes of antidepressant dmgs, and 
by electroconvulsive shock, but not by a variety of non-antidepressant drags (D’Aquila et 
al, 1994).
1.2. The HPA Axis
The CNS, through its control of secretion of releasing and inhibiting factors from 
the neuroendocrine hypothalamus into the hypothalamo-hypophysial portal system, 
regulates hormonal synthesis and secretion from the anterior pituitary, and, via its control 
of the pituitary hormones, regulates activity of peripheral target endocrine glands
(Figure.1.2.).
According to Checkley (1996), the central drive to the stress response of the HPA 
axis is organised by the parvocellular component of the paraventricular nucleus (PVN) of 
the hypothalamus (Figure.1.2.). CRH cells project to the external zone of the median 
eminence and release CRH into the hypophyseal portal system
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(Antoni, 1986; Plotsky, 1991), which carries the hormones to the anterior pituitary gland. 
CRH acts at the pituitary to increase pro-opiomelanocortin (POMC) gene expression and 
the release of POMC-derived peptides such as ACTH and p-endorphin. The rapid CRH 
stimulated secretion of ACTH is associated with induction of adenylate cyclase activity 
and an increase in cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) 
in corticotropes. ACTH, in turn, induces the synthesis and release of glucocorticoids 
(principally cortisol in primates and corticosterone in rodents) from the adrenal cortex.
In recent years a large body of evidence has emerged linking stressful life events 
with an increased vulnerability for affective and anxiety disorders. Stressful events often 
precede the onset of depression and stress has also been associated with the severity of the 
illness (Dunner et al, 1979; Hammen et al, 1992) and depression-like behaviours in 
animals (Anisman & Zacharko, 1982). This relationship is further supported by the fact 
that some of the common biological abnormalities observed in depressive illness are 
related to the HPA axis (Stokes & Sikes, 1988; Lesch & Lerer, 1991), which plays a 
pivotal role in the response to stress. Exposure to chronic stress is thought to play an 
important role in the aetiology of depression. In this disorder, a number of studies indicate 
an abnormal neuroendocrine system and a failure of normal adaptive processes to take 
place (Gold et al, 1988a,b). A reduced negative feedback response to exogenous 
glucocorticoids, is one of the most consistent findings, and is characterised by the failure in 
suppression of plasma cortisol levels following administration of the synthetic 
glucocorticoid, dexamethasone (Carroll et al, 1981; Arana et al, 1985). A significant 
number of depressed patients exhibit symptoms indicative of over-stimulation of the HPA 
axis (Murphy, 1991), with hypersecretion of basal cortisol (Carroll et al, 1976) and an 
increase in adrenal weight (Rubin et al, 1995).
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An understanding of the normal adaptive changes that occur in brain systems in 
response to stress forms a necessary foundation for the investigation of the relationship 
between stress and depressive illness, where such adaptive mechanisms presumably fail. 
An understanding of neurochemical changes underlying the adaptive response to stress and 
HPA axis activation is also crucial to the continuing development of effective 
pharmacological treatments for clinical depression and for the future identification of 
molecular screens for depressive illness.
The disinhibitory effects of hippocampal lesions on HPA activity implicate the 
hippocampus in glucocorticoid negative feedback inhibition of ACTH release 
(Jacobson & Sapolsky, 1991; Sapolsky et al, 1986). In support of this hypothesis, 
hippocampal lesion attenuates dexamethasone inhibition of stress-induced ACTH and 
CRH secretion in some paradigms (Feldman & Conforti, 1980; Feldman & Weidenfeld, 
1993). However, hippocampal damage does not affect the magnitude of HPA responses or 
negative feedback efficacy following hypoxia, suggesting that feedback effects may be 
stressor-specific (Bradbury et al, 1993). Further, hippocampal damage appears to increase 
responsiveness to mild but not severe stress (Kant et al, 1984). Thus, the influence of the 
hippocampus on HPA regulation appears to be stressor- and intensity-dependent, 
inconsistent with an obligatory role in glucocorticoid negative feedback.
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Figure.1.2: Schematic diagram of the HPA axis showing the sites of synthesis and
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(Adapted from Koelling, 1985; http://www.drieseacom/).
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Corticotropin-Releasing Hormone (CRH)
CRH, is a 41 amino-acid peptide that has been associated with several different 
endocrine, physiological, neurochemical and behavioural responses 
(for a review see Owens & Nemeroff, 1991). It is therefore not surprising to find a wide 
distribution of this neuropeptide throughout the central nervous system; ceU bodies and 
fibres that stain positive for CRH are heterogeneously but selectively distributed within 
several distinct structures including the isocortex; central nucleus of the amygdala; bed 
nucleus of the stria terminahs; arcuate, periventricular, supraoptic, suprachiasmatic, 
preoptic and paraventricular nucleus of the hypothalamus; and brainstem nuclei (i.e., locus 
coeruleus, dorsal vagal complex, and parabrachial nucleus; Swanson et al, 1983; Cassell & 
Gray, 1989). A schematic of the distribution of CRH-containing cell bodies and fibers in 
rat brain is shown in Figure. 1.3.
The primary neuroendocrine purpose of CRH is to increase the synthesis and 
release of ACTH fi-om the anterior pituitary (Vale et al, 1981; Spiess et al, 1981). In 
addition, it increases pituitary corticotroph density and may directly enhance the action of 
ACTH upon the adrenal gland. These actions are synergistic with weaker ACTH 
secretagogues including arginine vasopressin (AVP), oxytocin (OT), angiotensin-II and 
interleukin 1 (IL-1; Owens & Nemeroff, 1991).
Corticosteroids act at several loci to exert negative feedback inhibition on ACTH 
secretion (Keller-Wood & Dallman, 1984). Negative feedback effects have been 
demonstrated not only at the pituitary level, but also at hypothalamic and 
extrahypothalamic sites in the brain (Sayers & Portanova, 1974; Keller-Wood & Dallman,
1984). Consequently, corticosterone may inhibit ACTH secretion by reducing CRH release 
fi'om the hypothalamus as well as by direct actions on the corticotroph.
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Figure. 1.3. Major groups of CRH-producing neuronal perikarya (dots) and their fiber systems 
(arrows) are shown in a sagittal view of the rat brain (Adapted from Sawchenko and Swanson, 
1990).
The actions of CRH are mediated by specific high-affinity receptor sites located in 
the plasma membrane of the corticotroph (Wynn et al, 1983). These receptors have been 
identified in the pituitary and in several brain areas, including the cerebral and cerebella 
cortices, and structures related to the limbic system and the control of the autonomic 
nervous system (Wynn et al, 1983; De Souza et al, 1985). Many of these limbic structures 
containing CRH receptors have direct or indirect connections with the PVN of the 
hypothalamus (Swanson & Sawchenko, 1983). Consequently, modulation of neuronal 
activity by CRH-receptor interactions within these areas could influence anterior pituitary 
secretion by altering CRH release into the portal circulation. Administration of relatively
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high doses of dexamethasone has been shown to decrease CRH-receptors in the rat 
pituitary gland (Wynn et al, 1985), suggesting that loss or down-regulation of pituitary 
CRH receptors may partially mediate the inhibitory effect of glucocorticoids on ACTH 
secretion.
In the hypothalamus of rats, it has been shown that serotonin acting through a 
cholinergic intemeurone causes a dose-dependent release of CRH. Noradrenaline has been 
found to block the release of CRH induced by serotonin and this was caused by a direct 
action on the CRH neurones (Jones et al, 1976).
Molecular cloning studies have enabled the elucidation of receptor subtypes for the 
CRH system (Chen et al, 1993; Perrin et al, 1993); CRHi and CRH2, both of which 
activate adenylate cyclase cascades (Owens & Nemeroff, 1991; Grigoriadis et al, 1996). 
The CRHi receptors are found in high density within the pituitary, as well as the brain, 
particularly in the neocortex. CRH2 receptors are more abundant in the periphery, but are 
also found in some brain areas such as the septum, ventromedial hypothalamus and dorsal 
raphe nucleus (Potter et al, 1994). The CRH2 subtype exists in two different isoforms in 
both rat and human; these have been termed CRH2a and CRH2p (Chalmers et al, 1996), 
each having a different distribution (Lovenberg et al, 1995).
Although quite similar in their central distribution, the CRHi receptor mRNA is 
undetectable in several regions associated with CRH mRNA (Potter et al, 1994). For 
example, within hypothalamic regions known to have high basal CRH mRNA levels such 
as the PVN, very low and diffiise levels of the CRHi receptor mRNA have been measured 
(Potter et al, 1994). Interestingly however, is the fact that either an immune challenge or an 
immobilisation stress could induce a very selective and strong activation of the CRHi 
receptor mRNA within hypothalamic nuclei involved in the regulation of neuroendocrine 
functions, particularly the parvocellular division of the PVN (Rivest et al, 1995). This fact, 
taken together with CRH’s ability to activate its own gene expression selectively within the 
PVN (Parkes et al, 1993), supports the existence of an ultra-short loop positive feedback
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mechanism through which CRH may modulate its own biosynthesis. Excessive CRH 
production is prevented by multiple levels of negative feedback, that are present 
throughout the HPA axis, and mediated by corticosterone, ACTH, CRH binding protein 
and also CRH itself.
1. Stress and the role of Arginine Vasopressin (AVP)
In response to stress there is an increase in the synthesis of CRH mRNA in 
parvocellular cells in the PVN (Lightman & Young, 1988), an increase in CRH message in 
the median eminence and an increased release of CRH into portal blood. The extent and 
time course of changes in CRH in the PVN and median eminence of the hypothalamus 
following stress are highly dependent on the nature of the stressor as well as the state of the 
animal.
In patients with major depression, elevated CRH immunoreactivity was found in 
the CSF (Nemeroff et al, 1984). It was therefore hypothesised that the prolonged exposure 
of target cells to increased concentrations of CRH should result in a ligand-induced 
downregulation of receptors for the peptide. Indeed, in the anterior pituitary, CRH receptor 
number decreased after a long-lasting elevation of hypothalamic peptide release into the 
portal system (Hanger et al, 1988). However, in the brain, CRH binding sites seemed not 
to be affected by experimental conditions, such as chronic manipulations of the HPA 
activity, during which the neuronal release of CRH is increased (Hanger et al, 1988; 
Hanger & Aguilera, 1992). Based on these findings, it was concluded that different 
mechanisms exist which regulate the interactions of CRH with its receptors in the pituitary 
and in the CNS.
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Nemeroff et al (1988) reported a marked reduction in the number of CRH binding 
sites in the frontal cortex of suicide victims, and Anderson et al (1993) demonstrated a 
significant loss of CRH binding sites, in the hypothalamus, after severe chronic 
immobilisation stress in rats, and a downregulation of amygdala CRH binding sites was 
observed by Hanger et al (1993), as a result of high intracerebral CRH concentrations.
CRHi and CRHia receptors differ in their regulation in response to a variety of 
stressors. Various stressors, for example an immune challenge or immobilisation, have 
been shown to upregulate CRHi mRNA in the PVN of the hypothalamus 
(Lacroix & Rivest, 1996; Lee & Rivier, 1997), suggesting that this receptor subtype might 
primarily mediate the effect of stress on the HPA axis.
Two reports of mice lacking the CRHi receptor have confirmed a role for this 
receptor in anxiety-related behaviour (Timpl et al, 1998; Smith et al, 1998). CRHi 
receptor-deficient mice display decreased anxiety-like behaviour in the dark-light 
emergence task and the elevated plus-maze, both behavioural paradigms thought to 
measure anxiety in rodents. Both studies concluded that CRH mediates the behavioural 
responses to stressors by means of the CRH type 1 receptor (Timpl et al, 1998; Smith et al, 
1998).
CRH systems in the brain have a role in mediating not only the neuroendocrine, but 
also the autonomic and behavioural responses to stress. For example, CNS administration 
of CRH to laboratory animals produces physiological and behavioural changes almost 
identical to those observed in response to stress, including increased heart rate and mean 
arterial blood pressure due to alterations in the autonomic nervous system, suppression of 
exploratory behaviour in an unfamiliar environment, induction of grooming behaviour, 
increased conflict behaviour, and decreased food intake and sexual behaviour 
(Dunn & Berridge, 1990; Koob et al, 1993). The behavioural effects of centrally 
administered CRH can be reversed by CRH receptor antagonists and are independent of 
activation of the HPA axis. Furthermore, CRH receptor antagonists alone attenuate many
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of the behavioural consequences of stress, under-scoring the role of endogenous CRH in 
mediating many stress-induced behaviours (Heinrichs et al, 1995).
Although AVP is only a weak ACTH secretagogue on its own, it acts synergistically 
with CRH and is believed to play an important role in sustaining pituitary responsiveness 
during chronic stress (Gilles et al, 1982; Aguilera, 1998). There are two populations of 
CRH neurones in the PVN, one in which only CRH can be detected and another in which 
both CRH and AVP coexist (Whitnall et al, 1987). Studies based on the levels of 
immunoreactive peptide and mRNA for CRH and AVP have suggested that differential 
regulation of these peptides in the PVN plays an important role in determining the 
responsiveness of the HPA axis during chronic stress (Gilles et al, 1982; Aguilera, 1998). 
Differences in the regulation of AVP and CRH transcription are emphasised by studies 
which have demonstrated that the response of the AVP gene in CRH neurones to 
corticosterone is more sensitive than that of the CRH gene (Makino et al, 1995b; Ma et al,
1997), and that the glucocorticoid receptors in the PVN are downregulated in response to 
repeated stress (Makino et al, 1995a; Herman et al, 1995). This suggests a complex 
regulatory mechanism by which repeated stress may temporarily impair glucocorticoid 
feedback and thus facilitate AVP gene expression in the CRH neurons. More recently, the 
development of in situ hybridisation techniques with probes directed against introns has 
allowed a more detailed analysis of the regulation of CRH and AVP gene expression in the 
PVN (Fremeau et al, 1986; Ma & Aguilera, 1999).
The different time courses of CRH and AVP transcript responses clearly imply 
different regulatory mechanisms for the transcription of these genes, as has been suggested 
in previous studies (Herman et al, 1990; Ma & Aguilera, 1999). Differential sensitivity to 
corticosterone feedback (Kovacs & Sawchenko, 1996), second messengers, and 
transcription factors (Kovacs et al, 1998) may aU be involved.
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2. Clinical Relevance
The hypothalamic paraventricular CRH neurones play a key role in the HPA 
response to stress. These CRH neurones have been hypothesised to be involved in the 
pathophysiological response of the HPA axis in various stress-related human pathologies, 
e.g. depression (Holsboer et al, 1992). This hypothesis is largely based on reports showing 
that in depressed patients: (a) 24-hour cortisol excretion was elevated (Sacher et al, 1973); 
(b) there was decreased CRH binding in the frontal cortex (Nemeroff et al, 1988); (c) the 
HPA axis was often unable to respond appropriately to exogenous corticosteroids, as 
measured by the dexamethasone suppression test (Carroll et al, 1981); {d) ACTH 
responses to test doses of ovine CRH (Holsboer et al, 1985) or human CRH (Holsboer et 
al, 1987) were blunted, which may be due to a down-regulation of anterior pituitary CRH 
receptors (Holsboer et al, 1985; Gold et al, 1988a,b), and {e) elevated CRH concentrations 
have been reported in the cerebrospinal fluid (CSF) of patients with depression (Nemeroff 
et al, 1984).
According to Raadsheer and colleagues (1994), these blunted responses in 
depressed patients have been interpreted as an index of CRH hyperexposure because rats 
that were chronically exposed to CRH develop a reduced CRH receptor efficacy, resulting 
in blunted ACTH responses to a CRH challenge (Aguilera et al, 1990). These findings are 
believed to reflect desensitised CRH receptors at corticotrophic cells or restricted secretory 
response of ACTH to CRH, or both, caused by increased basal levels of cortisol. The 
restricted secretory response is supported by normalised net ACTH output in metyrapone- 
pretreated depressive patients (Lisansky et al, 1989).
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1.2,2, Pro-Opiomelanocortin (POMC)
The POMC gene is predominantly expressed in the anterior and intermediate lobes 
of the pituitary, although lower levels of expression are detected in other tissues, for 
example the immune system (Bateman et al, 1989). The primary protein product of the 
POMC gene is a 285 amino acid precursor that can undergo differential processing to yield 
at least eight hormones (Figure.1.4.), dependent upon the location of synthesis and the 
stimulus leading to their production (Smith & Funder, 1988).
CRH induces rapid secretion of ACTH (also called corticotropin) and a variety of 
other peptides from corticotropes of the anterior pituitary. ACTH is the main 
physiologically active product of CRH activity, and is derived by post-translational 
modification of POMC. Longer-term responses of corticotropes to CRH include a marked 
increase in POMC mRNA (Droin et al, 1987).
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Figure.1.4. Processing of the POMC precursor protein. Cleavage sites are indicated by the 
numbers 1 to 7 and consist of the sequences, Arg-Lys, Lys-Arg or Lys-Lys. Adrenocorticotrophic 
hormone (ACTH) and p-lipotropin are products generated in the corticotrophic cells of the anterior 
pituitary under the control of corticotropin releasing hormone (CRH). Alpha-melanocyte 
stimulating hormone (a-MSH), eorticotropin-like intermediary peptide (CLIP), y-lipotropin and p- 
endorphin are products generated in the intermediary pituitary under the control o f dopamine. The 
numbers in parentheses below each hormone indicate the amino acids o f POMC present in each. 
The N-terminus o f ACTH is given as amino acid number 1. The presence and function o f y-MSH is 
unclear in humans, hence the dotted lines, although it is well understood in rodents, 
(http :// web. indstate. edu/theme/m wking/ peptide-hormones. htm)
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1.2.3, Structure and Function of the Adrenal Gland
The adrenal cortex is responsible for the production of three major classes of 
steroid hormones: glucocorticoids, mineralocorticoids, and androgens. It is composed of 
three main tissue regions: zona glomerulosa, zona fasciculata, and zona reticularis. 
Although the pathway to pregnenolone synthesis is the same in all zones of the cortex, the 
zones are histologically and enzymatically distinct, with the exact steroid hormone product 
depending on the enzymes present in the cells of each zone. The zona glomerulosa is 
mainly responsible for the conversion of cholesterol to corticosterone and aldosterone. 
Whereas, cells of the zona fasciculata and zona reticularis can make corticosteroids and the 
adrenal androgens (dehydroepiandosterone and androstenedione), but not aldosterone.
ACTH regulates the hormone production of the zona fasciculata and zona 
reticularis. ACTH receptors in the plasma membrane activate adenylate cyclase with 
production of cAMP. The effect of ACTH on the production of corticosterone is 
particularly important, with the result that a classical feedback loop is prominent in 
regulating the circulating levels of CRH, ACTH, and corticosterone.
Substantial evidence indicates a role for central serotonergic neurones in the 
regulation of the secretion of ACTH, corticosterone, OT, growth hormone (GH), renin and 
AVP (Chaouloff, 1993). Of the many 5-HT receptor subtypes, only a few have been 
characterised with respect to their role in neuroendocrine function, for example 5-HTia and 
5 -HT2A receptor involvement with ACTH (Hemrick-Luecke & Fuller, 1996).
1.2.4, Corticosteroid receptors
Two types of receptors for adrenal steroids have been identified in the brain 
(Reul & De Kloet, 1985). The type I corticosteroid receptor, also referred to as the 
corticosterone-preferring site or MR, has similar, if not equal, apparent affinity in vitro for 
both the endogenous mineralocorticoid (aldosterone) and glucocorticoid (corticosterone in 
rat and cortisol in humans; De Kloet et al, 1975; Sheppard & Funder, 1987). However, in
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vivo the apparent affinity of these steroids for the MR differs depending on the presence of 
tissue-modifying factors (Sheppard and Funder, 1986; Funder et al, 1988). The type II 
corticosteroid receptor (GR; classical dexamethasone-binding site) has higher affinity for 
glucocorticoids than mineralocorticoids (Funder et al, 1973; Sheppard & Funder, 1987).
GR is present in nearly aU mammalian tissues and has a multitude of physiological 
functions. In both the brain (in particular the hippocampus) and the anterior pituitary, this 
receptor is activated in response to stress and is thought to be important in terminating the 
stress response (Sapolsky et al, 1981), through the negative feedback effects of 
glucocorticoids on the HPA system (Feldman & Conforti, 1980; Dallman et al, 1989; 
Figure.1.2.).
MRs are almost exclusively septo-hippocampal in distribution, whereas GRs are 
found in the anterior pituitary, the ventromedial nucleus, and brain regions thought to be 
involved in the stress response encompassing the paraventricular, supraoptic, and arcuate 
nuclei of the hypothalamus, the median eminence, hindbrain noradrenergic and 
serotonergic cell bodies (Harfstrand et al, 1986; Reul et al, 1987b). This dual system may 
enable correct functioning with corticosteroid concentrations ranging from 0.5nM to 
50nM, during the diurnal cycle, and up to lOOnM or more in response to stress (Barden et 
al, 1995).
Functional differences between MR and GR in mediating corticosteroid negative 
feedback have been determined in part by the utilisation of selective MR and GR 
antagonists, for example RU40555 and RU38486 (Ratka et al, 1989; Weidenfeld & 
Feldman, 1993). These studies and others support the idea that MR maintains low basal 
activity of the HPA axis during the circadian trough (Dallman et al, 1987; DeKloet et al, 
1993) and that GR, with facilitation by MR, constrains the increased HPA axis activity 
during the circadian peak and during acute stress (Sapolsky et al, 1981; Spencer et al,
1998). The respective roles of MR and GR in negative feedback regulation are not yet fully 
elucidated. Electrophysiological and behavioural studies suggest that GR and MR might
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exert different, and even functionally antagonistic, effects (DeKloet et al, 1993). On the 
other hand, their effects on the HPA axis regulation appear to be synergistic (Dallman et 
al, 1989; Ratka et al, 1989). Understanding of the specific roles of GR and MR with 
respect to negative feedback regulation is clearly needed for a better understanding of the 
conditions associated with abnormal negative feedback.
The cellular response to glucocorticoids is dependent on both the availability of 
steroid and the presence and cellular concentration of fimctional receptor 
(Bloom et al, 1980; Vanderbilt et al, 1987). Ligand-induced down-regulation of GR and its 
increase in response to the removal of glucocorticoids by surgical ADX have been shown 
by steroid binding assays (McEwen et al, 1974; Reul et al, 1987a).
1. Gene expression
The nuclear receptors, like GR and MR, are characterised by a central DNA- 
binding domain (DBD), which targets the receptor to specific DNA sequences known as 
hormone responsive elements (HREs). The DBD is composed of two highly conserved 
zinc fingers that set the nuclear receptors apart from other DNA-binding proteins 
(Berg, 1989; Klug & Schwabe, 1995). The C-terminal half of the receptor encompasses the 
hgand-binding domain (LBD), which possesses the essential property of hormone 
recognition and ensures both specificity and selectivity of the physiological response.
In the absence of ligand, GR are predominantly maintained in the cytoplasm as an 
inactive multi-protein complex. This complex consists of two Hsp90 molecules plus 
immunophiUins (e.g. Hsp56), p59 and calreticulin (reviewed by Pratt, 1993). Entry of 
glucocorticoids into the cell and subsequent binding to the LBD of GR leads to a 
conformational change in the receptor called transformation (Yamamto, 1985). This causes 
dissociation of the multi-protein complex and allows nuclear translocation of GR by virtue 
of the nuclear localisation sequence within the DBD. Once within the nucleus, the 
transformed hormone-receptor complex then binds with increased avidity to specific DNA
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sequences termed GREs (for a review see Yamamto, 1985) to activate transcription of 
responsive genes (referred to as transactivation; Jantzen et al, 1987; Beato et al, 1996). 
Such interactions then regulate the transcription of selected genes (Yamamoto & Alberts, 
1976; Ringold, 1985). It is also known that the protein products of glucocorticoid 
responsive genes may themselves regulate the expression of other genes such that 
glucocorticoids could indirectly activate the expression of entire gene networks (Yamamto,
1985).
2. Stress
Stressful stimuli are known to affect OR and OR mRNA concentrations in the rat 
brain (Kitraki et al, 1999; Calvo & Volosin, 2001). Stress stimulates the HPA axis and one 
of the prime neuronal targets for corticosteroid action is the hippocampal formation 
(Herman et al, 1993; Hassan et al, 1999). This region is known to possess the greatest 
density of MR and OR binding and mRNA expression in the brain (Reul & DeKloet, 1985; 
Herman, 1993), indicating a capacity for this brain region to respond to a wide range of 
corticosteroid concentrations.
The importance of GRs in regulation of hippocampal fimction and cell viability 
mandates a keen understanding of mechanisms controlling cellular GR biosynthesis. 
Studies to date indicate that the hippocampal GR is upregulated at both the binding and 
mRNA level by adrenalectomy, suggesting corticosteroid autoregulation 
(Tomello et al, 1982; Reul et al, 1989). Stress and high-dose corticosteroid administration 
appear to downregulate hippocampal GR binding, also consistent with autoregulation 
(Sapolsky et al, 1984; Sapolsky & McEwen, 1985). However, effects at the mRNA level 
have been inconclusive (Herman et al, 1989a; Reul et al, 1989), suggesting the potential 
for dissociation between mRNA expression and functional receptor expression. In depth in 
vivo analysis of GR protein regulation has yet to be definitively explored. Furthermore,
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although corticosteroids are capable of influencing GR expression, there is no definitive 
understanding of the respective roles played by MR and GR in this action.
3. Clinical Relevance
Corticosteroids seem to play a key role in the triggering of depression, because:
(a) GRs are present in limbic brain regions, which are of relevance to depression, including 
the noradrenergic and serotonergic projections to the forebrain (Harfstrand et al, 1986);
(b) Corticosteroid receptors are intracellular and, when bound with corticosteroids, are 
translocated into the cell nucleus, where they bind to DNA and activate the transcription of 
mRNA (Beato, 1989). Such a genomic action of corticosteroids could provide a 
neurobiological basis for the known interaction between the genetic predisposition to 
depression and the effects of life events; (c) Diminished corticosteroid-receptor 
concentrations caused by a malfimctioning of systems involved in the regulation of 
corticosteroid-receptor gene expression {Late-delayed feedback inhibition) could be a 
causative factor in the defective feedback action of cortisol seen in patients suffering fi*om 
severe depression, and could thus explain their altered HPA function.; (d) GRs are not fully 
occupied under resting conditions and hence are sensitive to stress-induced 
hypercortisolaemia. They are known to be involved in the neuroendocrine effects of stress 
(Ratka et al, 1989), and may also be involved more generally in the neurobiology of stress; 
(e) The activation of GRs is required for the development of certain animal models of 
depression (Veldhuis et al, 1985); (f) There is considerable overlap between the degree of 
hypercortisolaemia seen in depression and in Cushing’s Syndrome. Consequently, if 
hypercortisolaemia affects mood in Cushing’s Syndrome, then it may also do so in 
depression.
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L2*5. Neurotrophins
Neurotrophic factors (Table.1.1.), a subclass of growth factors, are endogenous 
proteins that regulate the development, maintenance and survival of neurones. They 
contain at least three distinct families: the neurotrophins (e.g., NGF, BDNF, NT-3 and 
NT-4/5; Barden et al, 1982; Ip et al, 1992); the neuropoietic cytokines (e.g., CNTF, IL-6, 
leukemia inhibitory factor or LIF); and the fibroblast growth factors (e.g., acidic and basic 
FGF). The members of these families of neutrophic factors demonstrate significant 
homology (50% or more) and have varying affinities for particular classes of receptors. For 
example, neurotrophins bind to a low affinity receptor (p75) and to a family of closely 
related high affinity glycoproteins, tyrosine receptor kinases (Trk).
Table 1.1. Examples of Proteins Reported to Have Neurotrophic Properties.
Proteins with well-documented neutrophic Proteins with putative Neurotrophic
activity activity
Acidic fibroblast factor (aFGF) Cholinergic neuronal differentiation factor
(CDF)
Basic fibroblast growth factor (bFGF) Epidermal growth factor (EGF)
Brain-derived neutrophic factor (BDNF) Heparin binding Neurotrophic factor (HBNF)
Ciliary Neurotrophic factor (CNTF) Insulin
Interleukin 1, 3 and 6 (IL-1,3,6) Insulin like growth factors (IGFs)
Neurotrophin-3 (NT-3) Protease nexin 1 and 11
Neutrophin-4/5 (NT-4/5) Transforming growth factor alpha (TGFa)
Nerve growth factor (NGF)
Glial-derived neurotrophic factor (GDNF)
52
The neurotrophins are secreted by cells and act in target-derived, autocrine or 
paracrine fashion on cell surface receptors. While these growth factors have many effects 
on neurones, the two most profound effects are promotion of differentiation and survival 
during development. It is now recognised that both of these actions also may be maintained 
in adult brains, implicating neurotrophins in plasticity and the response to injury in adult 
and young animals (Lindsay et al, 1994).
Within the CNS, BDNF mRNA displays a much wider distribution than that of 
central NGF mRNA. Regions producing the mRNA encoding for BDNF include the 
hippocampus, dentate gyrus, amygdala, projection areas of the olfactory system, inner and 
outer pyramidal layers of the neocortex, claustrum, cerebellum, and superior colliculus 
(Hofer et al, 1990). It has been shown that BDNF and NT-3 are able to elevate intracellular 
calcium in hippocampal neurones (Beminger et al, 1993). This finding supports the view 
that neurotrophins might have autocrine and paracrine actions within this brain region.
The known receptors for the neurotrophins include three different glycoprotein 
tyrosine kinases (TrkA, TrkB, and TrkC; Figure.1.5; for a review see Chao, 1992), which 
are similar in nature to the receptors for the growth factors FGF and EGF. The different 
neurotrophins bind to these receptors with high affinity (K<j = 10’^ )^ and with specificity: 
NGF binds to TrkA, BDNF and NT-4/5 bind to TrkB and NT-3 binds to TrkC. A low 
affinity receptor, p75, binds NGF and the other neurotrophins with an approximate Kd of 
5x10'^, thus p75 has been referred to as a pan-neurotrophin.
Not only are the receptor mechanisms comparable for the various neurotrophic 
factors, but also the intracellular signalling pathways are very similar, even for such 
diverse molecules as NGF, CNTF and FGF (Boulton et al, 1994). Thus, a large group of 
diverse factors act on distinct receptors, leading to similar intracellular molecular changes, 
which can profoundly impact cell development and survival.
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Following the binding of homodimeric neurotrophins to Trk receptors and resultant 
receptor dimerization, downstream neurotrophin actions occur in two intracellular stages 
(Schlessinger & Ullrich, 1992). In many ways, these events resemble the actions of other 
tyrosine kinase-coupled growth factors.
1 The first cytosolic events are initiated by autophosphorylation of the tyrosine receptor 
kinase.
2 The second stage of the signalling process is gene transcription within the nucleus. 
This is mediated by mitogen-activated protein (MAP) kinase, S6 kinase II and 
possibly other activated regulatory proteins, which stimulate response elements, 
thereby inducing transcription of early genes such as c-fos, c-jun and c-myc 
(Marutu & Burgess, 1994). This stage of the signalling process is generally thought to 
account for the most profound effects of the neurotrophins, such as neuronal survival 
and neurite outgrowth.
It seems that at least in the intact rat brain the expression of the neurotrophins are 
confined largely to neurones. In addition, the levels of neuronal NGF and BDNF mRNAs 
are increased by enhanced neuronal activity following glutamate (Zafira et al, 1990) and 
muscarinic receptor stimulation (Berzaghi et al, 1993). The activation of glutamate 
receptors enhances the synthesis of BDNF and NGF in hippocampal neurones both in vitro 
and in vivo, whereas stimulation of the GABAergic system decreases their mRNA levels 
(Zafi*a et al, 1991). Therefore the fimctional state of the hippocampal neurone seems to 
determine the levels of BDNF and NGF mRNA. Moreover, depending on the conditions, 
activation of both major types of glutamate receptors, NMDA and non-NMDA receptors, 
are able to up-regulate neuronal BDNF and NGF mRNA levels.
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BDNF enhances survival, transmitter uptake, and total protein content in central 
GABAergic neurones (Knusel et al, 1991). Additionally, studies verified the augmented 
survival and uptake of dopamine fi-om mesencephalic substantia nigra neurones in culture, 
in response to BDNF (Dal Toso et al, 1988; Hyman et al, 1991).
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Figure.1.5. Neurotrophic factors and their receptors. Neurotrophin receptors (blue); All 
neurotrophins bind with low affinity to p75, which has no defined role in neurotrophin signalling. 
The neurotrophins selectively bind to high affinity Trk receptors and cause the Trk receptor to form 
homodimers and autophosphorylate, thereby triggering the intracellular signalling cascade. 
Neuropoietic cytokine receptors (green): CNTF binds with low affinity to the specific CNTF 
alpha-receptor moiety (CNTFR-alpha), which lacks a transmembrane domain. The CNTF:CNTFR- 
alpha complex interacts with two membrane spanning signalling molecules, gpl30 and LIFR-beta, 
thereby activating an associated tyrosine kinase (JAK/TYK), which transduces the initial 
intracellular signal. Fibroblast growth factor receptors ( ): FGF binds with low affinity to a
heparin sulfate proteoglycan FGF receptor which then facilitates binding of FGF monomers to the 
high affinity FGF receptor. This interaction leads to receptor autophosphorylation and signal 
transduction.
Note: Only principal ligandireceptor interactions are shown. High affinity receptors for a specific 
class of neurotrophic factors are represented with a dark colour, while the low affinity receptor has 
a lighter shade of that colour. Tyrosine kinase domains are shown in red. (Lipton & Kalil, 1995)
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1. Stress
Many types of brain insults induce modifications in neurotrophin mRNA expression in the 
CNS (Lindvall et al, 1994). Single or repeated immobilisation stress application or 
exogenously applied corticosterone markedly reduce BDNF mRNA and protein levels in 
the hippocampus (Barbany & Persson, 1992; Schaaf et al, 1998). Inversely, adrenalectomy 
(ADX) results in an increase in BDNF mRNA levels in this structure (Barbany & Persson, 
1992; Chao ef a/, 1998).
2. Clinical Relevance
There are several lines of evidence that suggest BDNF is involved in the action of 
antidepressant treatment and in the stress-induced hippocampal adaptation and 
pathogenesis of depression (Duman et al, 1997a) in the adult animal: (a) Direct infusion of 
BDNF protein into the midbrain exerts antidepressant effects in two models of depression, 
i.e. the forced swim and learned helplessness models (Siuciak et al, 1996); (b) Chronic 
administration of various classes of antidepressant drugs increases hippocampal BDNF 
mRNA with the induction following the time-course observed for the therapeutic effects of 
antidepressant treatments, and that antidepressant pre-treatment ameliorates stress-induced 
reduction of BDNF mRNA in this brain region (Nibuya et al, 1997); (c) BDNF exerts a 
strong trophic effect on serotonergic and noradrenergic neurones regulating morphology, 
neurotransmitter metabolism and firing patterns of these neuronal populations 
(Mamounas et al, 1995); (d) Chronic stress is known to result in neuronal damage and 
death. Decreased BDNF expression as a consequence of stress may play a role in stress- 
induced neuronal damage.
Finally, BDNF mRNA expression is regulated by CREB (Tao et al, 1998) whose 
activity could thereby underlie some of the long-term effects of antidepressant treatment 
(Nibuya et al, 1996). Regions exhibiting an up-regulation of BDNF in response to 
antidepressant administration overlap closely with the regions that show an up-regulation
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of CREB. This spatial correlation suggests that CREB may contribute to the 
antidepressant-induced increase in hippocampal BDNF expression. A role for the cAMP 
system in mediating the antidepressant-induced increase in BDNF expression is supported 
by studies with the phosphodiesterase (PDE) inhibitors papaverine and rolipram (Nibuya et 
al, 1996).
L2,6. Regulation
Three integrated regulatory forces are imposed on the HPA axis to co-ordinate 
adrenal secretions through times of inactivity or stress: (1) a circadian rhythm of basal 
activity derived from the suprachiasmatic nucleus (Cascio et al, 1987), (2) stress-induced 
responses of the HPA system are far more complex and involve afferent inputs from 
numerous brain regions, including noradrenergic innervation from the brain stem A1 and 
A2 cell groups, locus coeruleus (Szafarczyk et al, 1985), amygdala (Beaulieu et al, 1989), 
cerebral cortex and hippocampus (Jacobson & Sapolsky, 1991), and (3) feedback 
inhibitory actions of adrenal steroids exerted through corticosteroid receptors.
1. Circadian Rhythms
It is well established that the HPA axis exhibits a circadian rhythm in humans, rats, 
and other mammals, and basal steroid concentrations that oscillate in a circadian fashion 
cause this. The concentrations are correlated with the rest-activity cycle of the animal, 
rather than the light cycle. Thus, in man, steroids begin to rise in the early morning hours, 
peak around awakening, and then fall throughout the day. In nocturnal animals such as 
rats, the converse pattern is seen, whereby concentrations peak in late evening and are at a 
nadir in early morning. Connections between this cycle and rest-activity, sleep, and feeding 
behaviour have been made. The circadian rhythm in basal activity of the HPA axis results 
in total circulating corticosteroid concentrations that may be <10 nM at the nadir of the 
rhythm and about 700 nM at the peak of the rhythm in both man and rats. Of the total
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corticosteroid concentration, 99-95% is tightly bound in the circulation to transcortin and is 
unavailable for diffusion to brain sites. The amount of steroid bound depends on the 
concentrations of both steroid and transcortin in the circulation. Furthermore, at all times 
of the day, the system can be stimulated by stressors to cause corticosteroid concentrations 
that may exceed 1000 nM (for a review see DeKloet et al, 1993).
The effects of stress are superimposed on the basal rhythmicity, and there is 
evidence that stress responsiveness and the effectiveness of negative feedback may also 
oscillate across the cycle. Thus, at the trough of the rhythm, animals appear to be more 
sensitive to both stress activation and inhibition by glucocorticoids, suggesting that at this 
time, the axis is exquisitely responsive. The drive to the axis prior to awakening appears to 
be initiated by the SCN (Dallman, 1984), leading to enhanced tone of CRH, and resulting 
in increased activity throughout the HPA axis. However, other neuroregulators such as 
AVP, OT, and adrenaline are also known to possess ACTH-releasing activity, and 
immunoneutralisation of CRH does not completely abolish circadian rhythms of plasma 
ACTH (Carnes et al, 1990).
Occupancy of GR occurs in parallel with the stress-induced rise, subsequent fall, 
and the circadian variation of plasma corticosterone, which illustrates that GR mediate the 
feedback action of corticosterone on stress-activated brain processes (Munck et al, 1984; 
De Kloet & Reul, 1987). This view is supported by the presence of GR in neurones 
involved in the regulation of the stress responses, i.e., neurones of the paraventricular and 
supraoptic nuclei, the ascending aminergic neurons and cortical and limbic neurones 
(Reul & DeKloet, 1985; Kiss et al, 1988).
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2. Neurotransmitters
Glucocorticoids have complex and widespread interactions with neurotransmitter 
and neuropeptide systems. Most major neurotransmitter systems influence CRH. 
Acetylcholine, serotonin, angiotensin, endogenous cytokines, neuropeptide Y, 
noradrenaline, and dopamine stimulate CRH secretion, whereas glucocorticoids, glutamate, 
opiod-derived peptides, GABA, aldosterone and, in some circumstances, noradrenaline 
inhibit CRH release (Krishnan et al, 1991). Evidence for direct serotonergic, dopaminergic 
(Liposits & Paul, 1989), and GABAergic (Meister et al, 1988) innervation of the CRH 
perikarya of the PVN has also been provided.
Serotonergic neurones projecting fi*om the midbrain raphe nuclei form synapses 
with CRH-containing neurones in the PVN of the hypothalamus that control 
pituitary-adrenocortical fimction (Fuller & Snoddy, 1990). Drugs that enhance serotonergic 
fimction such as direct-acting 5-HT agonists, 5-HT precursors, uptake blockers and 
releasing agents have been shown to increase the release of CRH, ACTH and 
corticosterone in vivo (Fuller & Snoddy, 1990; Van de Karl, 1991). From among the 
multiple subtypes of serotonergic receptors in the brain, the 5-HTia and 5-HTzA/2c subtypes 
appear to mediate activation of HPA fimction (Fuller & Snoddy, 1990). 8-OH-DPAT, an 
agonist selective for the 5-HTia subtype, has been shown to increase corticosterone levels. 
This effect can be blocked by 5-HTiA-selective antagonists but not by non-5-HTiA 
antagonists (Fuller & Snoddy, 1990). The 5-HTia subtype of serotonergic receptors is an 
important target in the treatment of neuropsychiatrie disorders such as anxiety and 
depressive illness and 5-HTiA-selective compounds have been shown to be clinically 
effective antidepressants and anxiolytics (Blier et al, 1990).
Stress has also been shown to alter levels of 5-HTia receptors in rats. However, 
different stressors appear to produce variable effects on 5-HTia receptors. For instance, 
restraint stress has been shown to produce an increase in 5-HTia receptors in the CA4 and 
the infrapyramidal dentate gyrus (Mendelson & McEwen, 1992). This is surprising since
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adrenalectomy also produces an increase in 5-HTia receptors and exogenous 
corticosterone administration prevents this increase (Mendelson & McEwen, 1992; 
Tejani-Butt & Labow, 1994). However, decreases in 5-HTia binding in the hippocampus 
have been reported following other stressors such as two weeks of chronic unpredictable 
stress (Tejani-Butt & Labow, 1994) or chronic social stress (McKittrick et al, 1995). It 
must be noted that these stress paradigms are qualitatively very different and involve 
different durations of exposure to stressful stimuli. Different stressors produce variable 
effects on corticosterone as well as 5-HT release.
The interaction between the serotonergic system and the HPA axis is bi-directional 
in that glucocorticoids also affect the state of the serotonin receptor system. Corticosteroids 
can alter several aspects of serotonergic neurotransmission including 5-HT metabolism, 
turnover and release (Curzon, 1972). In addition, adrenal steroids can also directly regulate 
the expression of 5-HT receptors (Biegon et al, 1985; De Kloet et al, 1986). With specific 
regard to the 5-HTia receptor system, reduction in corticosteroid level following 
adrenalectomy is associated with an increase in 5-HTia receptor expression (Mendelson & 
McEwen, 1992; Tejani-Butt & Labow, 1994) and 5-HTia receptor mRNA in rat 
hippocampus (Lopez et al, 1993). These increases are prevented by replacement treatment 
with corticosterone (Chalmers et al, 1993). Changes in 5-HTia receptor density and 5-HT 
concentrations following adrenalectomy parallel the activity and responsiveness of the 
HPA axis (Burnet et al, 1992).
3. Feedback
The secretion of hypothalamic, pituitary, and target tissue hormones is under tight 
regulatory control by a series of feedback and feedforward loops. These modes of negative 
feedback mediated by corticosterone can be distinguished (Keller-Wood & Dallman, 1984) 
into fast feedback, intermediate or delayed feedback mechanism, and genomically 
mediated feedback.
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(a) Fast feedback, which includes the actions (within lOmin) of corticosterone on the 
multisynaptic control of ACTH secretagogues released in the median eminence. It does not 
involve protem synthesis and may occur presumably at the level of the cell membrane 
(Dallman & Yates, 1969; Jones, 1979). Evidence for this feedback comes from the 
following experiments: (i) Lesions to the hippocampus or to its projections to the PVN 
result in impairment of fast feedback and consequently in prolongation of the stress 
response (Herman et al, 1989b; Jacobson & Sapolsky, 1991); and (it) Fast feedback can be 
investigated in man by measurement of the suppression of ACTH and/or p-endorphin 
following an infusion of hydrocortisone (Young et al, 1991). Changes in excitability via 
membrane receptor complexes such as the GABAa receptor may underlie fast feedback 
action and rapid changes in excitability of antidromically identified CRH neurones, 
following glucocorticoid iontophoresis, may be involved as well 
(Saphier & Feldman, 1988). Fast feedback is also desensitised upon chronic exposure to 
stress (Young et al, 1990).
(b) Intermediate or delayed feedback mechanism, which involves gene-mediated 
steroid effects on stimulus secretion coupling, excitability, and intracellular signal 
transduction pathways. This operates between one and 24 hours after plasma corticosteroid 
concentrations have risen. The degree of this inhibition is proportional to the integrated 
release of corticosteroids over time and the delay from this release. In this feedback 
inhibition, synthesis of CRH and ACTH are inhibited, rather than their release. It is seen in 
the presence of pathologically high corticosteroid concentrations or following treatment 
with synthetic glucocorticoids such as dexamethasone. Intermediate or delayed-feedback 
can be tested by the suppression of HPA function following dexamethasone administration, 
a test that involves glucocorticoid receptors in the pituitary (Miller et al, 1992). The 
delayed-feedback inhibition is responsible for changes in gene transcription involved in the 
stress response. These changes in gene transcription include decreased CRH expression in 
the hypothalamus (Imaki et al, 1991; Kovacs & Mezey, 1987) and decreased POMC
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(Eberwine & Roberts, 1984) and CRH type 1 receptor expression in the pituitary (Sakai et 
al, 1996).
(c) Genomically mediated feedback, has a much slower time course, whereby 
glucocorticoid receptors negatively control gene expression, decreasing rates of 
transcription of critical genes such as POMC. Indeed, the negative regulation starts 
immediately upon receptor activation by steroids, but its consequences on the cell, in terms 
of mRNA and peptide levels take hours or even days to manifest, because of their intrinsic 
kinetics and the presence of large reserves. It takes place exclusively at the level of the 
gene. It includes the blockade of stress-induced CRH (and AVP) gene expression in 
parvocellular paraventricular nucleus and POMC gene expression in anterior pituitary 
corticotrophs. GRs may control peptide gene expression directly or in interaction with 
other transcription factors (Akerblom et al, 1988). In late-delayed feedback, there is 
reduced transcription of RNA for POMC and reduced translation of POMC from mRNA 
(see Figure. 1.2.).
In a living organism, all these mechanisms are probably activated simultaneously, 
but they come into play in different time domams; fast feedback is likely to set the 
magnitude and duration of each response, whereas genomic feedback sets the range of 
stress responsiveness of an organism. In addition, these feedback mechanisms can be seen 
as different lines of defence, with fast feedback being more sensitive, rapid and brain 
mediated, and genomic feedback being slower but having more profound effects at 
multiple levels of the axis.
The secretion of CRH and AVP appears to be under tight corticosteroid feedback 
control during the basal circadian trough and peak as well as during CRH/AVP responses 
to stressors. Although ACTH-secreting cells in the anterior pituitary respond to 
corticosteroids in vitro, with inhibition of ACTH synthesis and secretion, it seems likely 
that this effect is primarily a positive feedback that is involved during high level 
corticosteroid secretion (Levin et al, 1988). Interestingly, the basal levels of steroids at the
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peak are thought to be sufficiently high to occupy a majority of MR 
(estimates vary from 60% to 90%) but only occupy a small proportion of GR (-10%). 
Thus, there may be elements of the axis (e.g., AVP in mpPVN) that are particularly 
sensitive to circadian drive and are modulated by MR, whereas others are particularly 
stress responsive and only modulated by GR or both receptors.
L2,7. Adaptation
Depending on the stress paradigm, repeated stress can result in adaptation or 
desensitisation of the HPA axis to the homotypic stressor (Kant et al, 1987; Ma & 
Lightman, 1998). However, exposure of repeatedly stressed animals to a novel stress 
usually results in a greater ACTH response than that seen in naïve control animals 
(Hashimoto et al, 1988; Bhatnagar & Dallman, 1998).
There is good evidence that when adaptation to a repeated stressor occurs there is 
preservation or even sensitisation of the hormonal response to a heterotypic stress 
(Vemikos et al, 1982; Aguilera, 1998). This suggests that the hypothalamus, and other 
brain regions, are able to differentiate between different types of stress and modify their 
response in the light of previous experience.
It is possible that adaptation to the repeated homotypic stress is due to 
desensitisation of the afferent pathways to the PVN at the synaptic levels or at the 
parvocellular neurone itself, and that the novel stress uses different pathways and 
neurotransmitters. However, despite the habituation, there is little evidence of 
desensitisation, as AVP responses to the repeated stress are preserved (Ma et al, 1997), and 
microdialysis experiments have shown that noradrenaline turnover to the PVN is increased, 
rather than decreased, during repeated immobilisation (Pacak et al, 1992).
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Different types of stressors (physical vs. psychological, painfiil vs. non-pain&l) are 
likely to engage the system from different starting points. A major stumbling block to 
assess the differences has been the need to develop a strategy for detecting stress activation 
in the CNS. This is a prerequisite to carrying out lesion studies to disrupt the pathway and 
begin to delineate its components. One approach is to measure peripheral indices of stress 
-  corticosterone and ACTH increases in plasma. However, the ability to monitor CNS 
correlates of acute activation by various stressors is critical to discerning the existence of 
unique pathways as well as common elements. The measure has to be rapid enough to 
detect the activation before negative steroid feedback dampens or even reverses the 
response. Several studies (Watanabe et al, 1994; Lee et al, 2001) have been undertaken in 
an effort to map brain regions activated by various stressors, using lEGs such as c-fos, 
c-jun and ziE268 as markers for each neuronal activity.
Stimulatory stressfiil information is conveyed to the PVN through ascending 
catecholaminergic projections from the brain stem (Swanson & Simmonds, 1989; 
Palkovits et al, 1992). In addition, studies based on intermediate early gene expression, 
retrograde tracer, and lesioning of selective pathways have revealed that 
somatosensory/nociceptive stressors, such as restraint, activate limbic areas in the brain, 
includiug the hippocampus, neocortical areas, amygdala, bed nucleus of the stria 
terminalis, and some hypothalamic and thalamic nuclei (CuUinan et al, 1993; Li et al, 
1997). The limbic structures activated by somatosensory stressors all have direct or 
indirect connections to the PVN and contain GABA neurones known to inhibit the HPA 
axis (Herman & CuUinan, 1997). Lesions of the prefrontal cortex, hippocampus, and 
central amygdala have been reported to potentiate HPA axis responses to somatosensory 
stressors, supporting the idea that responses to this type of stressor can be modulated by 
limbic inhibitory circuitry (Herman & CuUinan, 1997). One possible pathway involved in 
the increased responsiveness to the heterotypic stressor is the parabrachial-posterior- 
paraventricular-thalamus-amygdala-parvoceUular-paraventricular-hypothalamus pathway,
64
as lesions of the posterior PVN of the thalamus increase ACTH responses to restraint in 
previously chronically stressed animals, but not naive animals 
(Bhatnagar & Dallman, 1998). Influences from hypothalamic nuclei, such as the arcuate, 
ventromedial hypothalamic, and medial preoptic area, may also affect parvocellular 
neuronal activity during stress. In addition, other neurotransmitters and neuropeptides, 
including CRH itself, could modulate PVN activity through these pathways. Thus, 
processing and integration of somatosensory/nociceptive stimuli in the limbic system could 
activate or suppress inhibitory pathways to the PVN, enhancing or inhibiting parvocellular 
neurone responses depending on previous experiences and the type of stimulus.
1.3. Antidepressants
1,3,1, Mode of Action
There is a high degree of variation among people vdth depression in terms of 
symptoms, course of illness, and response to treatment, indicating that depression may 
have a number of complex and interacting causes. This variability poses a major challenge 
to researchers attempting to understand and treat the disorder. However, recent advances in 
research technology are bringing scientists closer than ever before to characterising the 
biology and physiology of depression in its different forms and to the possibility of 
identifying effective treatments for individuals based on symptom presentation.
Many of the biological theories of depression have been intimately related to the 
chemical effects of antidepressant medications discovered in the late 1950s. Three main 
biochemical theories of depressive illness have been postulated and are summarised in 
Table.1.2.
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Table.1.2. Main Biochemical Theories Of Depressive Illness (Tyrer & Marsden, 1995):-
HYPOTHESIS CHIEF TENET EVIDENCE IN SUPPORT
Amine-deficiency hypothesis Central deficiency of 5-HT and Reserpine-induced depression.
noradrenaline MAOIs and amine-reuptake drugs
are antidepressants
Adrenergic supersensitivity a  and fi central receptors are Most antidepressants down-regulate
hypothesis supersensitive receptors after chronic dosage.
Treatment effects only shown after 
chronic dosage.
Cholinergic hypothesis Excess cholinergic compared Many antidepressants are
with adrenergic activity anticholinergic, cholinergic drugs
may induce depression.
These theories have been developed fi-om evidence available fi-om first generation 
antidepressants, TCAs and MAOIs, and the efficacy and models of action of newly 
introduced atypical compounds need to be considered. New antidepressants have a variety 
of pharmacological actions and although these include several properties possessed by 
TCAs and MAOIs, they show important differences as well. Although there is no common 
pharmacological action possessed by all those compounds demonstrated to have 
antidepressant efficacy, the down-regulation of B-receptors is found with most of the drugs.
Existing antidepressant drugs, except SSRIs, are known to influence the 
functioning of certain neurotransmitters in the brain, primarily the monoamines, serotonin 
and noradrenaline. Previous medications -  TCAs and MAOIs -  affect the activity of these 
neurotransmitters simultaneously. Their disadvantage is that they can be difficult to 
tolerate due to side effects or, in the case of MAOIs, dietary restrictions. Recent 
medications, such as SSRIs, have fewer side effects than the older drugs, making it easier 
for patients to adhere to treatment. Both generations of medications are effective in 
relieving depression, although some people will respond to one type of drug, but not 
another.
66
The “serotonin/noradrenaline/glucocorticoid link” hypothesis of affective disorders 
and the action of antidepressants, postulated by Pryor and Sulser (1991), has integrated the 
glucocorticoid receptor system into an amine hypothesis of affective disorders. A 
fimctional link between aminergic and endocrine signalling (corticosteroids) beyond the 
receptors has been demonstrated in C6 glioma cells at the level of preproenkephalin gene 
expression (Yoshikawa & Sabol, 1986). In vivo, the regulation of preproenkephalin gene 
expression depends on serotonin, as chronic fluoxetine enhanced the expression of 
preproenkephahn mRNA in the rat amygdala, and this effect disappeared in rats with 
depleted concentrations of brain serotonin (Rossby et al, 1996).
Effective antidepressant drug therapy normalises the plasma cortisol levels, but this 
takes at least 2-3 weeks. This suggests that while facilitation of monoaminergic 
neurotransmission may be the initial mechanism of action of most antidepressants, their 
beneficial effects are likely due to adaptive processes beyond the acute effects of the drug. 
These may be mediated by alterations in neuronal gene expression.
Antidepressant medications take several weeks to be clinically effective even 
though they begin to alter brain chemistry with the very first dose. Research now indicates 
that antidepressant effects result firom slow-onset adaptive changes within brain cells, or 
neurones. Further, it appears that activation of chemical messenger pathways within 
neurones, and changes in the way that genes in brain cells are expressed, are the critical 
events underlying long-term adaptations in neuronal fimction relevant to antidepressant 
drug action. A current challenge is to understand the mechanisms that mediate, within 
cells, the long-term changes in neuronal fimction produced by antidepressants and other 
psychotropic drugs and to understand how these mechanisms are altered in the presence of 
depression.
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At least three observations suggest that blockade of monoamine reuptake and 
inhibition of amine metabolism may be insufficient to explain the action of 
antidepressants; (a) iprindole, trazodone and mianserin are clinically effective 
antidepressants despite lacking the above properties and are known as "atypical" 
antidepressants for this reason; (b) reuptake blockade and inhibition of monoamine 
metabolism occur immediately after instigation of therapy, yet clinical signs of 
improvement in depression is generally delayed for 2-3 weeks; (c) cocaine is a blocker of 
amine uptake, but is not an effective antidepressant (Stahl, 1984).
Earlier research was done on the acute effects of these drugs in brain systems, but 
these acute effects do not appear to fully explain their antidepressant effects. It was later 
recognised that their chronic effects were quite different and may be better to help 
understand their therapeutic effects. Long-term studies of drug effects are considered more 
relevant because most antidepressants show a time lag of between one and three weeks 
before effects on mood are seen.
Long-term administration of antidepressant influences monoaminergic systems, not 
only presynaptically but also postsynaptically. Presynaptic and postsynaptic receptors 
change in a complex manner and to a different extent in different brain areas 
(Sulser, 1979; Chamey et al, 1981). Down-regulation is generally involved. A down- 
regulated postsynaptic receptor should be associated with diminished fimction while down- 
regulation of presynaptic receptors should enhance function. Evidence suggests that 
chronic administration of TCAs is associated with a down-regulation of post-synaptic 
p-adrenergic receptor sites accompanied by a loss in sensitivity of adenylate cyclase to 
stimulation by noradrenaline or isoproterenol (Sulser et al, 1978). These changes not only 
occur after treatment with the TCAs and with the MAOIs, but also with atypical 
antidepressants such as iprindole and mianserin and even with ECT (Chamey et al, 1981). 
Enhancement of monoaminergic functions is believed to underlie the therapeutic efficacy 
of antidepressants.
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1,3,2, Effect on the HPA axis
Previous research has shown that there is a neurochemical and a behavioural 
similarity between the response to antidepressant treatment and the response to stressfiil 
stimulation in animals. The neurochemical similarity concerns the regulation of brain 
adrenergic receptors. Both antidepressants and stress, when administered chronically, have 
been found to reduce the density of p-adrenoceptors in various regions of the rat brain 
(Sellinger-Bamette et al, 1980; Stone & Platt, 1982). These reductions are accompanied by 
corresponding decreases in noradrenaline-sensitive adenylate cyclase activity
(Vetulani et al, 1976; Stone & Platt, 1982). The behavioural similarity between 
antidepressants and stress concerns changes in the vulnerability of animals to the adverse 
effects of stress. Both forms of treatment, when given chronically, have been shown to 
make animals more resistant to behavioural deficits caused by exposure to subsequent 
inescapable stress (Sherman et al, 1979).
Consistent findings in depressed patients are hyperactivity in the HPA axis with 
high plasma concentrations of ACTH and cortisol. Long-term antidepressant treatments 
seem to normalise this hyperactivity, suggesting a link between the HPA axis and the 
action of antidepressant treatments.
The process of adaptation to stress has been associated with increases in binding at 
5-HTiA receptors in the hippocampus as well as enhancement of sensitivity to 5-HT 
agonists (Kennet et al, 1985b). On the other hand, prolonged exposure to high levels of 
corticosterone, such as might occur in animals that continue to secrete corticosterone in 
response to a repeated stressor, has been found to reduce numbers of 5-HTia receptors in 
the hippocampus (Mendelson & McEwen, 1992), whereas ACTH treatment increases 
binding to 5-HTi receptors in cerebral cortex. In view of the relationships between stress, 
serotonin and depression, there is reason to suspect that the mechanisms by which the 
antidepressant drugs act may be most obvious when evaluated in animals being subjected 
to stress. Indeed, there is evidence that stress may even enhance the effects of some
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antidepressant drugs. For example, Nankai and colleagues (1991) presented evidence that 
restraint stress enhances the ability of desipramine to down-regulate serotonin transporter- 
binding sites in prefrontal cortex and hypothalamus. These studies raise the possibility that 
stress may alter the effects of antidepressant drugs on regional neurochemistry. Moreover, 
the opposite action of antidepressants, such as imipramine and tianeptine, on serotonin 
uptake raise the question whether these drugs share common effects on brain chemistry or 
produce entirely different patterns of response.
Recent work has raised the possibility that among the many long-term targets of 
antidepressant treatments may be regulation of neurotrophins. A role for BDNF in the 
action of antidepressant treatments is supported by several lines of evidence. First, 
electrical (e.g. ECT) or chemical-induced seizures increase the expression of BDNF and its 
receptor, TrkB, in the brain (Isackson et al, 1991). Second, stress decreases the expression 
of BDNF in the hippocampus and other limbic brain regions (Smith et al, 1995a,b), an 
effect that could contribute to the atrophy of stress-vulnerable neurones in the 
hippocampus (Sapolsky et al, 1985; Stein-Behrens et al, 1994). Stress-induced atrophy, 
and, in extreme cases, cell death, may contribute to the loss of hippocampal control of the 
HPA axis and hypercortisolism often exhibited in depression (Herman et al, 1989b; Young 
eta/,1991).
The different serotonin receptor subtypes are known to selectively couple to and 
regulate several intracellular signal transduction pathways, including the cAMP, 
phosphatidylinositol (PI), and calcium pathways. These intracellular pathways would be 
expected to mediate the actions of drugs that act on the serotonergic system. In addition, 
the influence of long-term activation of these receptor-coupled second messenger systems 
in response to chronic drug administration could lead to adaptations that contribute to the 
therapeutic action of these treatments. Recent studies have begun to examine adaptations 
of these pathways in response to chronic antidepressant administration 
(for a review see Duman et al, 1997a). One system that has been examined in some detail
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is the cAMP second messenger system. It has been demonstrated that chronic 
administration of SSRIs, as well as other types of antidepressants, results in adaptations of 
the cAMP second messenger pathway, including upregulation of CREB.
Upregulation of the transcription factor CREB indicates that specific target genes 
may also be regulated by, and could mediate the action of chronic antidepressant 
administration. Various classes of antidepressants increase the expression of CREB 
(Nibuya et al, 1996). Among the multiple target genes that could be regulated by CREB is 
BDNF (Duman, 1998). Chronic administrations of SSRIs, or other types of 
antidepressants, increase the expression of BDNF and TrkB in hippocampus 
(Nibuya et al, 1996). This may result from adaptations of intracellular pathways. Chronic 
antidepressant drug treatments, like chronic ECS, increase nuclear levels of cAMP- 
dependent protein kinase and CREB (Nestler et al, 1989). Up-regulation of the cAMP- 
PKA-CREB cascade by chronic antidepressant drug treatments could underlie the 
increased expression of BDNF and TrkB mRNA.
The possibility that increased expression of BDNF and TrkB results fi-om 
upregulation of the cAMP pathway and CREB is supported by both correlative and direct 
information. First, the time course for both increased expression of CREB and BDNF/TrkB 
is similar, and the expression of both CREB and BDNF/TrkB is observed in the same 
layers of hippocampus (i.e., CAl and CA3 pyramidal and dentate gyrus granule cell layer). 
Second, infusion of CREB antisense decreases basal and ECS induction of BDNF in 
hippocampus (Duman et al, 1994). Third, chronic administration of inhibitors of 
phosphodiesterase, the enzyme responsible for cAMP breakdown, increases the expression 
of CREB and BDNF (Nibuya et al, 1996). Fourth, studies in cultured cells demonstrate 
that activation of the cAMP pathway increases the expression of BDNF and TrkB 
(Condorelli et al, 1994). These results indicate that the expression of BDNF and TrkB are 
positively regulated by the cAMP pathway and CREB.
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Although the hypothesis that antidepressant treatments lead to an increase in 
neurotrophin concentrations because of activation of CREB (Duman et al, 1997b) is 
attractive, some data is not consistent with it. For example, chronic administration with 
venlafaxine did not elevate the mean steady-state concentration of CREB mRNA and also 
significantly reduced the amount of phosphorylated CREB in nuclear lysates of the rat 
cortex (Rossby et al, 1999).
One effect of BDNF, that could be relevant to the therapeutic actions of 
antidepressants, is regulation of serotonin neurones. Local infusion of BDNF into midbrain 
or cerebral cortex is reported to increase serotonin levels (Siuciak et al, 1994) and to 
protect serotonin neurones fi-om neurotoxin-induced damage (Mamounas et al, 1995).
Repeated stress can result in neuronal atrophy and death of vulnerable neurones, 
and can increase the vulnerability to other neuronal insults, including excitotoxins, 
hypoxia-ischaemia, and hypoglycaemia (McEwen & Gould, 1990; Stein-Behrens et al, 
1994). In addition to increasing the expression of BDNF mRNA, the ability of 
antidepressant treatments to block the down-regulation of BDNF mRNA by stress could 
also help reduce the damaging effects of stress. In support of this hypothesis, chronic 
administration of an atypical antidepressant, tianeptine, is reported to block the atrophy of 
hippocampal neurones resulting fi-om stress (Watanabe et al, 1992).
Future studies will determine if chronic antidepressant treatments have similar 
neuroprotective effects against stress, as well as other neuronal insults. In addition, 
elevated expression of BDNF could play a role in the reinstatement of hippocampal 
feedback inhibition of the HPA axis in response to antidepressant treatments: 
hypercortisolism in depression is thought to result, at least in part, fi-om loss of 
hippocampal inhibition (Young et al, 1991).
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Several antidepressants, such as imipramine, fluoxetine, idazoxan and phenelzine, 
have been shown to decrease CRH gene expression in the rat PVN (Brady et al, 1992). 
Although long-term administration of tianeptine did not alter CRH mRNA levels, 
indicating that the reduction of CRH content in the hypothalamus cannot be ascribed to an 
action at the transcriptional level (Delbende et al, 1994). This study, in agreement with 
other reports (Chappell et al, 1986), revealed that chronic administration of tianeptine 
reversed the effects of stress at different levels of the HPA axis. Acute stress was shown to 
cause a significant reduction of CRH content in the hypothalamus without affecting ACTH 
level in the pituitary, and chronic treatment abolished stress-evoked inhibition of CRH. 
Similarly, tianeptine significantly reduced the increase in plasma ACTH and corticosterone 
levels induced by restraint stress (Delbende et al, 1994). It is believed that tianeptine 
modulates the activation of the HPA axis through its capacity to reduce the availability of 
serotonin to its receptors. Since TCAs increase the glucocorticoid receptor level in the 
hippocampus and hypothalamus (Figure.1.6; Peiffer et al, 1991), the modulatory activity of 
tianeptine on the HPA axis might be mediated through restoration of the negative feedback 
action of glucocorticoid hormone at the hippocampal or hypothalamic level.
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Figure.1.6. A novel mechanism for antidepressants acting on the HPA system. 
Schematic representation of the antidepressant-induced increases in GR and MR gene 
expression that suggests a novel mechanism of action for these drugs on the HPA system. 
Stimulatory (+) and inhibitory (-) actions of neural inputs to brain regions involved in 
HPA-system regulation, and the sites of corticosteroid regulation are shown. The sites, at 
which antidepressants have stimulatory actions on GR or MR, or both, are indicated. 
(Barden et al, 1995).
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1.4. Aims and Objectives of the Thesis
Several classes of antidepressants have been demonstrated to increase 
corticosteroid receptor binding and mRNA in various regions of the rat brain over a period 
similar to the time course in which therapeutic effects are observed in depressed patients. 
For this reason, it has been suggested that the up-regulation of corticosteroid receptors, 
thus normalising defective HPA activity, may be a mechanism common to the various 
classes of antidepressants used in the therapy of depression.
Many studies have focused their investigations on corticosteroid receptor 
alterations in adrenalectomised or ‘naive’ animals in animal models of depression. 
Adrenally-intact animals were used in these studies in order to determine the possible 
changes in GR in animals that have not undergone any surgical procedures and in the 
presence of endogenous ligand, thereby allowing for a closer comparison to clinical 
observations of GR alterations following stress and antidepressant administration.
Restraint stress was used as an established animal model of depression, to define 
transcriptional and translational mechanisms underlying HPA axis regulation in vivo, by 
examining GR mRNA, CRH type 1 receptor mRNA and BDNF mRNA. The features of 
restraint stress as a stress paradigm (chapter 5 and 7) suggest that a dysfiinctional HPA 
axis, as reflected by defective negative feedback resulting firom stress-induced 
corticosteroid receptor down-regulation, would be observed. Behavioural and 
endocrinological investigations (chapter 3 and 4) were conducted on the predator stress 
model, as it has not been studied or developed as extensively as the restraint stress 
paradigm has.
The work presented in this thesis is primarily concerned with monitoring HPA axis 
alterations under various stress situations and following administration of an SSRI, namely 
paroxetine, using plasma levels of corticosterone and ACTH as indicators of stress. Plasma 
corticosterone and ACTH were measured using radioimmunoassays, glucocorticoid 
receptors were quantified using radioligand-binding assays, and GR mRNA, CRH type 1
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receptor mRNA and BDNF mRNA were quantified using RT-PCR and agarose gel 
electrophoresis.
Measurements were also made to compare endocrinological measures with behavioural 
parameters (elevated plus-maze and/or sucrose preference) as measured in the restrained 
rat, and a stress-related paradigm encompassing predator stress exposure. Therefore the 
aims of this work were;
1. To establish a behavioural paradigm based on predator stress, which could be expanded 
to a potential model for chronic stress/depression.
2. To determine the effects of predator stress on elevated plus-maze measures, sucrose 
preference, plasma corticosterone and glucocorticoid receptor binding in various brain 
regions of mice.
3. To examine the effects of acute and chronic restraint stress on anhedonia, as well as 
GR binding, GR mRNA, CRH type 1 receptor mRNA and BDNF mRNA in various 
brain regions of rats.
4. To investigate the effects of acute and chronic administration of an SSRI, paroxetine, 
on anhedonia, plasma corticosterone and ACTH secretion, as well as GR binding, 
GR mRNA, CRH type 1 receptor mRNA and BDNF mRNA in various brain regions of 
rats.
5. To investigate the effects of acute and chronic administration of an SSRI, paroxetine, 
in combination with restraint stress on anhedonia, plasma corticosterone and ACTH 
secretion, as well as GR binding, GR mRNA, CRH type 1 receptor mRNA and BDNF 
mRNA in various brain regions of rats.
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CHAPTER 2. BIOCHEMICAL METHODS AND MATERIALS
2.1 Introduction
In this initial experimental chapter, the basic methodology employed in this thesis 
will be described.
2.2 Introduction to radioligand binding studies
Receptor binding studies are possible because of the high affinity that some 
agonists and antagonists have for their receptor. Consequently, at low concentrations of 
drug, a high proportion is bound to the receptor compared to the proportion which binds to 
non-receptor sites. Although only minute amounts of receptor are present in most tissues 
(typically less than Ipmol/mg protein), the amount of drug bound can be measured by 
radiolabelling it and measuring the amount of radioactivity bound to the tissue. It is 
essential to separate the bound drug from that which is free in solution, and this can be 
achieved by filtration (drug bound to the tissue is retained on the filter paper, but unbound 
drug passes through) or by centrifugation (in which the bound drug is trapped in the tissue 
pellet).
Prior to the widespread use of in vitro binding assays, the properties of receptors 
were inferred from the measurement of biological responses. The utilisation of radioligand 
binding assays to characterise receptors provides an enormous amount of information and 
also a direct approach to the study of drug-receptor interactions.
Ligand binding techniques are a direct means of studying drug or neurotransmitter- 
receptor interactions. They use the capacity of highly radiolabelled compounds to interact 
with specific receptors in a given tissue. Ligands are chosen for their high afiSnity for a 
specific type of receptor and tissue containing a high density of that particular receptor is 
usually studied. However, this is not always the case, especially in the brain. Frequently a 
particular ligand will label more than one receptor and a given tissue will invariably
77
contain different receptors. This implies that careful consideration must be given to the 
methodology employed and to the definition of specific receptor.
2,2, L Receptor binding assay procedure
Tissue preparations containing the receptor of interest are incubated to equilibrium 
with one or more concentrations of the appropriate radioligand. Separation of the bound 
firom firee ligand is dependent on the equilibrium dissociation constant {Kè) of the 
radioligand for the binding site. For ligands with K6. values of lO’^ Mor less, rapid vacuum 
filtration through glass fibre filters is generally the most appropriate method whereas for 
ligands with higher values, separation by centrifugation, column chromatography and 
precipitation of Hgand-receptor complex and adsorption of fi-ee ligand techniques are 
applied (Bylund, 1992).
In the case of vacuum filtration, the radioactivity bound to the filter is termed the 
total binding. This consists of:
i) Specific receptor binding - radioligand bound to its binding site on the 
receptor of interest and;
ii) Non-specific binding - radioligand bound to other non-receptor 
components in the tissue preparation (e.g. membrane proteins and lipids, 
glass fibre filters).
The non-specific component of this binding can be measured by the inclusion of 
parallel samples of a non-radioactive compound that is known to interact with the receptor 
system under investigation at a concentration sufficient to totally displace the radioligand 
fi'om specific binding sites.
There are two types of experimental protocols that have been used during this
thesis:
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1. Saturation binding experiments measure the equilibrium binding of a range of 
concentrations of the radioactive ligand (^H-dexamethasone). The relationship between 
binding and ligand concentration can be analysed to determine the number of sites, Bmax, 
and the ligand affinity, Kd of certain receptors (glucocorticoid) within particular brain 
regions (cortex and hippocampus).
2. Competitive binding experiments measure equilibrium binding of a single 
concentration of radioligand at various concentrations of an unlabelled competitor. This 
data can be analysed to determine the affinity of the competitor for the receptor.
2.3 Corticosteroid receptor binding assay using rat and mouse brain tissues 
2,3.L Animal husbandry
Experiments were carried out using male Wistar rats (body weight 200 -  250 g) 
bred in the Biological Research Facility at St. George’s Hospital Medical School or male 
BALB/c mice (body weight 20-25 g) from the Nescot breeding colony. Animals were 
group-housed and maintained in a temperature (19-22°C) and light 
(light period 07.00-21.00 h) controlled room. A standard laboratory diet and drinking water 
were available ad libitum.
2,3,2,Dissection of rat and mouse brain regions
Male Wistar rats and male BALB/c mice were killed by cervical dislocation and 
decapitation. The brain was rapidly removed onto ice and the cortex and hippocampi 
dissected as follows. The cortices were separated and dissected on either side of the mid­
line with curved iris forceps. The hippocampi, which were clearly visible, were removed 
by gently teasing them out from under the cerebellum and away from the cortices with the 
iris forceps, and placing them into ice-cold vials. The striata, which were clearly visible, 
were removed by pinching them with the iris forceps, care being taken not to remove any 
underlying tissue. The cortices were then carefrilly cut away from the rest of the brain, and
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cut into quarters (rat brain) or left as halves (mouse brain) and placed into separate ice-cold 
vials.
2.3.3. ^H-Dexamethasone Radioactive Ligand
^H-Dexamethasone (specific activity 81 -  89 Ci/mmol) was obtained fi*om 
Amersham International Pic. The ligand was kept at -20°C and diluted to the required 
concentrations with incubation buffer on the day of the experiment.
2.3.4,Buffers
For list of drugs and chemicals (and suppliers), see section 2.6.3. All buffers for the 
receptor binding assays were made with distilled water. The required pH at 20°C was 
achieved by using 6 M HCl. The buffers were kept at 4°C or on ice throughout the 
experiments.
i) Incubation buffer (TEDGM) (pH 7.4):
Component (final assay concentration)
10 mM Tris
1 mM EDTA (disodium salt)
35 mM Sodium molybdate
1 mM DTT
10 % Glycerol
ii) Wash buffer (pH 7.4):
10 mM Tris-HCl buffer
80
2.3.5. Tissue Preparation
Rat or mouse cortex and hippocampi were homogenised in 20 or 30 volumes (w/v), 
respectively, of ice-cold incubation (TEDGM) buffer (pH 7.4), using a motor driven teflon 
pestle and glass homogeniser (homogeniser speed 1400 rpm x 10 up/down strokes). The 
resulting homogenate was centri&ged at 105,000 x g for 1 h 10 min at 4°C using an 
Optima L70 Ultracentrifuge fitted with a 70.1 Ti rotor (Beckman Instruments Inc). The 
resulting supernatant was decanted immediately and stored on ice for the assay.
2.3.6,GR binding assay incubation procedure (general)
Assays were performed in 10 mL borosilicate test tubes (16mm x 16mm x 100mm), 
which were maintained on ice throughout the assay procedure. The total incubation volume 
for the assay was 250pL consisting of:
i. 100 pL of tissue cytosolic preparation (equivalent to 5 mg wet weight of original 
tissue).
ii. 100 pL of ^ H-dexamethasone solution (0.625-20 nM final assay concentration)
iii. 50 pL displacing compound (at a range of concentrations) or 10% EtOH (the 
diluent for the displacing compound)
Total binding containing the tissue preparation, ^H-dexamethasone and 10% EtOH 
was determined in duplicate.
Non-specific binding containing the tissue preparation, ^H-dexamethasone and the 
displacing agent was determined singly or in duplicate.
The assay was initiated by the addition of tissue supernatant following which the 
tubes were thoroughly mixed and placed in a refi*igerator, at 4°C, for approximately 24 h 
(20-26 h). Tissue supernatant was also stored at -70°C for subsequent protein 
determination using the method of Lowry and colleagues (1951).
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2,3,7.Separation of bound andfree radioligand
The assay was terminated by rapid vacuum filtration (600 mm Hg) through 
Whatman glass fibre GF/F filter strips (Whatman International Ltd, U.K.), pre-treated for 
approximately 24 h with 0.3% PEI, using a Brandel Cell Harvester (Semat Technical Ltd, 
U.K.). The filters were quickly washed with 16 mL of ice-cold lOmM Tris-HCl wash 
buffer (pH 7.4). This minimised the amount of non-specific binding bound to the glass 
fibre filters. The procedure of filtration and washing was conducted over approximately 
15 sec.
2.3.8,Determination of radioactivity and scintillation counting
The glass fibre filters were cut out of the strips and placed into individual 10 mL 
plastic scintillation vials. 6 mL of scintillation fluid (Optiphase Safe, Wallac, U.K) was 
added and the vials capped and shaken for 1-2 h before being transferred to the liquid 
scintillation counter (2200CA Tri-Carb LSC, Packard Instruments, U.K.) for the 
determination of radioactivity.
2.3.9. ^ H-dexamethasone standards
The amount of radioligand added to the assay on each experimental day was 
determined by the inclusion of standards. These consisted of 100 pL aliquots of each 
concentration of ^H-dexamethasone used in the assay and were used for subsequent 
calculations. They were prepared, in duplicate, on each experimental day and counted to 
determine the total assay concentration of radioligand.
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2.3.10. Calculations and analysis o f results
Specific binding was defined as the difference between total binding and that 
occurring in the presence of a maximum concentration of displacing agent 
(non-specific binding). This was calculated as the difference of the mean values of 
replicate determinations of total and non-specific binding. The blank 
(radioactive counts determined by only 6ml of the scintillation cocktail) were subtracted 
fi*om all the standards as well as the total and non-specific values. The precise method of 
calculation will be given in greater detail in each experimental section.
2.3.11, Determination of the saturability of^H-dexamethasone binding to rat cortical 
cytosolic preparations
1, Introduction
Saturation experiments investigate the specific binding of ligand to the receptor at 
various concentrations of radioligand to obtain estimates for Bmax (a measure of the 
receptor concentration in the sample) and Kd (the equilibrium dissociation constant). One 
of the most important and relevant uses of Bmax and determinations by saturation 
binding studies is the estimation of changes in receptor concentration and affinity in 
disease or following pharmacological or other experimental interventions.
This section aims to demonstrate that the GR assay method used in the present 
experiments generates reliable saturation binding data relating to the specific binding of 
^H-dexamethasone to rat cytosolic tissue preparations.
2 Methods
Assay procedures were carried out as described in section 2.3. Binding was 
determined at a range of ^ H-dexamethasone concentrations (0.625-20nM). Specific binding 
was defined in the presence of 0.5pM RU 28362.
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3. Calculations and analysis o f results
Radioactivity from saturation experiments (in dpm) were converted to the 
appropriate units (^H-dexamethasone standards to nM, and TB and NSB incubations to 
finoles/assay). Mean values were obtained from the replicate determinations of TB and 
NSB following which specific ^H-dexamethasone binding was calculated by subtracting 
NSB values from TB values.
The converted data was subjected to non-linear regression analysis 
(GraphPad Prism v2.1) to give estimates of Bmax and Ka following which, Bmax values were 
converted to finoles/mg protein using protein values determined for each of the samples. 
For the preliminary saturation experiments, the data were also displayed as Scatchard plots 
with subsequent linear regression analysis, visual inspection of which provided some 
indication as to whether the hgand-receptor interaction being studied was described 
adequately by a simple bimolecular reaction. Hill plots of the saturation data enabled the 
quantitation of deviation of the hgand-receptor interaction from the law of mass action. 
Differences in binding constants between groups were determined using Students t-test or 
ANOVA with a significance level set at p<0.05.
4. Results
Figure 2.1(A) shows a typical saturation plot of ^H-dexamethasone binding. The 
non-specific binding of ^H-dexamethasone in rat cortical preparations increased linearly 
over the hgand concentrations 0.625-20 nM. The total and specific binding 
(defined using 0.5 pM RU 28362) of ^ H-dexamethasone appeared to saturate at the higher 
hgand concentrations.
Non-linear regression analysis yielded a Bmax value of 23.6 finoFassay, equivalent 
to a Bmax of 171 finoFmg protein. A Kd value of 2.41 nM was obtained from this plot.
84
Figure 2.1(B) shows a Scatchard plot of the data in Figure 2.4.1(A) with subsequent 
linear regression analysis resulting in a Bmax of 23.5 finoFassay equivalent to a Bmax of 170 
finoFmg protein and a Kd of 2.17 nM.
Figure 2.1(C) shows a Hill plot of the saturation data from Figures 2.4.1(A) and 
2.4.1(B). A Hill coefficient (nn) of 1.23 ± 0.21 was obtained from this plot.
The results of several saturation assays are shown in a representative plot 
(Figure 2.1.). Non-linear regression analysis using a one-site binding model resulted in 
similar values for binding parameters as Scatchard analysis. Statistical analysis of the data, 
using t-tests showed no significant differences between Bmax values estimated by non­
linear regression and those estimated by Scatchard analysis (whether expressed in finoFmg 
tissue or finoFmg protein). One-way analysis of variance of the Kd data showed no 
significant differences in Kd values when calculated using non-linear regression, Scatchard 
or Hill analysis.
The mean Bmax value calculated from these experiments (using non-linear 
regression analysis) was 139 ± 12 finoFmg protein and the mean Kd value calculated was 
2.15 ± 0.38 nM.
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(A) Representative saturation plot of 
H dexamethasone binding to GR in 
rat cortical cytosolic preparations.
GR binding assays were carried out as 
described in section 2.3. Data represent 
the mean (± standard deviation) for total 
binding and non-specific binding 
determinations in duplicate. At a ligand 
concentration of 3nM, mean (± SD) 
values for bound dpm were;
Total binding = 2348 ± 52 
Non-specific binding = 533 ± 0 
Specific binding = 1815 + 52 
% specific binding = 77.3%
Bmax = 23.6 fmol/assay
Equivalent to 171 finol/mg protein 
Kd = 2.41 nM
(B) Scatchard plot of H-
dexamethasone binding to GR in a rat 
cortical cytosolic preparation (using 
data shown in Figure 2.1 A)
Binding parameters (Bnjax and Kq) were 
calculated using linear regression
analysis. Values obtained were;
(C)
Bmax= 23.5 fmol/assay
(converted using protein 
finol/mg protein)
Kd = 2.17 nM
value=170
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(C) Hill plot of ^H-dexamethasone 
binding to GR in a rat cortical 
cytosolic preparation (using data 
shown in Figure 2.1A).
y-axis = LoglO (B/(B„,ax-B)) where;
B = specific ^H-dexamethasone 
binding at particular ligand 
concentration.
Bmax = Bmax values using 
Scatchard analysis.
Linear regression analysis was used to 
calculate the slope of the plot, which 
corresponds to the Hill coefficient.
Hill coefficient (nH) = 1.23+ 0.21 
The Hill binding constant {K^  of "H- 
dexamethasone is calculated fi-om the x- 
axis where log 10= (B/(Bmax)) = 0
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2.3.12. Selective displacement of ^ H-dexamethasone binding to rat cytosolic preparations 
using competition binding assays
1. Introduction
Competition experiments are important in defining the pharmacology of the 
binding between the ligand and the receptor. Given a single radioligand whose affinity for 
a particular receptor subtype has been established, radioligand competition assays provide 
a means for determining the binding affinity of any other unlabelled compound for the 
same receptor. Applications of the radioligand competition experiment include the 
validation of assays, screening for identification of ligands for a particular receptor, 
investigation of the interactions of various compounds with receptors and the 
determination of receptor density and affinity by use of the same compound as the labelled 
and unlabelled ligand. Competition experiments measure the binding of a single 
concentration of radiolabelled ligand in the presence of various concentrations of 
unlabelled ligands. The generation of an inhibitory constant, I C 5 0  or Ki is generally the 
purpose of performing displacement binding assays.
2. Methods
Assay procedures were carried out as described in section 2.3. Competition studies 
were carried out at a single concentration of 3nM ^H-dexamethasone. Compounds tested 
for competition were added in concentrations ranging fi-om 5x10’^  ^ to SxlO'^M. Specific 
binding was defined using 0.5pM RU 28362. The compounds tested for displacement of 
^H-dexamethasone binding to corticosteroid receptors were RU28362, dexamethasone, 
corticosterone, hydrocortisone, aldosterone and ethanol.
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3. Calculations and analysis o f results
Mean values were calculated from the replicates and converted to % specific 
binding. 1 0 0 % and 0 % specific binding were equivalent to the amount of 
^H-dexamethasone binding in the absence and presence of 5pM hydrocortisone, 
respectively. Competing drugs were tested over a range of concentrations for their capacity 
to compete for this specific binding. The data was plotted on a semilogarithmic plot 
resulting in a displacement curve and an IC50 value was determined by non-linear 
regression analysis (GraphPad Prism v3.0). This was subsequently used to calculate the Ki 
for each unlabelled compound using the equation of Cheng and Prusoff (1973). Ki values 
are expressed in Table 2.1. as geometric means of several determinations as, due to the log­
normal distribution of drug affinities, these appear to be best described in this manner 
rather than by using arithmetic means.
4, Results
Table 2.1. summarises the competition experiments for each compound tested while 
Figure 2.2. displays representative competition experiments for each compound. 
Comparison of one-site vs two-site competitive binding was determined using Graphpad 
Prism v3.0, using an F-test (Table 2.2). All of the steroids tested competed for specific ^H- 
dexamethasone binding to rat cytosolic fractions in a concentration-dependent manner. The 
affinity of competitors for ^H-dexamethasone binding to GR ranged from 0.018 -  6.03nM 
with the following rank order of potency; RU28362 > dexamethasone > corticosterone > 
hydrocortisone > aldosterone, with no displacement of specific binding by EtOH. These 
results from the competition binding studies have also demonstrated a glucocorticoid-like 
pattern of receptor binding (Vedder et al, 1993).
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Table 2.1.
Displacement of specific ^ H-dexamethasone binding to GR in rat cytosolic preparations by 
RU 28362, dexamethasone, corticosterone, hydrocortisone, aldosterone and ethanol.
COMPOUND TESTED 
FOR DISPLACEMENT
Ki
(nM)
RU 28362 0.018 (0.0068-0.049)
Dexamethasone 0.87 (0.48-1.58)
Corticosterone 3.16 (1.15-8.69)
Hydrocortisone 4.83 (2.06-11.32)
Aldosterone 6.03 (3.23-11.2)
EtOH —
Summary of values obtained from experiments testing the displacement of specific 
^H-dexamethasone binding to GR in rat cytosolic preparations by various compounds. Data from 
four independent experiments conducted on separate occasions were fitted to one-site competition 
curve resulting in estimations of IC50 (concentration of unlabelled compound which causes 50% 
displacement of maximal binding) from which Kj (affinity of the competing compound for the 
receptor) was calculated using the Cheng-Prusoff equation for each compound. The Kd value of ^ H- 
dexamethasone binding obtained in parallel saturation experiments used in these calculations was 
2.5nM. Ki is expressed as a geometric mean with numbers in parentheses indicating the range for
each value.
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Displacement of specific ^H-dexamethasone binding from GR in rat cytosolic preparations by 
RU28362 (A), dexamethasone (B), corticosterone (C), hydrocortisone (D), aldosterone (E) and 
EtOH (F). Rat cytosolic fractions were prepared as described in section 2.3.5. Data shown is from a 
single experiment and fitted to a one-site and/or a two-site competition curve.
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Table 2.2.
Comparison of two-site vs one-site analysis of the competion binding data.
RU 28362
Dfii,Dfd 4 ,1 7
F 1.948
P value 0.07
Best Fit Equation One-Site
DEXAMETHASONE 
Dfii,Dfd 2 ,  19
F 8.384
P value 0.0025
Best Fit Equation Two-Site
CORTICOSTERONE 
Dfii,Dfd 2721
F 26.06
P value <0.0001
Best Fit Equation Two-Site
HYDROCORTISONE 
Dfii,Dfd 2 ,  12
F 4.771
P value 0.0299
Best Fit Equation Two-Site
ALDOSTERONE
Dfii,Dfd 2 ,21
F 2.57
P value 0.06
Best Fit Equation One-Site
Data from the individual experiments from Figure2.2 were fitted to one-site and two-site 
competition curves to determine the comparison of fits.
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2.3.13, Statistical analysis
Statistical evaluations were carried out using one- and two-way analysis of 
variance, according to the data, as well as the Student’s t-test. The level of significance was 
chosen as p < 0.05. A more detailed account of data compilation and subsequent analysis 
will be given in each experimental section.
2.3.14. Protein determination using the Lowry Method
1. Introduction
Protein content in our tissue samples was estimated using the colorimetric method 
of Lowry et al (1951). This method utilises hydrolytic reactions to break the protein down 
into its constitutive amino acids. A coloured complex results fi-om interactions between an 
alkaline copper-phenol reagent and tyrosine and tryptophan residues in the protein. The 
protein content of the sample is estimated via a spectrophotometric reading of absorbance.
2. Methods
The Lowry protein assay was adapted firom the standard protocol 
(Lowry et al, 1951). The presence of Tris and glycerol as components of the incubation 
buffer used in the CR assay, posed a problem. These two compounds are found to interfere 
with the measurement of protein by the Lowry method by contributing blank colour and/or 
decreasing chromophore development with protein (Rej et al, 1974). This distortion was 
overcome by diluting the tissue samples with distilled water (1:4) therefore effectively 
diluting out the interfering components. Incorporation of the same amounts of these 
compounds in the standards also overcame the problems we encountered. The standard 
curve was therefore constructed in incubation buffer that had been diluted with distilled 
water by the same factor as the samples for the protein assay.
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3. Results
Standard curves obtained in the Lowry protein assay were linear over the range of 10-80pg 
BSA (see Figure 2.3.).
Figure 2.3.
Protein determination using the Lowry method
0.8-1
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I  -0 0.4-
1
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▼ BSA concentration
mean protein concentration  
attained in Low ry a s s a y s
Standard curve and mean protein concentration obtained using the Lowry assay. Standard curves 
were linear over the range of 10-80pg BSA. Average values in our studies were 41pg/100pL 
volume (160 pg/assay when multiplied by 4, the dilution factor for the tissue samples).
4. Protein determination using Lowry method
Protein values obtained using this method were very consistent. Dilution of the 
samples and construction of the standard curve in diluted incubation buffer overcame the 
problem of interfering compounds such as Tris and glycerol.
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2.4 Radioimmunoassay (RIA)
2,4. L Introduction
The gamma-B corticosterone assay kit (Immunodiagnostic Systems Ltd (IDS), 
Tyne and Wear) utilised ^^^I-labelled corticosterone and a specific anti-corticosterone 
antiserum, the ACTH assay kit (Diagnostic Systems Limited (DSL), USA) utilised 
^^ I^-labelled ACTH and a specific anti-ACTH antiserum to determine the levels of 
corticosterone and ACTH in EDTA-plasma samples by the double antibody technique.
Radioimmunoassay follows the basic principle that there is competition between a 
radioactive and non-radioactive antigen for a fixed number of antibody binding sites. The 
percentage BOUND radiolabeUed antigen decreases as a function of the increasing 
concentration of unlabeUed antigen in the test sample. Separation of the BOUND and 
FREE radiolabelled antigen is necessary in order to determine the quantity of unlabelled 
antigen. This is accomplished by the addition of a second antibody directed towards the 
immunoglobulin present in the original antiserum. The quantity of unlabelled antigen in an 
unknown sample is then determined by comparing the radioactivity of the precipitate, after 
centrifugation and decanting, with values established using known standards in the same 
assay system.
2.4,2, Preparation o f Samples
For Chapter 4, trunk blood was collected in chilled, 50ml centrifuge tubes. The 
blood was stored at -20°C for 1 h and then left at room temperature for 20 min. The blood 
clot was dislodged and the supernatant transferred, by careful pipetting, to a clean 
centrifuge tube. The supernatant was then centrifuged in a Centaur centrifuge at room 
temperature (2000 x g for 10 min). Plasma was stored in plastic tubes at -70°C.
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For Chapters 5-7, trunk blood was collected in ice-chilled, 10ml EDTA-coated 
tubes. Samples were immediately centrifiiged in a Centaur centrifuge at room temperature 
(2,500 X  g  for 20 min), and plasma aliquots were stored at -70°C until analysis of 
corticosterone and ACTH concentrations. The sensitivity of the corticosterone assay was
0.39ng/ml, and the ACTH assay was 3.5pg/ml.
Due to the high concentrations of corticosterone and ACTH within the plasma, 
samples were diluted with either corticosterone buffer (1:10 dilution) or ACTH buffer 
(1:2 dilution).
Tubes were prepared in duplicate for TC, NSB, Bo, corticosterone standards and 
samples as described in the RIA kit protocol. The amount of radioactivity in the tubes was 
counted for at least 1 minute in a gamma counter.
2.43. Specificity
According to data supplied by the manufacturer of the kit, the cross-reactivity of 
the ACTH antiserum has been measured against various compounds (Table. 2.3.). The 
percent cross-reactivity is expressed as the ratio of the ACTH concentration to the 
concentration of the reacting compound at 50% binding of the 0 pg/ml ACTH Standard.
95
Table 23.
The cross-reactivity of the ACTH antiserum in the commercial kit 
against various compounds.
COMPOUND % CROSS­
REACTIVITY
ACTH (1-39) 100
ACTH (1-24) 100
ACTH (22-39) 0.03
a-Melanotropin 0.09
ACTH (1-10) ND
ACTH (4-11) ND
ACTH (34-39) ND
p-Melanotropin ND
T-Melanotropin ND
Corticotropin-Like Intermediate Peptide ND
ND = Non-Detectable (<0.01)
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2.5. RNA extraction with reverse-transcriptase polymerase-chain reaction (RT-PCR) 
and Agarose gel electrophoresis.
2.5,1. RNA Extraction
1. Materials
Glassware, materials and solutions were treated with DEPC to inactivate RNases. 
Glassware, Eppendorf tubes and tips were soaked in distilled water with 1% (v/v) DEPC, 
incubated at 37°C overnight, and then autoclaved.
2. Homogenisation
Frozen rat cortex (0.1-0.2g) was weighed and transferred to the glass-teflon 
homogeniser, on ice, and a 10 x weight of cortex, of RNA isolator™ was added. The tissue 
was homogenised at 1400 revolutions per minute (6 up and down strokes), and was kept on 
ice throughout. The RNA Isolator™ contains chaotropic agents, which rapidly denature 
and inactivate cellular RNases, but homogenisation was also performed rapidly in order to 
immediately inactivate the RNases. The tissue homogenate was divided into equal 
proportions and transferred to Eppendorf tubes and incubated in a fume-cupboard for 
7 min at room temperature to permit complete dissociation of nucleoprotein complexes.
3. Phase separation
Phase separation was achieved by adding 0.2 ml of chloroform per 1 ml of RNA
Isolator™. The tubes were capped and mixed by gentle inversion until completely
emulsified, resulting in a pale-pink cloudy solution. They were incubated at room
temperature, in the fiime-cupboard, for 15 min and centrifuged in a JOUAN A14
microcentrifiige, at 12500 x g for 15 min, at 4°C. The contents of the tubes separate into 3
distinct layers: a lower red, phenol-chloroform phase; a white opaque interphase; and a
colourless, upper aqueous phase. The low pH of the phenol allows the RNA to selectively
partition into the aqueous phase, fi*ee fi*om DNA and protein, which remain in the organic
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phase. The volume of the top aqueous layer is about 60% of the volume of RNA isolator™ 
used for homogenisation.
4. RNA precipitation
The top, aqueous phase was carefully pipetted into an Eppendorf tube, therefore 
still resulting in two Eppendorfe per sample. The isolated RNA was concentrated by 
precipitation with isopropanol.
The precipitation of DNA and RNA, which is allowed to form in the presence of 
moderate concentrations of monovalent cations, is recovered by centrifugation and re­
dissolved in an appropriate buffer at the desired concentration. This technique is rapid and 
is quantitative even with picogram amounts of DNA and RNA. The three major variables 
are:
1. The temperature in which the precipitate is allowed to form.
2. The type and concentration of monovalent cations used in the precipitation mixture.
3. The time and speed of centrifiigation.
Therefore 1 ml of isopropanol was added to each tube, and the contents mixed by 
gentle inversion. 400 pi was transferred to an Eppendorf tube, resulting in 3 tubes each 
containing ~800 pi of solution. Five hundred microlitres of isopropanol was added to each 
tube, and the contents mixed by gentle inversion. This resulted in a cloudy solution, 
suggesting the precipitation of RNA. The tubes were incubated for 15 min, at room 
temperature, to allow fiiU RNA precipitation to occur. The tubes were centrifuged m a 
JOUAN A14 microcentrifiige, at 8700 x g for 15 min, at 4®C and the supernatant was 
decanted without disturbing the gel-like pellet, containing RNA.
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5. RNA wash
The pellet was washed once by adding 1 ml of 75% ethanol and mixed by gentle 
inversion, to remove any contaminating salts that may inhibit enzymatic reactions. 
Therefore, using at least 1 ml of 75% ethanol per 1 ml of RNA Isolator™ used for the 
initial homogenisation. The tubes were centrifuged in a JOUAN A14 microcentrifuge, at 
5600 X g for 5 min, at 4°C. The ethanol was decanted without disturbing the pellet, and the 
tubes were dried on absorbent tissue in a fume-cupboard for 5 min, with the vent on. 
Complete evaporation of the 75% ethanol wash is required when the RNA samples are to 
be used for RT-PCR, as any residual ethanol may affect enzyme activity. After drying, all 
remaining ethanol will have evaporated leaving only the pellet and possibly water in the 
tubes. It is important not to let the RNA pellet dry completely as this will greatly decrease 
its solubility.
The pellets in two of the tubes, were then re-suspended in 20 pi, and mixed by 
gentle pipetting and the contents were then transferred to the third tube, and mixed by 
gentle pipetting (1 tube containing all the isolated RNA from one tissue sample, suspended 
in 40 pi of DEPC-treated, sterilised water). The isolated RNA suspended in water was 
stored at -70°C for up to 3 months.
6, Determination o f absorbance
Wavelength scanning of the absorbance of the RNA isolation, was performed on a 
Philips PU8700 Series UV/Vis Spectrophotometer (© Pye Unicam Ltd, Cambridge).
99
7. Calculation o f RNA recovery from isolation methods
(a) Spectrophotometric Determination o f the Amount o f RNA or DNA:
For quantitating the amount of RNA or DNA, absorbance was measured at 
wavelengths of 260 nm and 280 nm. The reading at 260nm allows calculation of the 
concentration of DNA in the sample. An OD of 1 corresponds to approximately 50 pg/ml 
for double-stranded DNA, 40 pg/ml for single-stranded DNA and RNA, and -20 pg/ml for 
single-stranded oligonucleotides. The ratio between the readings at 260 nm and 280 nm 
(OD260/OD280) provides an estimate of the purity of the nucleic acid. Pure preparations of 
DNA and RNA have OD260/OD280 values of 1.8 and 2.0 respectively. A higher ratio 
indicates that there is DNA contamination in the sample, whereas a lower ratio indicates 
protein or phenol contamination of the sample.
(b) RNA concentration (jug):
One A260 nM unit equals 40 pg of RNA/ml of suspension. Therefore:
• A260 nM value *40 = pg RNA / pi of sample pipetted into the curvette (i.e., 5 pi)
• pg RNA -r 5 = pg RNA / pi
• If 40pl of suspension isolated from a set amount of tissue (mg), then 
40 *(pg RNA/ pi) = pg RNA / 40 pi or pg RNA / amount of tissue (i.e., 110 mg)
• Then pg RNA 4-IIOmg = pg RNA / mg tissue
The yield from cortex was 1 -  1.5 pg RNA / mg tissue.
2.5.2. DNase treatment 
L Solutions
(a) RQl RNase-Free DNase, lunit/pl
(b) Restriction Endonuclease (RE) Multicore Buffer (Ix)
Contains 25 mM Tris-Acetate (pH 7.5 at 37°C), 100 mM potassium 
acetate, 10 mM magnesium acetate and 1 mM DL-dithiothreitol (DTT).
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(c) 1% (v/v) DEPC-treated sterilised, deionised water.
(d) Chloroform AnalaR grade (BDET).
(e) Isoamylalcohol AnalaR grade (BDH).
(f) Phenol (Sigma).
(g) Absolute 99.9% Ethanol AnalaR grade (BDH).
2. Phenol-chloroform-isoamylalcohol extraction
Isolated RNA samples were removed from -70°C, and the RE multicore buffer and 
RQl RNase-free DNase were removed from -20°C to defrost at room temperature and then 
kept on ice throughout the procedure. In separate Eppendorf tubes for each sample, the 
following reaction was mixed using gentle pipetting:
2 pi of RE multicore buffer 
1 pi of RQl RNase-free DNase 
18 pi of isolated RNA 
The tubes were centrifuged up to 800 x to quickly mix the contents, at room 
temperature using the JOUAN A14 microcentrifuge and incubated in a 37°C waterbath for 
1 h. During incubation the Phenol-Chloroform-Isoamylalcohol (PCI) solution was 
prepared, in a fiime-cupboard, using the following ratios:
Phenol Chloroform Isoamvlalcohol
25 24 1
Making sure that the solutions were mixed in the correct order, i.e., isoamylalcohol 
then chloroform then phenol. The chloroform denatures proteins and facilitates the 
separation of the aqueous and organic phase, and the isoamylalcohol reduces foaming 
during extraction.
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After incubation, the tubes were centrifiiged briefly up to 1394 x g, at room 
temperature, using the JOUAN A14 microcentrifiige. 20 pi PCI solution was added to each 
tube containing the digested sample, and vortexed for 60 sec to mix the contents. The tubes 
were incubated on ice for 2 min. Following centriftigation, the contents of the tubes 
separated into 2 layers: a clear phenol-chloroform phase and a colourless, upper aqueous 
phase. RNA remains exclusively in the aqueous phase whereas DNA partitions to the 
lower phase.
The top, aqueous phase was carefiilly pipetted into an Eppendorf tube, so not to 
disturb the DNA in the lower phase. 2.5-fold amount of absolute alcohol was added to each 
tube (therefore, if 20 pi of the aqueous layer was removed, then 50 pi of absolute alcohol 
was added), and the contents mixed by gentle inversion. The tubes were incubated at -20°C 
for 1 h and centrifiiged in a JOUAN A14 microcentrifiige, at 12500 x g for 10 min, at room 
temperature. The supernatant was removed by pipetting, without disturbing the gel-like 
pellet containing RNA, on the side and bottom of the tube.
The pellet was washed once by adding 500 pi of 75% ethanol and mixed by gentle 
inversion, to remove any salts present. The tubes were centrifuged in a JOUAN A14 
microcentrifiige, at 5600 x g for 4 min, at room temperature. The ethanol was removed by 
pipetting, without disturbing the pellet, and the tubes were dried on absorbent tissue in a 
fiime-cupboard for 5 min. Complete evaporation of the 75% ethanol wash is required 
when the samples are to be used for RT-PCR, as any residual ethanol may affect enzyme 
activity. After drying, all remaining ethanol will have evaporated leaving only the pellet 
and possibly water in the tubes. It is important not to let the RNA pellet dry completely as 
this will greatly decrease its solubility. The pellet in each tube, was then re-suspended in 
20 pi of DEPC-treated, sterilised water, and mixed by gentle pipetting. This was stored at - 
70°C for up to 3 months.
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3, Determination o f absorbance
Refer to section 2.53 J .
4, Calculation o f RNA recovery after DNase treatment 
Refer to Section 2.5.3.8.
2,5,3, Reverse-Transcription Polymerase Chain Reaction (RT-PCR)
1, Introduction
Numerous techniques have been developed to measure gene expression in tissues 
and cells. These include Northern Blots, coupled reverse transcription and PCR 
amplification (RT-PCR), RNase protection assays, in situ hybridisation, dot blots and 81 
nuclease assays. Of these methods, RT-PCR is the most sensitive and versatile.
RT-PCR employs AMV or MMLV (or MuLV) reverse transcriptases for first 
strand cDNA synthesis. Second strand cDNA synthesis and subsequent PCR amplification 
is performed with thermostable DNA polymerases (e.g., Thermus flavus (Tfl) DNA 
polymerase).
The PCR process amplifies short (approximately 100-500bp) segments of a longer 
DNA molecule. A typical RT-PCR reaction includes the sample of target RNA, reverse 
transcriptase, a thermostable DNA polymerase, two oligonucleotide primers, dNTPs, 
reaction buffer and magnesium. The components of the reaction are mixed and placed in a 
thermal cycler, which is an automated instrument that takes the reaction through a series of 
different temperatures for varying amounts of time. This series of temperature and time 
adjustments is referred to as one cycle of amplification. Each RT-PCR cycle theoretically 
doubles the amount of targeted template sequence (amplicon) in the reaction. Ten cycles 
theoretically multiply the amplicon by a factor of about one thousand; 20 cycles, by a 
Actor of more than a million in a matter of hours (Figure 2.4.).
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Prior to the amplification cycles an initial step is required in RT-PCR, where target 
RNA is converted to cDNA using 3' primers and the enzyme reverse transcriptase. 
Following the first-strand cDNA synthesis, the reverse transcriptase is inactivated and the 
RNA/cDNA hybrid is then denatured by a 2 min incubation at 94°C. This step leads 
directly into the second-strand cDNA synthesis and PCR amplification phase of the 
procedure. After this initial stage, each cycle of PCR amplification consists of a number of 
steps; dénaturation, annealing and polymerisation. Each step denatures the template 
producing two oligonucleotide-primed single-stranded DNA templates, sets up the 
polymerisation reaction, and synthesises a copy of each strand of the template being 
targeted. These steps are optimised for each template and primer pair combination. The 
initial step in a cycle denatures the target DNA by heating it to 95°C or higher for 15 sec 
to 2 min. In the dénaturation process, the two intertwined strands of DNA separate fi*om 
one another, producing the necessary single-stranded DNA template for the thermostable 
polymerase.
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Amplifying DNA by the polymerase chain reaction (PCR; Weaver & Hedrick, 1992)
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The next step of a cycle reduces the temperature to approximately 40-60°C. At this 
temperature, the oligonucleotide primers can form stable associations (anneal) with the 
separated target DNA strands and serve as primers for DNA synthesis by a thermostable 
DNA polymerase. This step lasts approximately 30-60 sec.
Finally, the synthesis of new DNA begins when the reaction temperature is raised 
to the optimum for the thermostable DNA polymerase. For most thermostable DNA 
polymerases this temperature is approximately 74°C. Extension of the primer by the 
thermostable polymerase lasts approximately 1-2 min. This step completes one cycle, and 
the next cycle begins with a return to 95°C for dénaturation. After 20-40 cycles, the 
amplified nucleic acid may be analysed for size, quantity, sequence, etc., by gel 
electrophoresis, or used in fijrther experimental procedures (e.g., cloning).
2, Solutions
(a) Avian Myeloblastosis Virus (AMV) Reverse Transcriptase, 20 u n its/p i (Promega)
One unit is defined as the amount of enzyme which catalyses the incorporation of 
1 nmol of dTTP into acid-insoluble form in 10 min at 37°C in 50 mM Tris-HCL 
(pH 8.3), 40 mM KCL, 8.75 mM MgCE, 10 mM DTT, 0.1 mg/ml BSA, 1.0 mM 
radiolabelled dTTP, 0.25 mM poly(A)4oo and 0.25 mM oligo(dT)so.
(b) Tfl DNA Polymerase, 5 units /  p i (Promega)
This is a thermostable enzyme with a molecular weight of approximately 94,000 
daltons isolated from Thermus flavus.
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(c) dNTPMix, 10 nM (Promega)
The dNTPs used were greater than 98% triphosphates content, and were provided at a 
concentration of 100 nM in water at pH 7.5. To create the 10 nM dNTP mix, lOOpl of 
each of dATP, dCTP, dGTP and dTTP were mixed together in a sterile DEPC-treated 
Eppendorf tube and 600pl of nuclease-free water was added (1:10 dilution). The 
Eppendorf tube was vortexed to thoroughly mix the contents, and stored at -20°C.
(d) A M V / Tfl lOx Reaction Buffer (Promega)
It contains 200 mM Tris-Acetate (pH 8.9 at 25®C), 100 mM ammonium sulphate, 
750 mM potassium acetate, and 0.5% Tween.
(e) M gS04,25 mM (Promega)
(f) Reverse Oligonucleotide Primer (Go-Oli-Go ™, Pharmacia Biotech)
I. 6-Actin
The p-actin primer pairs used in this study were designed with the aid of a Mac 
GeneJockey program from published g-actin cDNA sequences (Nudel et al, 1983) to 
amplify sequences within the coding region of P-actin (nucleotides 262-542).
Sequence (5-3 ): TAG AAC CTC CTT GCA GOT CC
MW = 5810; Tm = 64.4; pg/OD = 31.4
II. Brain-Derived Neutrophic Factor
The BDNF primer pairs used in this study were designed with the aid of a Mac 
GeneJockey program from published BDNF cDNA sequences (Maisonpierre et al, 1991) 
to amplify sequences within the coding region of BDNF (nucleotides 286-835).
RBDNF2 Sequence (5 -3’): TCT ATC CTT ATG AAC CGC CAG C
MW = 6609; 65.9 nmol; Tm = 66.0; pg/OD = 32.8
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III. Corticotrophin Releasing Factor-Receptor 1
No. 563 Sequence (5 -3 ): AAG CCG AGA TGA GGT TCC AGT GG
The CRH-Rl primer pairs used in this study were designed with the aid of a Mac 
GeneJockey program from published CRH-Rl cDNA sequences (Perrin et al, 1993) to 
amplify sequences within the coding region of CRH-Rl (nucleotides 221-562).
IV. Glucocorticoid Receptor
The GR primer pairs used in this study were designed with the aid of a Mac GeneJockey 
program from published GR cDNA sequences (Miesfeld et al, 1986) to amplify sequences 
within the coding region of GR (nucleotides 225-676).
No. 225 Sequence (5-3 ): TCT CAG GCA GAT TCC AAG CAG C
MW = 6704,3; Tm = 69.9; pg/OD -  32.0; nmol = 64.6
(g) Forward Oligonucleotide Printer (Go-Oli-Go Pharmacia Biotech)
I. B-Actin
Sequence (5-3 ): ACA ATG CCG TGT TCA ATG G
MW = 5954; Tm = 64.2; pg/OD = 34.1
II. Brain-Derived Neutrophic Factor
FBDNFi Sequence (5-3 ): CGA GAG GTC TGA CGA CGA CG
MW = 6173; 43.7nmol; Tm= 68.8; pg/OD = 31.0
III. Corticotrophin-Releasing Factor
No. 221 Sequence (5 -3 ): TGG ACC TCA TTG GCA CCT GCT GG
IV. Glucocorticoid Receptor
No. 676 Sequence (5-3 ): TT CAC ACT GCC TCC GTT GGT GC
MW = 6653.2; Tm = 73.6; pg/OD = 35.0; nmol = 54.0
(h) 1% (v/v) DEPC-treated, sterilised water
(i) lOObp DNA ladder (Promega)
The ladder consists of 11 double-stranded DNA fragments with sizes of 100, 200,
300, 400, 500, 600, 700, 800, 900, 1000 and 1500 bp. The 500 bp is present at triple the
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intensity of the other fragments and serves as a reference indicator. All other fragments 
appear with equal intensity on the gel.
The 100 bp ladder is supplied in 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, and was 
mixed well prior to use. Five microlitres (650 ng) of the ladder contains approximately 150 
ng of the 500 bp DNA fragment and 50 ng of each of the other ten DNA fragments. It was 
stored at -20°C.
Blue/Orange 6X Loading Dye: This dye is used for loading DNA samples into gel 
electrophoresis wells and tracking migration during electrophoresis. It was composed of 
15% Ficoll® 400, 0.03% Bromophenol blue, 0.03% xylene cyanol FF, 0.4% orange G, 
10 mM Tris-HCL (pH 7.5) and 50 mM EDTA. The concentration used in the subsequent 
experiments was one part loading dye for every five parts 100 bp DNA ladder.
5. RT-PCR Protocol
(a) Mastermixes
I. B-Actin:
Reagent pi / RNA sample
1% (v/v) DEPC-treated, sterilised water 12.55
AMV-ZyZ (lOx) Reaction Buffer 3.10
dNTP mix 2.60
Forward Primer 1.25
Reverse Primer 1.25
25mM MgS0 4  2.50
AMV Reverse Transcriptase (20units/pl) 0.25
Tfl DNA Polymerase (5 units/pl) 0.50
RNA sample 1.00
Total Volume for RT-PCR Reaction = 25pl/RNA sample
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II. BDNF mRNA:
1% (v/v) DEPC-treated, sterilised water 
AMV-jyZ (lOx) Reaction Buffer 
dNTP mix
Forward Primer (FBDNFi)
Reverse Primer (RBDNF2)
25mM MgS0 4
AMV Reverse Transcriptase (20units/pl) 
Tfl DNA Polymerase (5 units/pl)
RNA sample
Total Volume for RT-PCR Reaction
14.75
3.00
1.00
1.25
1.25 
2.00 
0.25 
0.50 
1.00
25pl/RNA sample
ni. CRH-Rl mRNA:
1% (v/v) DEPC-treated, sterilised water 
A M V -^ (lOx) Reaction Buffer 
dNTP mix
Forward Primer (221)
Reverse Primer (563)
25mMMgS04
AMV Reverse Transcriptase (20units/pl) 
Tfl DNA Polymerase (5 units/pl)
RNA sample
Total Volume for RT-PCR Reaction
12.00
3.00 
3.25
1.00 
1.00 
2.50 
0.25 
1.00 
1.00
25pFRNA sample
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IV. GR mRNA:
Reagent
1% (v/v) DEPC-treated, sterilised water 
AMV-Tfl (lOx) Reaction Buffer 
dNTP mix
Forward Primer (676)
Reverse Primer (225)
25mM MgS0 4
AMV Reverse Transcriptase (20units/pl) 
Tfl DNA Polymerase (5 units/pl)
RNA sample
Total Volume for RT-PCR Reaction
pi / RNA sample 
12.35 
3.10 
2.60 
1.20
1.50
2.50 
0.25 
0.50 
1.00
25pl/RNA sample
The mastermix (prior to the addition of the RNA sample) was dispensed in the above 
order, in one Eppendorf tube (therefore, if there were 6 sanq)les then 6 x each volume of 
the components of the mastermix were dispensed into one Eppendorf tube). All the 
components were kept on ice throughout. They were vortexed before being added into the 
mastermix, hut the completed mastermix was mixed by gentle pipetting before being split 
into the required Eppendorf tubes (24 pi per Eppendorf). Then 1 pi of RNA sample was 
added to each Eppendorf tube, containing the mastermix, and then centrifuged at a pulse up 
to 800 X g, at room temperature, using the JOUAN A14 microcentrifiige. The eppendorf 
tubes went through a pre-heat program before the RT-PCR was initialised. This was to 
prevent the primers attaching to unwanted sequences within the RNA sample, before 
RT-PCR.
(b) Pre-heat Method:
52°C for 3 min.
I l l
(ç) OMN-E Thermal Cycler (Hybaid) Method:
I. B-Actin:
42°C for 50 min (RNA converted to cDNA) - one cycle
94°C for 5 min (AMV-RT is inactivated and the RNA/cDNA hybrid denatured) -  one 
cycle
94°C for 60 sec (DENATURATION)
55°C for 60 sec (ANNEALING)  ^ 35 cycles
72°C for 60 sec (POLYMERISATION)
II. BDNF mRNA:
48°C for 45 min (RNA converted to cDNA) - one cycle
94°C for 2 min (AMV-RT is inactivated and the RNA/cDNA hybrid denatured) -  one 
cycle
94°C for 30 sec (DENATURATION)
61.9°C for 60 sec (ANNEALING) y 40 cycles
72°C for 120 sec (POLYMERISATION)
III. CRH-Rl mRNA:
48°C for 45 min (RNA converted to cDNA) - one cycle
94°C for 2 min (AMV-RT is inactivated and the RNA/cDNA hybrid denatured) -  one 
cycle
94°C for 60 sec (DENATURATION)
69.5°C for 60 sec (ANNEALING) 7 40 cycles
72°C for 120 sec (POLYMERISATION)
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IV. GR mRNA:
48°C for 45 min (RNA converted to cDNA) - one cycle
94°C for 2 min (AMV-RT is inactivated and the RNA/cDNA hybrid denatured) -  one 
cycle
94°C for 30 sec (DENATURATION)
69°C for 60 sec (ANNEALING)  ^ 40 cycles
70°C for 60 sec (POLYMERISATION)
2,5,4. 2% Agarose gel electrophoresis 
1, Introduction
Factors affecting the rate of DNA migration in agarose gels (Figure.2.5.), include:
(a) Molecular size o f the DNA. Molecules of linear, double-stranded DNA, which tend
to become orientated in an electric field in an end-on position, migrate through gel 
matrices at rates that are inversely proportional to the logio of the number of base pairs. 
Larger molecules migrate more slowly because of greater fi-ictional drag and because 
they worm their way through the pores of the gel less efficiently than smaller 
molecules.
(b) Agarose concentration. A linear DNA fi*agment of a given size migrates at different 
rates through gels containing different concentrations of agarose. There is a linear 
relationship between the logarithm of the electrophoretic mobility of DNA (p) and the 
gel concentration (t), which is described by the equation: log p = log po - KtT where po 
is the free electrophoretic mobility of DNA and Kr is the retardation coefficient, a 
constant that is related to the properties of the gel and the size and shape of the 
migrating molecules. Thus, by using gels of different concentrations it is possible to 
resolve a wide size range of DNA molecules (Table 2.4.).
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Table 2.4
Range of separation in gels containing different amounts of agarose.
Amount of agarose 
in gel (g)
Efficient range of separation of 
Linear DNA molecules (kb)
0.3 5-60
0.6 1-20
0.7 0.8 - 10
0.9 0.5-7
1.2 0.4-6
1.5 0.2-8
2.0 0.1-2
(c) Conformation o f the DNA. Superhelical circular (form I), nicked circular (form II), and 
linear (form III) DNAs of the same molecular weight migrate through agarose gels at 
different rates.
(d) Applied Voltage. At low voltage, the rate of migration of linear DNA fragments is 
proportional to the voltage applied. However, as the electric field strength is raised, the 
mobility of high-molecular-weight fragments of DNA increases differentially. Thus, 
the effective range of separation in agarose gels decreases as the voltage is increased.
(e) Direction o f the Electric Field. DNA molecules larger than 50-100kb in length migrate 
through agarose gels at the same rate if the direction of the electric field remains 
constant.
(f) Base Composition and Temperature. Either the base composition of the DNA or the 
temperature at which the gel is run does not significantly affect the electrophoretic 
behaviour of DNA in agarose gels. Thus, in agarose gels, the relative electrophoretic 
mobilities of DNA fragments of different sizes do not change between 4°C and 30°C. 
In general, agarose gels are run at room temperature.
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(g) Presence o f Intercalating Dyes. Ethidium bromide, a fluorescent dye that is used to 
detect DNA in agarose gels, reduces the electrophoretic mobility of linear DNA by 
about 15%. The dye intercalates between stacked base pairs, extending the length of 
linear and nicked circular DNA molecules and making them more rigid.
(h) Composition o f the Electrophoresis Buffer. The electrophoretic mobility of DNA is 
affected by the composition and ionic strength of the electrophoresis buffer. In the 
absence of ions (e.g., if electrophoresis buffer is omitted from the gel by mistake), 
electrical conductance is minimal and DNA migrates very slowly, if at all. In buffers of 
high ionic strength (e.g., if 10 x electrophoresis buffer is used by mistake), electrical 
conductance is very efficient and significant amounts of heat are generated. Several 
different buffers are available for electrophoresis of native double-stranded DNA. 
These contain EDTA (pH 8.0) and TAE, TBE, or TPE.
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Figure 2.5.
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The effect of (A) agarose concentration, (B) applied voltage, (C) electrophoresis buffer, and (D) 
ethidium bromide on migration o f DNA through Agarose gels (Ausubel et al, 1987).
2. Materials
(a) Fast-Trak Gel System (Hybaid):
Mini Apparatus: 1, 6.5 x 10.0 x 1.5cm UV transparent gel tray.
1 X main chamber assembly with built-in level and levelling feet.
1 X interlocking safety cover with leads.
1 X comb holder.
1 X 10-well comb.
116
Midi Apparatus: 1,10.0 x 20.0 x 1.5cm UV transparent gel tray.
1 X main chamber assembly with built-in level and levelling feet.
1 X interlocking safety cover with leads.
2 X comb holders.
2 X 20-well combs.
(b) Camera (Polaroid CU-5 88-46, Genetic Research Instrumentation Ltd)
Hood size: 13.97 x 19.05 cm.
Area photographed: 10.80 x 13.65 cm.
Magnification: 0.65 X
Lens: 12.70 cm.
(c) Microwave (Toshiba)
(d) Polaroid Film (Polaroid Type 667, coaterless black and white, instant film 8.26 x 
10.80 cm.)
Lens Aperture/exposure time:
Recommended exposure meter setting:
Spectral sensitivity:
Contrast:
Resolution:
Image size:
Processing time:
(e) Power pack (Vodam® SAE 2761, Shandon Southern) 
(0 UV illuminator
P8, 2 sec 
ISO 3000/36° 
Panchromatic 
Medium
12-14 line pairs/mm 
7.30 X 9.53 cm.
60 seconds
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3, Chemicals
(a) Agarose Electrophoresis Grade (GIBCO BRL, Life Technologies, Scotland).
(b) Bromophenol blue (pH 2.S-4.6; Hopkin & Williams, Searle Company).
(c) 95% Ethidium Bromide (Sigma).
(d) Ficoll (Sigma)
4, Solutions
(a) 10 X TBE Buffer
109.03g Tris-base, 55.65g Boric acid and 9.31g of EDTA dissolved in 800ml of 
sterilised, deionised water. The volume was increased to 1 litre, adjusting the pH to 8.2 
using 6M NaOH and then stored at room temperature or 4°C.
(b) Agarose
2% agarose is used in this gel electrophoresis.
(c) Loading Buffer 
25% (w/v) Ficoll
0.25% (w/v) Bromophenol Blue 
- Dissolved in sterilised, deionised water
(d) Ethidium Bromide Solution (2f7-Diamino-10-ethyL9-phenyl-phenanthidinium 
bromide; lOmg/ml stock solution)
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2.5.5. Agarose Gel Electrophoresis Protocol:
Ix TBE buffer was made up on the day of the gel electrophoresis, i.e., 35 ml of 1 Ox 
TBE (refer to Section 2.5.5.2a) made up to 350 ml with sterilised, deionised water for a 10- 
well gel electrophoresis experiment. This allowed 30 ml of 1 x TBE buffer to be used to 
dissolve 0.6 g of pure agarose (2% agarose gel), which was then gently heated for 
approximately 2 min on full power in a microwave, stirring the gel mixture throughout. 
This was then cooled before pouring into the gel apparatus, and inserting the comb for the 
wells. It was left for approximately 30 min to allow the gel to set, before gently removing 
the comb and pouring the remaining 1 x TBE buffer (approximately 320 mis) over the gel 
and immersing it for approximately 30 min, prior to the experiment.
RT-PCR samples containing loading buffer (5 pl/sample) were removed from -70° 
and defrosted at room temperature, and kept on ice before loading the sample onto the 
agarose gel, (3-actin was used as an internal control and included on each gel. 15 pi of each 
sample was loaded into a well of the horizontal gel and 145V was applied between the 
ends of the gel for approximately 75 min, generating an electric field. Electrophoresis was 
carried out in pH 8.2, determined by the 1 x TBE buffer. Since the DNA molecules are 
negatively charged they move towards the anode, the size of the molecule being the major 
fector that determines the rate of movement.
The DNA can be visualised under UV light after staining with 0.5-1 pg/ml 
ethidium bromide. Ethidium bromide is often included in the gel, but alters the mobility of 
linear molecules. Therefore, at the end of the electrophoresis, the agarose gel was removed 
and immersed in 0.5-1 pg/ml ethidium bromide for 20 min, allowing time for the nucleic 
acids to be sufficiently stained. The ethidium bromide was removed and the gel immersed 
in sterilised, deionised water for approximately 40 min to wash any of the excess dye from 
the gel. The gel was visualised on a UV transilluminator, and a Polaroid photograph was 
taken, before discarding the gel Sum intensity of the bands calculated using ID Image 
Analysis Software from Kodak Scientific Imaging Systems.
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2.6 Drugs and chemicals
2,6,1 Kits
Kit
Gamma-B Corticosterone Assay Kit 
ACTHRIAKit
Supplier
(IDS, UK) 
(DSL, USA)
2,6,2 Drugs 
Drug
Aldosterone (d-aldosterone) 
Dexamethasone 
Hydrocortisone 
Paroxetine HCl
RU 28362 (lip , 17P-dihydroxy-6-methyl“ 
17a( 1 -propynyl)-androsta-1,4, 6-trione-3- 
one)
Molecular
Weight
360.4
392.5
362.5 
374.8
Supplier
Sigma
Sigma
Sigma
Glaxo SmithKline
352.45 Pfizer
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2,6,3 Chemicals
Chemical
Agarose (electrophoresis grade)
AMV Reverse Transcriptase (20 units/pl)
AMV/ 7/7 (lOx) Reaction Buffer 
Boric Acid
Bovine Serum Albumin (BSA)
Bromophenol Blue (pH 2.8 -  4.6)
Chloroform (AnalaR grade)
Copper Sulphate. 5HzO (Analytic reagent)
1,2,4,6,7 [^H]-dexamethasone 
Diethylpyrocarbonate (DEPC)
Dithiothreitol (DTT)
100 bp DNA ladder
100 mM dNTPs (dATP, dCTP, dGTP, dTTP) 
Absolute Ethanol (AnalaR grade)
Ethidium Bromide (95%)
Ethylenediamine-Tetraacetic Acid dihydrate (EDTA) 
FicoU
Folin & Ciocalteu’s Phenol Reagent 
Glycerol (Glycerine minimum 99%)
Isoamylalcohol (AnalaR grade)
Isopropanol alcohol (AnalaR grade)
MgS0 4  (25mM)
Optiphase Safe
Supplier
GIBCO BRL/Life
Technologies
Promega UK, Ltd.
Promega UK, Ltd.
Sigma
Sigma
Hopkin & Williams 
/ Searle Co.
BDH
May & Baker Ltd.
Amersham
Sigma
Sigma
Promega UK, Ltd.
Promega UK, Ltd.
BDH
Sigma
Sigma
Sigma
Sigma
Sigma
BDH
BDH
Promega UK, Ltd. 
Wallac
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Phenol
Poiyethylenimine (50% in water; PEI)
Potassium Chloride
Restriction Endonuclease Multicore Buffer (Ix) 
RNA Isolator^”
RQl RNase-free DNase (1 unit/pl)
Sodium Carbonate anhydrous (GPR grade) 
Sodium Chloride (AnalaR grade)
Sodium Hydroxide
Sodium Molybdate Dihydrate (ACS Reagent)
Tfl DNA Polymerase (5 units/pl) 
Tris-hydroxymethylaminomethane hydrochloride 
Trisodium Citrate dihydrate
Sigma 
Aldrich 
Fisons Ltd. 
Promega UK, Ltd. 
Genosys
Biotechnology Inc.
Promega UK, Ltd.
BDH
BDH
Prolabo
Sigma
Promega UK, Ltd.
Prolabo
Sigma
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CHAPTER 3. PREDATOR STRESS STUDY: Development and 
Optimisation of Behavioural Testing Protocols 
3.1 Introduction 
3,LI. Elevated-Plus Maze
The elevated plus-maze is claimed to be an “ethologically valid” animal model of 
anxiety because it uses “natural stimuli” that can induce anxiety in humans. It is assumed 
that the open arms of the maze combine the fear of a novel, brightly lit open space and the 
fear of balancing on a relatively narrow, raised platform. By contrast, the closed arms have 
high walls forming a narrow alley that affords good protection from potential predators 
(it is possible that these fears may be similar to agoraphobia, vertigo and xenophobia, 
respectively; Dawson & Trickelbank, 1995). When a rat or mouse is allowed to freely 
explore the elevated plus-maze for a fixed time, it spends only 20-25% of its time 
exploring the open arms, suggesting that these assumptions are correct.
The utility of the plus-maze is dependent upon rate-dependency factors, with low 
anxiety baselines less than optimal for detecting anti-anxiety effects and high baselines 
virtually useless for detecting anxiety enhancement (Rodgers & Cole, 1993).
Although such problems can be partially surmounted by the selection of 
appropriate genetic strains and optimal test conditions, a number of authors 
(Cruz et al, 1994; Rodgers & Johnson, 1995; Espejo, 1997) have argued that test 
sensitivity, reliability, and ecological validity may be improved by focussing upon what the 
animals actually do in the maze, as well as their physical location. In this context, and 
stemming from the work of the Blanchards’ on antipredator defence in rodents 
(Blanchard et al, 1994), several research groups have begun to routinely score aspects of 
the actual behavioural acts and postures displayed by animals in the maze as well as the 
more usual spatiotemporal measures.
123
Whereas diverse behaviours were observed (e.g., rearing, grooming, head-dipping), 
there were high levels of risk assessment (i.e., stretch-attend postures) shown by mice in 
this test. This finding was not only consistent with the view that risk assessment is a 
dominant response in potentially dangerous situations, but also with subsequent studies 
confirming that mice generally display higher levels of this behaviour than rats. 
Furthermore, it was also apparent that several behaviours (including risk assessment) were 
predominantly exhibited fi*om relatively protected/safe areas of the maze 
(closed arms and/or centre platform), a finding that not only confirmed the importance of 
thigmotactic cues in maze exploration but also suggested the potential utility of 
differentiating these behaviours as a function of where on the maze they occurred 
(“percentage protected” measures).
Mice that are exposed to the scent of an aggressive conspecific show a comparable 
increase in risk assessment in the absence of consistent alterations in the classical measures 
of anxiety. The latter findings imply that enhanced anxiety may not necessarily be 
accompanied by significant changes in open arm entries or time spent on the open arms 
(Rodgers & Cole, 1993).
Physiological confirmation of the aversive or stressfiil effects of plus-maze 
exposure is provided by evidence of post-test elevations in pain latencies 
(Rodgers & Cole, 1994) and skin conductance levels (Haller et al, 1998). Furthermore, 
consistent with the effects of various physical and psychosocial challenges 
(for a review see Haller et al, 1998), exposure to the plus-maze produces a significant 
increase in plasma corticosterone (Pellow et al, 1985; Holmes et al, 1998).
Previous studies have shown that a broad range of prior stress has an anxiogenic 
effect on rats and mice tested in the plus-maze, although some negative results were also 
found. For example, prior immobilisation was found to be anxiogenic 
(Martijena et al, 1997) or to have no effect (McBlane & Handley, 1994). Furthermore, it
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was shown in rats that prior stress (habituation to a novel environment and footshock) 
decreased the percentage of time spent in the open arms (Da Cunha et al, 1992).
A major problem with the elevated plus-maze is that numerous variables are known 
to influence maze results, with the result that several contradictory findings are reported in 
the literature (Trullas & Skolnick, 1993; Rodgers & Johnson, 1995).
The principal organismic variables of interest are species, strain, age and gender, all 
of which have been shown to affect behavioural baselines in the maze 
(Rodgers & Cole, 1994). For example, significant strain differences have been reported for 
rats (Costall et al, 1989) and, particularly, mice (Cole et al, 1995; Trullas & Skolnick, 
1993).
Housing conditions, lighting levels, time of testing and test duration, pretesting, 
prior handling, prior stress and prior maze experience have also been shown to radically 
affect basal anxiety levels in the plus-maze (for a review see Rodgers & Cole, 1994). For 
example, individual housing increases anxiety in rats but decreases it in mice, a difference 
that may relate to species variation in social organisation (Rodgers & Dalvi, 1997).
In addition to the above factors, which have been more or less systematically 
studied for their impact on plus-maze behaviour, a range of other less well-researched 
variables can be identified. Although not often mentioned in research reports, they may 
nevertheless have a significant bearing upon inter-laboratory variability in pharmacological 
profiles, and include: light/dark cycle and lighting levels in the holding facility; duration of 
adaptation to laboratory conditions prior to testing; presence of experimenter during 
testing; elevation of the maze; material from which maze is constructed; height of maze 
walls; transparency/opacity of walls; open arm flooring; definition of an arm entry; and so 
forth (Rodgers & Dalvi, 1997).
125
Repeated testing is one of the procedural variables where contradictory results have 
been reported. Some laboratories have found stable test-retest profiles 
(Lister, 1987; File, 1992), although the majority have reported reduced open arm 
exploration (File, 1990; Rodgers & Johnson, 1995). The literature is based on inter-test 
intervals of days and weeks. It is well known that repeated exposure to a novel 
environment leads to habituation of the behavioural responses (Claus & Bindra, 1960), 
emerging inactivity or stationary patterns over time (Kaesermann, 1986), a fact that 
deserves further investigation concerning the elevated plus-maze.
Sucrose Preference
Chronic sequential exposure to a variety of mild unpredictable stressors (CMUS) 
causes performance deficits in behavioural paradigms that measure responsiveness to 
rewards in a variety of different ways. For example, CMUS depresses the consumption of, 
and preference for, palatable sweet solutions (i.e., sucrose and saccharin). These 
behavioural changes may be maintained for several months, but normal behaviour has been 
reported to be restored by chronic administration (3-4 weeks) of tricyclic or atypical 
antidepressants. This attenuation of sucrose preference has been interpreted as anhedonia, a 
loss of reinforcing capacity, a core symptom in the diagnosis of depression 
(DSM-IV, 1994).
Results fi*om a study by Calvo-Torrent et al (1999) show that predatory stress 
attenuates the level of sucrose intake after 2-3 weeks of chronic exposure, similar to that 
observed with a variety of other stressors in rats (Katz, 1982; Papp et al, 1996) and mice 
(Monleon et al, 1995). Thus, this study by Calvo-Torrent et al (1999), showed that the 
sucrose intake test sensitively detects changes in mice after exposure to predatory stress.
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3.2 Methods
3.2,L Elevated Plus-Maze (EPM)
1. Animals
Forty-three adult male BALB/c mice weighing about 30g were singly housed and 
maintained in a controlled temperature (24°C), constant humidity (-55%) and a 12h 
lightidark cycle (lights on from 7:00h to 19:00h). Mice were bred in our laboratory at 
Nescot, and were left for at least three weeks with food and tap water available ad libitum, 
to habituate to the single housing. The use of these animals in the following scientific 
procedures were regulated by the Animals (Scientific Procedures) Act 1986.
2. Method
An elevated plus-maze (50cm off the ground) made from white, opaque plexiglass 
was used. It comprised of two opposing “open” arms (30 x 5 x 0.25cm) and two opposing 
“closed” arms (30 x 5 x 15cm) with a 5cm square central area. A muslin cloth attached to a 
wooden frame (128 x 110cm) enclosed the entire maze, but the top part of the frame was 
covered in a mesh material, so it did not obscure the observer’s view of the mice. Attached 
to the top of the wooden frame, centrally directed over the maze (70cm above the maze), 
was a 60W bulb (approximately 1500 Lux) directly illuminating the entire maze, but not 
close enough to heat it up. During the test periods, only the spotlight over the maze 
provided illumination within the test room.
For the plus-maze tests, the mice were moved to the test room, in their home cages, 
immediately prior to being tested, to prevent adaptation (Figure. 3.1.). Each mouse was 
placed in the central square, facing an enclosed arm, and allowed to freely explore the 
maze for 5 min. Both spatiotemporal and ethological measures (Table.3.1.) were recorded 
for every minute of the total time (0-1 min, 1-2 min, 2-3 min, 3-4 min & 4-5 min), to give 
an indication of the change in behaviours over the total time the mouse was exposed to the 
maze. In view of the importance of thigmotactic cues in plus-maze exploration
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(Treit et al, 1993), stretch-attend postures, scaiming and sniffing (denoted with * in 
Table.3.1. ) were further differentiated as “protected” (i.e., occurring on/ffom the relative 
security of the closed arms/centre platform) or “unprotected” (i.e., occurring on/from open 
arms). Data for the latter measures are, therefore, given both as total scores and “percent 
protected” scores [(protected/total) x 100]. After the test, the animal was returned to its 
home cage. The plus-maze apparatus was carefully mopped after each test using soapy 
water to remove any residual odour due to urine or faeces from the mice themselves.
5. Statistical Analysis
A statistical approach was used to identify patterns of behavioural change within 
and between trials whereby the entire dataset, i.e., standard measures and all ethological 
measures from Trial 1, were analysed by factor analysis using a principal components 
solution with orthogonal rotation (varimax) of the factor matrix: this method ensures that 
the extracted factors are independent of one another. Factor pattern matrices were 
identified using a combination of the Kaiser criterion (factors must have eigenvalues < 1) 
and the Cattell Scree test (on a simple line plot, the point at which the smooth decrease in 
eigenvalues levels off to the right; Hendrie, 1991). The factor loading of each behavioural 
item indicates how well that item correlates with the factor(s); (range -1.0 to +1.0) and, in 
accordance with previous studies (Montgomery, 1955; Hendrie et al, 1996), only factor 
loadings of >0.4 are reported.
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Table.3.1.
Categories of behaviour analysed on the EPM.
Total Entries
Open Entries 
Closed Entries 
% Open Arm Entries
% Closed Arm Entries
Open Arm 
Closed Arm 
% Open Arm
% Closed Arm
% Centre
Number of entries to any arm of the maze. An entry was defined 
as all four paws crossing the line into the arms.
Number of entries to an open arm.
Number of entries to a closed arm.
The number of open arm entries, expressed as a % of the total 
arm entries.
The number of closed arm entries, expressed as a % of the total 
arm entries.
Time the mouse spent on the open arms.
Time the mouse spent on the closed arms.
The time spent in the open arms, expressed as a % of the duration 
of the session.
The time spent in the closed arms, expressed as a % of the 
duration of the session.
The time spent in the centre, expressed as a % of the duration of 
the session.
Non exploratory Behaviours: 
Freezing / Immobility 
Self-Grooming
Risk Assessment Behaviours: 
Closed Arm Returns
End-Exploring
Sniffing*
Scanning*
Stretch-Attend
Posture*
Rearing
Defecation
Number of squats or cringes.
A species-typical sequence beginning with the snout, progressing 
to the ears and ending with a whole body groom.
Exiting from a closed arm with only the forepaws and then 
returning into the same arm.
The number of times the mouse reached the end of an arm. 
Olfactory exploration of the maze floor and walls, and occasional 
air sampling
Where the mouse investigates its surroundings, often 
accompanied with body stretches and including head-dipping. 
This is the exploratory movement of the head/shoulders directed 
over the sides of the maze.
Forward elongation of head and shoulders followed by retraction 
to original position.
The number of times that the mouse rises onto its hind-limbs. 
Total number of faecal boli that the mouse left in the different 
sections of the plus-maze after the duration of the session.
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4, Results o f the Factor Analysis of Trial 1
The behavioural measures comprised of some 15 items (Table 3.2.), and the 
correlations between the different behavioural measures in Trial 1 of the EPM is shown in 
Table 3.3A and B, Kaiser and Scree plot analyses identified 4 “factors” or components, 
which together accounted for 71.3% of the total variance in this dataset (Table 3.4.). The 
estimation of significant “factors” is determined by examination of the eigenvalues and 
their relative magnitudes in the correlation matrix.
Factor 1 showed high loadings for closed arm entries, % open arm entries 
(negative loading), % closed arm entries, % time on open arms (negative loading), % time 
on closed arms, total end-exploring, total head-dipping/scanning (negative loading) and 
total rearing. Total stretch-attend postures (negative loading) loaded only moderately on 
this factor.
Total arm entries, open arm entries, and closed arm entries loaded heavily on 
Factor 2, whilst total end-exploring loaded only moderately on this factor. Total sniffing 
loaded heavily on Factor 3. Total closed arm returns and total defecation loaded heavüy on 
Factor 4. All loadings are positive unless otherwise stated, and Factor 1 correlates to 
anxiety. Factor 2 to locomotor activity. Factor 3 with risk assessment and Factor 4 with 
decision-making and approach/avoid behaviours.
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Table 3.2.
Spatiotemporal and ethological description of behaviour displayed by control male BALB/c
mice (n = 43), in a five minute EPM test.
Behaviour Mean ± sem
Total number of arm entries 3.2 + 0.37
Number of open arm entries 1.7 + 0.20
Number of closed arm entries 1.5 + 0.27
Number of closed arm returns 1.0 + 0.30
% Open arm entries 61.0 + 5.57
% Closed arm entries 39.0 + 5.57
% Time on open arms 45.0 + 5.35
% Time on closed arms 32.0 + 5.45
Total counts of sniffing 59.3 + 2.72
Total counts of grooming 0.6 + 0.12
Total counts of end-exploring 2.9 + 0.46
Total counts of head-dipping (HD)/scanning 27.1 + 1.84
Total counts of stretch-attend postures (SAP) 27.5 + 2.23
Total counts of rearing 1.5 + 0.37
Total counts of defecation 5.3 + 0.44
% Protected sniffing 57.0 + 0.14
% Protected head-dipping (HD)/scanning 50.0 + 0.14
% Protected stretch-attend postures (SAP) 55.0 + 0.14
This table summarises the data set upon which the present factor analyses were performed. 
This analysis included all spatiotemporal and behavioural measures recorded using a video-camera 
in Trial 1.
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Table 3.4.
Orthogonal factor loadings for standard plus-maze measures, plus all ethological measures.
Variable Factor 1 Factor 2 Factor 3 Factor 4
Total Arm Entries — 0.908 — —
Open Arm Entries — 0.785 — —
Closed Arm Entries 0.646 0.606 — —
Closed Arm Returns --- — — 0.559
% Open Arm Entries -0.901 — — —
% Closed Arm Entries 0.901 — — —
% Time on Open Arms -0.789 — — —
% Time on Closed Arms 0.859 — --- —
Total Sniffing — — 0.844 —
Total grooming — — — —
Total end-exploring 0.647 0.477 — —
Total head-dipping (EID)/scanning -0.761 — — —
Total stretch-attend postures (SAP) -0.434 — — —
Total rearing 0.6878 — — —
Total defecation — — — 0.500
Factor loadings of < 0.4 are not included. The four factors account for 71.3% of the total variance.
5. Discussion
The factor analysis incorporated all plus-maze parameters analysed in Trial 1, 
including the various ethological measures related to murine defensive behaviour. Four 
factors emerged from this investigation of the data (Table 3.4.), which confirmed previous 
investigations in this area (Rodgers & Johnson, 1995). Factor 1 (anxiety) retained very 
high loadings on traditional spatiotemporal measures. Importantly, several ethological 
measures (end-exploring, head-dipping/scanning, SAP and rearing), previously interpreted 
as indicative of anxiety (Rodgers et al, 1994), were also found to load moderately/highly 
on this factor. These latter items are probably related by virtue of reflecting a reluctance to
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leave the security of the closed arms. Factor 2 (locomotor activity) included total arm 
entries as well as closed arm entries. Total sniffing/olfactory investigation was the only 
measure to load highly on Factor 3 (risk assessment), which is arguably a very important 
means of information gathering in a macrosmatic species and so represents risk 
assessment. Factor 4 seems homologous with decision-making, approach/avoid 
behaviours. The moderate loadings of closed arm returns and defecation tend to confirm its 
relationship with decision making, as the former occurs exclusively in closed arms while 
the latter almost always occurs in secure areas of the maze.
In conclusion, the factor analysis confirms that this elevated plus-maze allows the 
observation of primary spatiotemporal indices of anxiety as well as a range of defensive 
behaviours. Not only does the behavioural profile comprise factors related to anxiety and 
locomotor activity as previously thought, but also includes dimensions that appear to be 
related to vertical activity, exploration, risk assessment, and decision-making. So this EPM 
was chosen to be used in the following predator stress study.
3.2.2 Sucrose Consumption and Sucrose Preference
The purpose of this experiment was to ascertain the difference between a one-bottle 
sucrose consumption test and a two-bottle sucrose preference test on group-housed male 
BALB/c mice.
1. Animals
Twenty-four male BALB/c mice (Nescot breeding colony) weighing fi*om 20-26g 
were housed in groups of 6 animals per cage and maintained in a controlled temperature 
(24°C), constant humidity (-55%) and a 12h light:dark cycle. Mice were housed as above 
for at least 7 days with fi*ee access to food and water before the experiment. The use of
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these animals in the following scientific procedures were regulated by the Animals 
(Scientific Procedures) Act 1986.
2. Methods
Two cages of 6 mice were water and food deprived for 4 h (08:00 to 12:00), and 
then given a pre-weighed bottle containing a sucrose solution (0-4% w/v) for 4 h (12:00 to 
16:00). Two other cages of six mice were also food and water deprived for 4 h (08:00 to 
12:00), and given a pre-weighed bottle containing a sucrose solution and a pre-weighed 
bottle of tap water for 4 h (08:00 to 12:00). After the sucrose tests the mice were given fi*ee 
access to food and water overnight (16:00 to 08:00). Therefore each cage of six mice had 
access to two different sucrose solutions over two days.
The bottles were weighed before and after the 4 h test (weight of bottle plus liquid 
(before) -  weight of bottle plus liquid (after) = weight / volume of liquid consumed in 4 h 
per cage). The amount of water and sucrose consumed in the two-bottle test was calculated 
as a percentage of the total amount of liquid consumed per cage, and divided by the 
number of mice per cage (n=6), to give the average amount of water and sucrose consumed 
per mouse. Body weights were monitored daily, and compared against their weights prior 
to the experiment. Six empty cages containing a bottle of water and a bottle containing a 
1% sucrose solution were assessed for leakage over the 4 h test periods. These bottles were 
weighed before and after the tests.
3, Statistical Analysis
Statistical evaluations were made with paired or unpaired Student’s t test, as 
indicated, or analysis of variance.
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4. Results
In the two-bottle test, sucrose was preferred over water at all the sucrose 
concentrations, with maximum preference of 62% observed at 2% sucrose 
(F=1.0, P=0.0145), due to a 174% increase in sucrose intake compared to the other 
concentrations (Table.3.5,).
Table 3.5.
Two-bottle sucrose preference test in group-housed male BALB/c mice
Sucrose
Concentration
(% w/v)
Sucrose
Intake/cage
(g)
Sucrose 
Preference / cage 
(% w/v)
0.5 4.7 52
1.0 4.2 57
2.0 11.5 62
4.0 3.8 52
Intake of water and different concentrations of sucrose (0.5%, 1%, 2%, and 4% w/v) over 
4 h using the two-bottle preference test in BALB/c mice. Results are expressed as mean 
(whereby the amount shown was consumed by 6 mice for each concentration).
In the one-bottle test, significantly more of the 0.5% sucrose concentration was 
consumed over the other concentrations by 70% (Table 3.6. )
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Table 3.6.
One-bottle sucrose consumption test in group-housed male BALB/c mice.
Sucrose Sucrose
Concentration (% w/v) Intake/cage (g)
0.5 8.0
1.0 3.4
2.0 5.3
4.0 5.4
Intake of different concentrations of sucrose (0.5%, 1%, 2%, and 4% w/v) over 4 h using 
the one-bottle consumption test in BALB/c mice. Results are expressed as mean (whereby 
the amount shown was consumed by 6 mice for each concentration).
Therefore, the results are different between the one- and two-bottle tests, which 
indicates that the type of test used determines the sucrose concentration preferred as a 
reward by group-housed male mice. This can only be an assumption, as for each sucrose
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concentration, only one cage was used (therefore the sample size is too small for statistical 
analysis). There was no difference in body weights between the cages, suggesting the 
consumption from two bottles instead of one does not significantly affect the body weight. 
The small amount (0.5-lg) consumed per mouse (a similar amount to the leakage produced 
per bottle), suggesting that 4 h food and water deprivation followed by 4 h consumption is 
not sufficiently long to produce a quantifiable amount of consumed liquid. This may be 
due to the fact that mice are more active at night, and this test was conducted during the 
day when the mice were effectively asleep.
3.2.3. Sucrose Preference and Food Intake over 24h
Based on the results from the previous experiment, the food and water deprivation 
was increased to 6 h, as well as increasing the sucrose preference test period to 24h 
(so as to include the period when the mice are most active, at night). Leakage from these 
bottles was assessed over 24 h, in parallel with this experiment. The sample size was 
increased to five, whereby each cage acted as its own control and was tested with all of the 
sucrose concentrations (0-4% w/v), on separate occasions. Food consumption over the test 
period was also assessed.
1. Animals
Thirty male BALB/c mice as per Section 3.2.2.1.
2. Method
Mice were given free access to food and two bottles of water, counterbalanced 
across the feeding compartment, for 48 h prior to the experiment. Then the mice were 
water and food deprived for 6 h (08:00 to 14:00), and given a pre-weighed bottle 
containing a sucrose solution (0-4% w/v), a pre-weighed bottle of tap water, and a set
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amount of food pellets for 24 h (14:00 to 14:00). After the sucrose tests the mice were 
given fi'ee access to food and water for 18 h (14:00 to 08:00). Therefore each cage had 
access to all the sucrose solutions, therefore acting as their own control, over 5 days.
The bottles were weighed before and after the 24 h tests (weight of bottle plus 
liquid (before) -  weight of bottle plus liquid (after) = weight / volume of liquid consumed 
in 24 h per cage). The food pellets were also weighed before and after the 24 h tests 
(weight of food pellets (before) -  weight of food pellets (after) = weight / volume of food 
pellets consumed in 24 h per cage).
The amount of water and sucrose consumed in the two-bottle tests were calculated 
as a percentage preference per cage (% Sucrose Preference = [(Sucrose intake/Total liquid 
intake)* 100]), and divided by the number of mice per cage (n=6), to give the average 
amount of water and sucrose consumed per mouse, over 24 h. Body weights were 
monitored daily, and compared against weights prior to the experiment. Six empty cages 
containing a bottle of water and a bottle containing a 1% sucrose solution were assessed 
for leakage over the 24 h test periods, and were weighed before and after the tests.
3. Statistical Analysis
Statistical evaluations were made with paired or unpaired Student’s t test, as 
indicated, or analysis of variance.
4. Results
Expressed as a percentage preference, sucrose was slightly preferred over water, 
but there seems to be no significant variation between the different sucrose concentrations 
(Table 3.7.). Yet, the amount of fluid intake over the test period appears to be no different
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from the previous experiment. There appears to be the same amount of food consumed 
irrespective of the sucrose concentration.
Table 3.7.
Food, water and sucrose intake from group-housed male BALB/c mice
Sucrose Sucrose Total Food
Concentration Preference Fluid Intake Intake
(% w/v) (% w/v) (g) (g)
0 N/A 30.9 ± 2.4 32.0 ± 3.6
0.5 53.8 ±5.4 34.3 ±4.7 38.4 ± 5.2
1.0 58.4 ± 6.4 30.2 ±2.7 34.9 ± 2.8
2.0 55.6 ±2.2 31.6 ±2.5 31.4 ±3.2
4.0 59.4 ±11.5 28.0 ± 2.2 36.8 ±3.8
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Intake of sucrose (0-4% w/v), tap water and food intake from group-housed male BALB/c 
mice over 24 h, after 6 h food and water deprivation. Results are expressed as mean ± sem 
(n=5 per concentration).
3.2.4. Single-housing
The purpose of this experiment was to construct a sucrose concentration curve in 
singly-housed male BALB/c mice. Single-housing was chosen as a more reliable way to 
calculate the sucrose preference for each individual mouse to be tested.
1. Animals
Forty-eight male BALB/c mice weighing from 20-26g were singly housed and 
maintained in a controlled temperature (24°C), constant humidity (-55%) and a 12h 
lightidark cycle. These mice were bred in our laboratory. They were housed under these 
conditions for at least seven days with free access to food and two-bottles of water, 
counterbalanced across the cage, before the experiment. These mice were monitored daily 
for any significant changes in appearance, i.e. loss of weight, lack of movement, etc., due 
to the stress of being singly housed. The use of these animals in the following scientific 
procedures were regulated by the Animals (Scientific Procedures) Act 1986.
2. Method
Mice were given free access to food and two bottles of water, counterbalanced 
across the feeding compartment, for 48 h prior to the experiment. All the bottles to be used 
in the tests were labelled with their respective bungs, and tested for leakage over 24 h prior 
to the experiment; half containing tap water and the other half containing 4% w/v sucrose. 
Mice were then water and food deprived for 6 h (08:30 to 14:30), and given a pre-weighed
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bottle containing a sucrose solution (0-32% w/v), a pre-weighed bottle of tap water, and a 
set amount of food pellets for 24 h (14:30 to 14:30). For each sucrose solution, half the 
mice (n=3) had the sucrose bottle on the left side of the cage, and the other half had the 
sucrose bottle on the right side of the cage.
After the sucrose tests the mice were given free access to food and water for 
approximately 48 h. The test was repeated with the bottles switched to the other side of the 
cages, i.e. if the sucrose bottle was on the left side in the first test then it was changed to 
the right side in the second test.
3. Statistical Analysis
Statistical evaluations were made with paired or unpaired Student’s t test, as 
indicated, or analysis of variance.
4. Results
From 0-2% sucrose there was no preference for sucrose over water, but the 
preference for sucrose significantly increased to around 80% (at a sucrose concentration of 
16%; F=5.368, P<0.0001) and decreased slightly to about 65% preference at a 
concentration of 32% (Figure 3.1.). Food consumption seemed to mimic this with a 
gradual increase from just below 8g to 14g in association with 2-32% sucrose 
concentration (F=3.743 , P=0.0014). A concentration of 8% w/v sucrose solution was 
chosen to be used in the following experiments, as it was significantly preferred by 223% 
over water, allowing for changes due to stress to be monitored accurately.
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Figure 3.1.
Sucrose preference (% of total fluid intake ) and food intake (g) in singly housed male
BALB/c mice.
sucrose intake
water intake
(A)
(B)
Consumption of different concentrations of sucrose (0%, 0.5%, 1%, 2%, 4%, 8%, 16% and 32% 
w/v) over 24 h using the two-bottle preference test in singly housed male BALB/c mice 
(n = 6 per concentration). Results are expressed as mean (± sem). (A) Intake o f water and different 
concentrations of sucrose (0-32%), and (B) Intake of food, from singly housed male BALB/c mice, 
after 6 h food and water deprivation. Unpaired t-test analysis, where * = p <0.05, *** = p<0.001.
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3.2,5. With or without food and water deprivation
The purpose o f  this experiment w as to  ascertain the difference betw een prio r food
and w ater deprivation and no prior deprivation on  the sucrose preference test in singly
housed male BALB/c mice.
1. Animals
Fourteen male BA LB/c mice as per Section 3.2.4.1.
1 4 7
2. Method
Mice were given free access to food, one bottle of tap water and one bottle 
containing an 8% w/v sucrose solution, counterbalanced across the feeding compartment, 
for 48 h prior to the experiment. This served as a training period. The same bottles were 
used from the previous pilot study, therefore their leakage was known. Seven mice were 
then water and food deprived for 6 h (08:00 to 14:00), and given a pre-weighed bottle 
containing an 8% sucrose solution, a pre-weighed bottle of tap water, and a set amount of 
food pellets for 24 h (14:00 to 14:00). The other seven mice were not food and water 
deprived, but were given a pre-weighed bottle containing an 8% w/v sucrose solution, a 
pre-weighed bottle of tap water, and a set amount of food pellets for 24 h (14:00 to 14:00). 
Half of the mice, that were deprived and not deprived, had the sucrose bottle on the left 
side of the cage, and the other half had the sucrose bottle on the right side of the cage. 
After the sucrose tests the cages were given free access to food and water.
3, Statistical Analysis
Statistical evaluations were made with paired or unpaired Student’s t test, as indicated, or 
analysis of variance.
4. Results
Percentage preference for sucrose remained -86% with or without deprivation, and 
the amoimt of liquid consumed did not differ significantly (Table 3.8.). Therefore, the use
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of deprivation prior to the sucrose preference test does not appear to increase the volume of 
liquid consumed, or change the preference for sucrose. So to limit the number of stressors 
applied to the mice (i.e. single housing, odour and presence of rats, elevated plus-maze), 
deprivation was not used prior to the sucrose preference tests in subsequent experiments.
Table 3.8.
With or without 6 h food & water deprivation.
MEAN +/-SEM N
After 6 h food & water deprivation 85 ±3.1 7
Without 6 h food and water deprivation 88 ± 4.0 7
Sucrose preference (% w/v) of single-housed male BALB/c mice, after 24 h access to food, 
water and 8% sucrose solution, using the two-bottle preference test.
5. Conclusion
A two-bottle sucrose preference test was chosen, using singly-housed male 
BALB/c mice. This test was to be measured overnight. No food and water deprivation was 
to be carried out prior to the test and food intake would be included as part of the 
measurements.
CHAPTER 4. PREDATOR STRESS STUDY
4,1. Introduction
Several studies have shown that there are physiological and behavioural changes 
resulting from exposure to predatory stress. They include opiate and non-opiate-dependent 
analgesia (Hendrie & Neill, 1991; Kavaliers, 1988), increase immobility
149
(Hendrie et al, 1996) and increase of heart and breathing rate (Weiner, 1992). Moreover, if 
the exposure to a predator is prolonged, hyperthyroidism and a decrease of body weight are 
induced (Weiner, 1992). Additionally, there are decreases in food intake 
(Blanchard et al, 1993a; Hendrie & Neill, 1991) and inhibition of sexual behaviour 
immediately after the exposure to a predator (Blanchard & Blanchard, 1989). It is 
interesting to note that the predator stress in such studies is based on the threat of predation 
rather than on physical attack, indicating that the sensory stimuli (i.e., odours and calls) 
ft'om a predator specifically induce changes (Hendrie & Neill, 1991; Zangrossi & File, 
1992b).
The work of the Blanchards (Blanchard & Blanchard, 1989; Blanchard et al, 1998) 
provides evidence that the behaviours exhibited in the presence of a predator relate to fear, 
whereas those evoked by the odour of a predator indicate anxiety. However, there is also 
evidence to suggest that the nature of the anxiety induced by exposure to novelty and to 
predator odours may differ. There are also pharmacological differences; low doses of 
benzodiazepines have an anxiolytic effect in rat tests employing novelty, whereas only 
high doses change behaviour during exposure to cat odour. Behaviourally it has been 
shown that rats showing strong or weak avoidance of cat odour did not differ in other tests 
of anxiety. Interestingly, although on the first exposure there is a strong correlation 
between behavioural and corticosterone responses to cat odour, these measures dissociate 
with repeated exposures, with the corticosterone, but not the behavioural, response 
habituating.
Animals are capable of displaying diverse defensive reactions in response to 
external threats, e.g., a predator. In mammals (e.g., rats) such behaviours classically 
compromise fi'eezing, flight, defensive threat/attack and even death-feigning, and are 
dependent upon imminent threat and escape opportunity (Blanchard et al, 1990). However,
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research has shown that the rodent defensive repertoire is more elaborate than suggested by 
this classical description. In potentially dangerous situations (for example, when a predator 
has been seen but is no longer present), laboratory rats (Blanchard & Blanchard, 1989) and 
mice (Blanchard et al, 1995b) have been reported to engage in a cluster of behaviours 
collectively referred to as risk assessment. These responses, originally identified in 
specially constructed visible burrow systems, are characterised by cautious approaches to a 
surface area where a predator (cat) has briefly been presented and include; (i) scanning the 
danger area ft'om tunnel openings, (ii) stretch attend, or flatback, postures directed towards 
the danger area and (iii) stretched, or flatback, locomotion upon initial re-entry into the 
danger area. Very similar behavioural patterns have been observed in the rat defensive 
burying paradigm (Molewijk et al, 1995) and in mice exposed to conspecific odours 
(Kaesermann, 1986), supporting the contention that their function is to inform behavioural 
strategy in potentially dangerous situations (Blanchard et al, 1993b). As many animal 
models of anxiety are based upon exploration of novel (and hence, potentially dangerous) 
environments, it would be assumed that these situations should also elicit risk assessment.
More recently, Dielenberg et al (1999) demonstrated that rats confronted with a 
cat-odour impregnated collar displayed robust avoidance responses towards this stimulus. 
Such exposure also resulted in anxiogenic responses in the social interaction and elevated 
plus-maze tests (Zangrossi & File, 1992a), that is, when animals are no longer in the 
presence of the stressful predator odour.
Laboratory animals demonstrate a variety of endocrine changes in response to 
predator exposure. Groups of rats exposed to cat odour for the first time displayed 
significant increases in plasma corticosterone concentrations. However, this effect was
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found to habituate following five exposures (File et al, 1993) thus demonstrating a 
dissociation of behavioural and corticosterone responses to predator odour exposure.
Increased ACTH and plasma corticosterone concentrations were reported in rats 
five minutes afl:er cat exposure as compared to non-stressed controls
(Adamec & Shallow, 1993). This study also measured CRH, AVP and bombesin 
concentrations in specific regions of HP A circuitry. CRH levels were increased in the 
anterior hypothalamus and decreased in the dorsomedial hypothalamus. AVP 
concentrations were found to be reduced in the lateral hypothalamus.
These changes indicate that the status of the HPA axis is significantly altered 
following predator (odour) exposure. These data also verify the predator exposure 
procedure as being a stressful stimulus to many animals (i.e fish, marmosets, and squirrel 
monkeys) as elevations of ACTH and the concomitant release of corticosterone are 
hallmarks of the stress response (Weiner & Levine, 1992; Barros et al, 2001; Kagawa & 
Mugiya, 2002).
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4.2, Aims
To determine if the stress induced by predatory stimuli, as indicated by the plasma 
concentrations of corticosterone, would affect:
1. The specific binding of ^H-dexamethasone to cortical GR. We were particularly 
interested to see if any reductions in brain GR would occur following chronic predator 
stress which would be consistent with a GR down-regulation hypothesis in depression 
(refer to section. 1.3.3).
2 . Their behaviour in two tests -  namely the sucrose preference test, which has been used 
as an indicator of “depression” (WiUner et al, 1992; Papp et al, 1996) and the EPM test, 
which has been used as an indicator of “anxiety” (Pellow et al, 1985; Hogg, 1996).
4.3. Chronic Stress Study
As described in the previous chapter (Chapter 3), both sucrose preference and the 
EPM tests had been optimised in order to be used in this study. In the present study, 
predator stress was induced by exposing male BALB/c mice to the visual presence and 
odour of wild male Brown Norway rats housed in the same room. We decided to use 
BALB/c mice in our studies, as these are known to display high reactivity to stress 
(Lu et al, 1998; Karen Mellowdew, Institute of Psychiatry, personal communication) - with 
Brown Norwegian rats as the predator species (as these are not kept in our animal facihty 
and would possess a novel odour). Using the idea of predator odour as a chronic stressor 
and the visual presence of a predator as an acute stressor we aimed to produce a pattern of 
intense behavioural and endocrine responses that would be very slow to habituate. Rats 
have been observed, in nature as well as in the laboratory, to kill and consume mice 
(Karh, 1956; O’Boyle, 1975). Preliminary behavioural investigations by Griebel et al 
(1995), have clearly demonstrated the importance of the presence of a rat to ehcit the fiill 
range of specific fearfirl/defensive behaviours in the mouse.
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4,3A, Method 
L Animals
Adult male BALB/c mice from the Nescot breeding colony, weighing about 30g 
were singly housed and maintained in a controlled temperature (24°C), constant humidity 
(-55%) and a 12h light:dark cycle (lights on from 7:00h to 19:00h). Mice were left for at 
least three weeks with food and tap water available ad libitum, to habituate to the single 
housing. The use of these animals in the following scientific procedures were regulated by 
the Animals (Scientific Procedures) Act 1986.
2, Predator Stress Procedure
Due to the results from the previous chapter, a two-bottle sucrose preference test was 
chosen, using singly-housed male BALB/c mice. This test was to be measured overnight. 
No food and water deprivation was to be carried out prior to the test and food intake would 
be included as part of the measurements.
Mice were given 48h pre-exposure to a two-bottle test; one containing an 8% sucrose 
solution and one containing tap water, counterbalanced across the cage. The animals were 
given free access to food pellets during this training period. Mice were tested weekly, on 
the plus-maze and the two-bottle sucrose preference test for three weeks to achieve a 
stabilised baseline.
After the baseline of sucrose preference had stabilised, approximately three weeks, the 
mice that had not significantly preferred sucrose to the tap water (achieved >60% 
preference for sucrose) were excluded before the mice were placed into relevant groups. 
These groups were:
(1) Mice sacrificed after 4 weeks of the stressors (n =14),
(2) Mice sacrificed after 8 weeks of the stressors (n =14),
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(3) Mice sacrificed after 8 weeks of the stressors + 2 weeks after the stress was removed 
(n =14), and
(4) Mice sacrificed after 8 weeks of the stressors, and then tested for the first time on the 
elevated plus-maze (n =14).
Half of these groups {stressed group) were placed in a separate room and subjected to 
the predator stressor, whilst the others remained in their home room {control group; 
Figure.4.1.). The predator stressor involved continuous exposure to the odour of male 
Brown Norway rats, m cages within the room and the intermittent exposure of the mice to 
the visual presence of the male Brown Norway rats. This involved placing the mice, in 
their home cages, in a playpen (100 x 68 x 65cm) filled with foam packing (this was 
provided as a distraction for the rats as well as to support the cages within the playpen). 
Then placing 1 / 2 / 3  rats (the number of rats was random) into the playpen to move freely 
around for about 3 min. This stress procedure was conducted randomly in the morning or 
the afternoon, and at least once a day for up to 8 weeks.
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Figure.4.1
Stress Room
Elevated
Pliis-Maze
Room
Control Room
MICE RATS PLAYPEN
Allocation of animals during the different phases of the experimental proeedure.
All of the mice (except group 4) were tested weekly on the elevated plus-maze and 
the two-bottle sucrose preference test. The mice in the “stress” room were tested after their 
last acute stressor, and the controls were tested at the same time. Each time we took care to 
change clothes when entering and leaving the “stress” room, to avoid the transfer of odour 
etc, from the rats to the control animals.
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3. Elevated Plus-Maze (EPM)
As described in Section 3.2.1. The effects of repeated testing (“trials”) and “stress” 
on gross plus-maze profiles were initially analysed by two-factor repeated measures 
ANOVA (trials x stress), followed by Newman-Keuls comparisons. One further statistical 
approach was used to identify patterns of behavioural change within and between trials. 
The data for each 5-min trial were broken down into 1 min time bins and subjected to a 
three-factor repeated measures ANOVA (trial x stress x time bin), followed by Newman- 
Keuls comparisons.
The data was subjected to a two-factor repeated measures ANOVA analysis, unless 
otherwise stated. In addition, ANOVAs of separate groups were used and post hoc 
comparisons were carried out with the Newman-Keuls test. Student’s /-test was applied 
when necessary. In all cases, the level of significance used was p < 0.05.
4, Sucrose Preference Tests
For the two-bottle sucrose preference test, each mouse was given a pre-weighed 
bottle containing an 8% sucrose solution and a pre-weighed bottle containing tap water, 
counterbalanced across their home cage, for 17 h (16:00 to 09:00). Half of the mice were 
given the sucrose bottle on the left; side of the feeding compartment, and the other half 
were given the bottle on the right side of the feeding compartment. The bottles were 
alternated for each test, to prevent placement preference. Food consumption was also 
determined, over the 17 h test period, by re-weighing a set amount of food pellets. This 
involved collecting the remains of the pellets within the cage, to prevent these from being 
calculated as consumed. All tests were carried out in the home cage to prevent unnecessary 
stress and to avoid any extraneous effects attributable to a novel environment (Figure. 4.1.).
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The effects of repeated testing (“trials”) and “stress” on gross plus-maze profiles 
were analysed by two-factor repeated measures ANOVA (trials x stress), followed by 
Newman-Keuls comparisons.
5. Radioimmunoassay o f plasma corticosterone concentrations
Plasma corticosterone concentrations were measured by using gamma-B - 
Corticosterone radioimmunassay commercial kits (refer to Section 2.4.).
The effects of repeated testing (“trials”) and “stress” on gross plus-maze profiles 
were analysed by two-factor completely randomised ANOVA (trials x stress), followed by 
Newman-Keuls comparisons.
6. Specific binding of^H-dexamethasone to mouse cytosolic corticosteroid receptors
Mice, fi*om the “stress” room, were sacrificed 24 h after the last introduction of the 
acute stressor, and the controls were sacrificed at the same time. All sacrifice and 
dissection procedures were conducted as described in section 2.3.2. Preparation of mouse 
cytosolic fi-actions was carried out essentially as described in section 2.3.5. Subsequent 
procedures and analysis were carried out as described in section 2.3.
The effects of repeated testing (“trials”) and “stress” on gross plus-maze profiles 
were analysed by two-factor completely randomised ANOVA (trials x stress), followed by 
Newman-Keuls comparisons.
7. Protein measurement
Protein content was measured using Lowry’s method with bovine albumin as 
standard (Lowry et al, 1951).
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4.4. Results
4.4,L Corticosterone Radioimmunoassay
Statistical analysis indicated that time alone significantly affected the plasma 
corticosterone levels (F2,36=25.36; p<0.0001), and so did stress alone
(Fi,36=8.124; p=0.0072). The combined effect of time and stress was also highly 
significant (F2,36=5.351; p=0.0092).
Plasma corticosterone concentration did not differ fi*om controls in mice exposed to 
predator stress for 4 weeks, but was significantly higher (by 97%) in those exposed to 
predator stress for 8 weeks. Following 10 weeks of predator stress, plasma corticosterone 
did not differ fi*om controls (Figure 4.2A). Control values significantly varied between 10 
and 50 ng/ml.
When Group 2 (8 weeks of stress or non-stress with weekly EPM tests) was 
compared to Group 4 (8 weeks of stress or non-stress followed by the first EPM test) they 
were not significantly different, suggesting that the EPM test alone had no effect upon the 
plasma corticosterone levels (Figure 4.2B).
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Figure. 4.2.
Plasma corticosterone concentration following exposure
to predator stress.
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Plasma corticosterone concentration in singly-housed male BALB/c 
mice (n = 7 per group), were measured in samples taken immediately 
following exposure to predator stress. Data are expressed as 
mean ± sem. (A) Comparison between control mice left in their 
holding room (control group) and mice exposed to predator stress for 
4 weeks, 8 weeks or 10 weeks before they were sacrificed 
(stress group). (B) Comparison between mice exposed to 8 weeks o f 
EPM in combination with predator stress (8 + EPM) and mice 
exposed to a single EPM following 8 weeks o f predator stress (8). 
##, p<0.01 compared to control; **, p<0.01 compared to 4 weeks o f 
control; **, p<0.01 compared to 4 weeks exposure to predator stress.
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4,4»2, Glucocorticoid Receptor (GR) Binding
There was no significant difference in either Bmax or Kd values, between stressed 
and control mice (Table 4.1.). Although, control Bmax values steadily increased fi*om 110.8 
to 135.5 finol/mg protein.
Table 4.1.
Glucocorticoid receptor Bmax and IQ values in cortical cytosolic fractions, following exposure
to predator stress.
GROUPS N
Bmax 
(fmol/mg protein)
Kd
(nM)
4 weeks "control." 6 110.8+/-9.7 3.5 +/- 0.9
4 weeks "stress" 6 148.0 +/-14.0 2.6 +/- 0.4
8 weeks "control” 6 127.1 +/-16.8 2.7 +/- 0.5
8 weeks "stress" 6 122.3 +/-10.9 2.7 +/- 0.4
10 weeks "control” 6 135.5 +/-10.6 2.2 +/- 0.3
8 weeks "stress" + 2 weeks after 
the removal of "stress" 6 114.4+/-6.5 2.6 +/- 0.5
8 weeks "control" followed by
the first EPM test. 5 133.9 +/- 10.3 2.8 +/- 0.7
8 weeks "stress" followed by 
the first EPM test. 5 132.3 +/- 13.9 4.0+/- 1.2
Specific ^H-dexamethasone binding to cortical GR (taken from singly-housed male BALB/c mice) 
was measured following exposure to predator stress. Samples were taken immediately after 
exposure to predator stress. Data are expressed as mean ± sem. No statistically significant 
differences were found between control and stress groups.
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4.4,3. Sucrose Preference
Sucrose preference remained high throughout (~ 90%) and did not differ between 
the groups (Figure 4.3.). Food intake gradually decreased by 40% in the stressed mice 
(Figure 4.4.), from 5-3g, compared to the baseline, although it did not differ between the 
groups. No significant differences were found between and within groups in terms of body 
weights (Table.4.2.).
Table.4.2.
Body weights (g) of control and stress singly housed male BALB/c mice.
Session Trial
(weeks)
Groups
Control Stressed
Mean +/- SEM
N
Mean +/- SEM
N
BASELINE 1 29.9 +/- 0.03 55
2 29.9 +/- 0.03 55
3 29.9 +/- 0.03 55
STRESS 1 29.5 +/- 0.44 21 30.3 +/- 0.66 21
2 29.8 +/- 0.42 21 30.2 +/- 0.71 21
3 30.8 +/- 0.53 21 30.2 +/- 0.79 21
4 29.9 +/- 0.53 21 30.5 +/- 0.81 21
5 30.2 +/- 0.73 14 29.9 +/-1.15 14
6 30.5 +/- 0.76 14 30.3 +/-1.14 14
7 30.5 +/- 0.82 14 30.2+/-1.15 14
8 30.4 +/- 0.87 14 30.8+/-1.17 14
REMOVAL 1 30.7+/-1.04 7 29.7+/-1.00 7
OF STRESS 2 31.3+/-0.96 7 30.0 +/- 0.98 7
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Figure. 4.3.
Sucrose preference (% of total fluid intake) follow ing  
predator stress exposure.
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Sucrose preference (% o f total fluid intake) measured over 22 h, 
from singly-housed male BALB/c mice (n = 10 per group), 
immediately after exposure to predator stress. Data are expressed 
as mean ± sem. Comparison between control mice left in their 
holding room (control group) and mice exposed to predator stress 
(stress group), before they were sacrificed. Baseline values 
calculated prior to allocation to either o f the groups. ##, p<0.01 
compared to control.
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Figure. 4.4.
Food intake (g) fo llow in g  predator stress exposure.
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Food intake (g) m easured over 22 h, from  singly-housed male 
BALB/c mice (n = 10 per group), imm ediately after exposure to 
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between control m ice left in their holding room  (control group) 
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4,4,4. ElevatedPlus-Maze (EPM)
A) Effect of Repeated Test Experience and **Stress^ :^
L Arm Entries
After just one attempt on the elevated plus-maze, mice seemed to be significantly 
stressed, as they made almost no open arm entries by Trial 2 (Figure.4.5A and B).
Throughout the “stress” period (Trial 4-11) statistical analysis indicated that stress 
significantly afiected the percentage of open arm entries (Fi,264=H5.9; p<0.0001), as well 
as repeated trials (F7,264=1097; p<0.0001). Yet, only repeated trials significantly affected 
the percentage of closed arm entries (F7,264=3.687; p=0.0008). Statistical analysis also 
indicated that stress (Fi,264=6.676; p=0.0103) and repeated trials (p7^264=3.736; p=0.0007) 
significantly affected the total arm entries, including an 81% increase in the response by 
the stress mice compared to the controls in Trial 10 (Figure.4.6.), suggesting an increase in 
locomotion by the stressed mice.
As soon as the stress was removed, statistical analysis indicated that stress 
( F i ,2i= 7 6 .7 ;  p<0.0001) and repeated trials (F 2 ; z i= l l .G 9 ;  p=0.0005) significantly affected the 
percentage of open arm entries as well as the percentage of closed arm entries 
( F i ,3o= 2 1 .7 4 ;  p<0.0001 and F 2 ,3 o = 5 .4 5 4 ; p=0.0095, respectively). The stress group 
increased their percentage of open arm entries whilst the control response was decreased 
towards baseline values (Figure.4.5B). Therefore, the first two weeks after the removal of 
stress provoked an increase in open arm entries in the stress group and a decrease in the
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control group. This was emphasised by the significant decrease in the total arm entries 
(Fi,26=4.35; p=0.0470) by the control mice, during this period (Figure.4.5A).
F igure.4 .5 .
Percentage Arm entries on the EPM following exposure to predator stress.
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BALB/c mice (n=8 per group) were subjected to elevated plus-maze (EPM) tests immediately 
following predator stress exposure. Data are expressed as mean ± sem. (A) % open arm entries and 
(B) % closed arm entries during a 5 min trial per week (n = 21 for baseline and weeks 1-4 of the stress, 
n = 14 for weeks 5-8 of the stress, and n = 7 for the 3 weeks after the stress was removed). Mice were 
given free access to food and water throughout. Baseline values are the means prior to allocation to 
either of the groups. #, p<0.05; # #, p<0.01 compared to control; **, p<0.01; ***, p<0.001 compared 
to baseline, within the stress group.
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BALB/c mice (n=8 per group) were subjected to elevated plus-maze (EPM) tests immediately 
following predator stress exposure. Data are expressed as mean ± sem. Total arm entries 
(total counts of open + closed arm entries), during a 5 min trial per week (n = 21 for baseline and 
weeks 1-4 of the stress, n = 14 for weeks 5-8 o f the stress, and n = 7 for the 3 weeks after the stress
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was removed). Mice were given free access to food and water throughout. Baseline values are the 
means prior to allocation to either of the groups. #, p<0.05 compared to control; *, p<0.05; 
**, p<0.01; **, p<0.001 compared to baseline, within the stress group.
Figure.4.7.
Time spent in the different sections of the EPM following exposure to
predator stress.
(A)
BALB/c mice (n=8 per group) 
were subjected to elevated 
plus-maze (EPM) tests 
immediately following exposure 
to predator stress. Data are 
expressed as mean ± sem.
(A) Time shown as seconds 
spent on the open arms 
(% of the total time spent on the 
maze), (B) Time shown as
seconds spent on the closed 
arms (% of the total time spent 
on the maze) , and (C) Time 
shown as seconds spent on the 
centre platform (% of the total 
time spent on the maze), during 
a 5 min trial per week 
(n = 21 for baseline and weeks 
1-4 of the stress, n = 14 for 
weeks 5-8 of the stress, and 
n = 7 for the 3 weeks after the 
stress was removed). Mice were 
given free access to food and 
water throughout. Baseline 
values are the means prior to 
allocation to either of the 
groups. **, p<0.01 compared to 
baseline, within the controls.
S a
£>.=I I
50
45
40
35
30
25
20
15 -10
5
0
-5
-10
control
stress
T 1 1 I -
0  1 2  3  4
Baseline
6 7 8  9
Stress
Trials
10 11 12 13 14 
Post-Stress
(B)
s i
1 1
g, o o
l l l
100
90
80
70
60
50
40
30
20
10
0-1------1------1 1 h
0 1 2  3  4
Baseline
6 7 8 9 10 11 12 13 14
Stress Post-Stress
Trials
(C)
30
20
ill
0 1 2 3  4 5
Baseline
6 7 8 9
Stress
Trials
10 11 12 13 14
Post-Stress
1 6 8
Throughout the “stress” period (Trial 4-11) statistical analysis indicated that only 
repeated trials significantly afiected the percentage of time spent on the open arms 
(F7,264=8.831; p<0.0001) and the closed arms (F7,264=3.660; p=0.0009). As soon as the 
stress was removed, statistical analysis indicated that stress (Fi,25=5.687; p=0.0250) was 
only significant upon the time spent on the open arms. Time spent on the central platform 
was not statistically significant during the “stress” and “post-stress” trials, between the 
groups (Figure.4.7 A-C). Therefore, the mice, controls or stress, spent most if not all of 
their time in the closed arms.
i t  Non-exploratory Behaviour and Defecation
After 3 weeks of baseline measurements, grooming scores increased by 700%. 
During the “stress” period (Trial 4-11) statistical analysis indicated that stress significantly 
increased the grooming scores (Fi,264=5.656; p=0.0181), but had no significant effect after 
the removal of the stressors (Figure.4.8A). No fi'eezing/immobility was scored for any of 
the mice, throughout the study. Defecation scores were not statistically significant during 
the “stress” and “post-stress” trials, between the groups (Figure.4.8B).
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Figure .4.8.
Non-exploratory behaviour and defecation on the EPM 
following exposure to predator stress.
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BALB/c mice (n = 8 per group) were subjected to elevated plus-maze 
(EPM) tests immediately following exposure to predator stress. Data 
are expressed as mean ± sem. (A) Total counts of grooming and
(B) total counts of defecation, during a 5 min trial per week 
(n = 21 for baseline and weeks 1-4 of the stress, n = 14 for weeks 
5-8 of the stress, and n = 7 for the 3 weeks after the stress was 
removed). Mice were given free g(%pss to food and water throughout.
UL Risk Assessment Behaviour
Throughout the “stress” period (Trial 4-11) statistical analysis indicated that stress 
(Fi,264=94.25; p<0.0001) and repeated trials (F?^64=142.7; p<0.0001) significantly affected 
the number of returns into the closed arms (Figure.4.9A), as well as the responses of 
scanning with head-dipping (Figure.4.10B) by the mice (Fi^64=5.983; p=0.0151 and 
F?,264=7.391; p<0.0001, respectively). Sniffing responses and the number of stretch-attend 
postures (SAP) exhibited by the mice (Figure.4.10A and C), were only significantly 
affected by the repeated trials (F7,264=7.001; p<0.0001 and F?^64=3.609; p=0.0010, 
respectively), whereas the amount of rearing by the mice was significantly affected by 
stress (Fi^64=7.904; p=0.0053). The amount of exploring of the ends of the arms, by the 
mice, was not statistically significant between the two groups during this period.
As soon as the stress was removed, statistical analysis indicated that scanning with 
head-dipping was significantly affected by repeated trials (Fi,26=3.73; p=0.0377), the 
amount of rearing by the mice was significantly affected by repeated trials 
(F2,26=3.526; p=0.0442), and the number of SAPs were significantly affected by stress 
(Fi,27=9.041;; p=0.0057). Both sniffing and end-exploring responses were not statistically 
significant between the two groups after the removal of the stressors. Control values for all 
these behaviours were variable throughout the study.
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Overall, the risk assessment behaviour was increased in the stress mice during the 
introduction of stress (especially end-exploring and scanning with head-dipping), but there 
was no significant difference between stressed mice and controls during these trials. Once 
the stress was removed, previously stressed mice gradually decreased in all the behaviours 
whereas the controls remained stable or gradually increased. This is more pronounced in 
the scanning with head-dipping, but there were also no significant differences between 
stressed and controls in this period of the study.
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Figure.4.9.
Risk assessm ent behaviours exhibited on the EPM following 
exposure to predator stress.
BALB/c mice (n=8 per group) 
were subjected to elevated 
plus-maze (EPM) tests 
immediately following exposure to 
predator stress. Data are expressed 
as mean ± sem. (A) Total counts of 
closed arm returns, (B) total 
counts of end-exploring of the 
arms , and (C) total counts of 
rearing, during a 5 min trial per 
week (n = 21 for baseline and 
weeks 1-4 of the stress, n=  14 for 
weeks 5-8 of the stress, and n = 7 
for the 3 weeks after the stress was 
removed). Mice were given free 
access to food and water 
throughout. Baseline values are the 
means prior to allocation to either 
of the groups. #, p<0.05 compared 
to control; *, p<0.05 compared to 
baseline, within the control 
group; *, p<0.05; **, p<0.01;
***, p<0.001 compared to
baseline, within the stress group.
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Fîgure.4.10.
Risk assessm ent behaviours exhibited on the EPM following exposure
to predator stress.
BALB/c mice (n=8 per group) 
were subjected to elevated 
plus-maze (EPM) tests 
immediately following exposure 
to predator stress. Data are 
expressed as mean ± sem. 
(A) Total counts of sniffing, (B) 
total counts of head-dipping 
/scanning , and (C) total counts 
of stretch-attend postures (SAP), 
during a 5 min trial per week 
(n = 21 for baseline and weeks 
1-4 of the stress, n = 14 for 
weeks 5-8 of the stress, and 
n = 7 for the 3 weeks after the 
stress was removed). Mice were 
given free access to food and 
water throughout. Baseline values 
are the means prior to allocation 
to either of the groups.
#, p<0.05, ##, p<0.01
compared to control; *, p<0.05 
compared to baseline, within the 
control group; *, p<0.05;
***, p<0.001 compared to
baseline, within the stress group.
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4.5 Discussion
Plasma corticosterone concentrations were significantly elevated by chronic 
predatory stress, compared to controls, and this response was abolished 2 weeks after the 
removal of the stressors. According to previous investigations, exposing mice to a rat 
reliably increases plasma corticosterone concentrations and may affect immune 
functioning (Lu et al, 1999).
Previous findings (Pellow et al, 1985; Holmes et al, 1998) have shown that 
repeated exposure to the plus-maze results in significant elevated plasma corticosterone 
concentrations. The current results show there was no difference between the group of 
mice that had been tested on the plus-maze for the first time after 8 weeks and the group 
that had been tested weekly for 8 weeks, suggesting that repeated exposure to the plus- 
maze alone had no significant effect upon the plasma corticosterone levels in this current 
study.
There was no significant difference (Table.4.2.) in Bmax or IQ values of GR, 
between stressed and control mice throughout the study. There was a trend in Bmax 
towards an increase in the stressed mice at 4 weeks, compared to their controls, but this did 
not reach statistical significance, suggesting a possible upregulation of glucocorticoid 
receptors after 4 weeks of stress.
It would have been beneficial if the current study had examined GR mRNA as well 
as GR, as stressfiil stimuli are known to affect GR mRNA levels in the rat brain. A recent 
study by Paskitti and colleagues (2000) examined the effect of acute and chronic stress on 
the regulation of the expression of the GR and MR genes in the hippocampal formation. 
They concluded that acute stress decreases the availability of GR mRNA without 
demonstrably affecting transcription, suggesting reduced GR mRNA stability. Therefore 
acute stress decreases GR mRNA expression by largely post-transcriptional mechanisms. 
However, elevations in basal corticosterone secretion seen following chronic stress are not
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sufficient to markedly down-regulate GR/MR expression in a long-term fashion. Kitraki et 
al (1999), showed a statistically significant down-regulation of GR mRNA both in the 
hippocampus and in the cerebellum of rats stressed for 8, 10 and 14 days. The same degree 
of down-regulation was also detected in the same brain areas of rats stressed for 14 days 
and left undisturbed for 48h or 8 days after stress.
Transgenic mice expressing antisense RNA against GR have shown that 
impairment of GR evolves in disturbed neuroendocrine regulation and certain behavioural 
responses to stress. This life-long glucocorticoid receptor impairment has profound 
consequences for neuroendocrine regulation (unaltered corticosterone concentrations) and 
certain behavioural responses (increased grooming behaviour) to stress (Linthorst et al, 
2000).
The results obtained in this study showed that sucrose preference remained very 
high at about 80-90% (Figure 4.3.). Thus, this study did not show that the sucrose 
preference test detected any changes in the mice after exposure to predator stress. This 
contrasts with the results obtained in a similar study by Calvo-Torrent et al (1999), who 
showed that predatory stress attenuated the level of sucrose intake after 2-3 weeks of 
chronic exposure, similar to that observed with a variety of other stressors in rats 
(Katz, 1982; Papp et al, 1996) and mice (Monleon et al, 1995). There are a number of 
differences between these two experiments: the animals used (they use GDI mice, whereas 
we use BALB/c mice), test procedures differ (we handled our mice daily, theirs appeared 
unhandled; they tested during the dark phase, we tested during the light; they had food and 
water deprivation prior to the sucrose tests, we had food and water freely available 
throughout; our trials on the elevated plus-maze were 5 min, whereas theirs were 10 min), 
predatory stress procedures differed (their stress room consisted of male rats paired with 
females, offspring with their mothers as well as young group-housed male and female rats, 
whereas ours only consisted of group-housed male Brown Norway rats; their stressed mice
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could only smell and hear the rats, whereas ours also had the physical presence of the rats). 
Both the sucrose preference and elevated plus-maze data are very sensitive to 
methodological factors, any one (or combination) of these variables could account for the 
dififerences observed.
Food consumption followed a similar trend in both groups and gradually decreased 
throughout the study. No significant differences were found between groups and within 
groups in term of their body weights (Table.4.3.). So although the mice appeared to reduce 
their food intake after exposure to predator stress, this did not appear to have an impact 
upon their body weights.
Despite previous studies showing that individual housing can increase food 
consumption and body weight in rats, and that social isolation is associated with pain 
inhibition and increased measures of anxiety. Moles and Cooper (1995) did not fitnd any 
difference in the sucrose intake in individually housed male mice in comparison with male 
mice housed in pairs. This suggests that, unlike male rats, male mice do not consume a
higher amount of palatable food when housed in social isolation. Differences in the social 
organisation of the two species may account for the diverse impact of individual housing 
on isolation-induced food intake. In fact, as territorial animals, male mice tend, in natural 
situations, to be “behaviourally isolated” in that they do not tolerate mature conspecifics in 
their territory.
Muscat and Willner (1992) demonstrated that the reduction of sucrose consumption 
by chronic mild stress is independent of housing conditions. In particular, the effect does 
not depend upon the imposition of isolation stress on the control group. Therefore, this 
current study has not shown the widely hypothesised theory that there should be a 
significant reduction in sucrose consumption, and preference, by the stressed mice. It has 
also been suggested by Muscat and Willner (1992), that stressed animals actually tend to
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eat more than controls, rather than less, an effect also observed in other studies. This was 
not evident in the current study.
After a week’s exposure to the predator, the stress mice showed an increase in 
closed arm entries and total arm entries compared to their controls 
(Figure.4.5. and Figure.4.6.). There were also increases in non-exploratory behaviour, i.e. 
grooming (Figure.4.8A), as well as risk assessment behaviours, i.e., end-exploring, rearing, 
sniffing and scanning (Figure.4.9. and Figure.4.10.). After 8 weeks of chronic predatory 
stress, stressed mice visited the open and closed arms more frequently, although the time 
spent in them was unchanged from their controls. No differences were found between 
groups in terms of risk assessment or emotionality, as expressed by the amount of faecal 
boli present on the maze (Figure.4.8B).
The first two weeks after the removal of stress provoked an increase in open arm 
entries in the stress group and a decrease in the control group. This suggests that control 
mice were more stressed and did not want to enter the open arms and remained in the 
closed arms, and the stress mice become bolder and wanted to enter the open arms more 
frequently than before and stayed away from the closed arms. This is reflected in the total 
arm entries, whereby there is a 170% increase by the stress mice, compared to the controls, 
in Trial 13 (Figure.4.6.).
In an extensive investigation of the plus-maze performance of 16 inbred mouse 
strains, Trullas and Skolnick (1993) found that over 70% of the variance in open-arm 
activity measures could be attributed to genetic factors. Using a derived index of plus-maze 
responsivity, they were able to categorise strains into four distinct groups: nonreactive 
(e.g., BALB/c), intermediate-low reactive (e.g., C3H.SW/SnJ), intermediate-high reactive 
(e.g., DBA/2J), and high reactive (e.g., C57BL/6J).
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Despite these strain differences in initial response patterns, present findings 
confirm that prior maze experience produces major changes in the way in which rodents 
react to this test (Lee & Rodgers, 1990; Gonzalez & File, 1997). Ethological analysis 
demonstrates that changes occur in many of the behaviours and not just the conventional 
plus-maze indices. Measures that were displayed consistently between trials were entry 
latency (decrease), centre time (decrease), head dipping (decrease), percent open entries 
(decrease), closed-arm entries (increase), and closed time (increase). Thus, on retest, mice 
move more rapidly from the centre platform into a closed arm, spend more time in the 
closed arms and less time on the centre platform, and show less exploratory head-dipping. 
The present results from the control mice confirm this, although they showed an increase 
in exploratory head-dipping.
According to Calvo-Torrent et al (1999), after being exposed to chronic predatory 
stress, stressed mice showed a higher level of anxiety (spent less time on the open arms 
and showed a lower frequency of unprotected head-dipping) than controls, although no 
differences in the level of emotionality were observed.
There is a relationship between preference for the closed arms and the total number 
of arm entries. An animal that has a marked aversion to the open arms is restricted to 
exploring only two (closed) arms, in contrast to the animal that does venture out on to the 
open arms. It is suggested that it would therefore habituate more rapidly to the two closed 
arms, thereby making fewer total entries than the animal that explores all four arms. The 
present results showed that the mice, in both groups, remained almost exclusively in the 
closed arms, but the stressed mice significantly enter more arms than the control mice. So 
although they appeared to be limited to only two closed arms, the stressed mice seemed 
more active and preferred to move rapidly between the two arms.
The influence of the central square on the behaviours detected in the plus-maze is 
largely unknown, although it has been suggested that the exploratory behaviours seen in
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this area of the maze may relate to some kind of assessment and/or decision-making 
process. In this current study, time spent on the central platform was not statistically 
significant between the groups. Although, two factors relating to central square activity 
were identified in the factor analysis performed in the Fernandes and File study (1996), 
and these factors were considered to separately reflect assessment and/or decision-making 
related to the openness and to the height of the maze viewed from the protected areas of 
the maze. Previous factor analyses have also identified factors related to central square 
activity, and this area may, thus, play an integral role in determining the avoidance of the 
open arms of the plus-maze.
Either forced or voluntary passage onto the open arms of the EPM has been 
associated with elevated plasma corticosterone concentrations, increased freezing, and 
production of faecal boli, hormonal and behavioural changes that are indicative of 
increased anxiety. Expression of the open arm data as % of the total number of arm entries 
(% open entries) or total time spent (% total time) on either the open or closed arms 
corrects for overall changes in exploration of the maze and helps reduce activity-induced 
artefacts. Locomotor activity was assessed by monitoring the total or closed arm entries, 
the latter being a purer measure as it changes independently of % open entries and % total 
time.
The behaviour of the mice on the EPM did not appear to change with repeated 
testing according to this present data, although contradictory results have been described in 
the literature. Treit et al (1993) not only reported that rats increase their avoidance of open 
arms on retest, but also found no evidence of habituation after 18 daily trials. Furthermore, 
a single forced exposure to the open arms greatly reduced 24 h retest escape latencies from 
an open arm and markedly increased time spent in the enclosed arms. This evidence 
suggests that rodents retain a strong memory for the threat posed by the open arms, and it 
is consistent with an experimentally induced sensitisation of fear.
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The EPM data in this study appears badly flawed, perhaps due to the set-up alone 
being too “stressfiil,” i.e., maybe the 60W spotlight was too bright or the experiment 
should have been conducted under less intense red light, the mice may have needed time to 
habituate to the test room before being placed onto the maze, using opaque perspex made 
the maze more anxiolytic with the light, maybe we should have tested during the dark 
phase etc. These factors may have contributed to an anxiogenic effect caused by the plus- 
maze alone in this study, attributing to the mice remaining primarily in the closed arms and 
therefore proving impossible to detect a change with the added predator stressor.
Falter et al (1992) showed that none of the environmental changes, including light 
intensity, form or height of the maze, or a stressful experience prior to testing, such as 
immobilisation or electric shock, was able to alter the pattern of exploration in the plus- 
maze. The lack of effect of such a wide range of stressors suggests that the anxiety 
modelled in the plus-maze in that particular rat population was rather a situational-bound 
response, elicited in rodents introduced into that particular environment.
A similar resistance in the baseline exploration level in control animals, to 
modification by external factors, has previously been reported by Fellow (1986) who found 
that neither habituation, increased illumination, nor isolation, induced significant changes 
in the exploration of the control animals. Nevertheless, under certain extreme conditions, it 
is possible to decrease significantly the open arm visits in control animals. For instance, by 
increasing the light intensity on the plus-maze from 20 lux up to 1200 lux, Morato and 
Castrechini (1989) succeeded in reducing significantly the exploration of the open arms. 
Long-term social isolation from the day of weaning constitutes another extreme condition. 
Isolated animals are aggressive and neophobic as well as show an anxiety-like profile in 
the elevated plus-maze test and increased locomotor activity (Hilakivi et al, 1989).
One important inter-laboratory variation in plus-maze methodology is the presence 
of open arm ledges. Ledges have been added to the open arms to both encourage open arm
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exploration and to prevent animals falling off the maze following drug administration. 
However, the results of Fernandes and File’s (1996) study have shown that the inclusion of 
ledges on the open arms is not a trivial alteration in plus-maze construction. Comparison of 
the factor analyses on the behaviours measured in the plus-mazes, with and without ledges, 
found clear distinctions between the two mazes.
The presence of ledges not only reduced the value of the number of closed arm 
entries, as a measure of activity in the maze, again stressing the need for caution when 
interpreting activity in this test, but on trial 1 also shifted the loading of unprotected head- 
dipping from the factor reflecting anxiety to a separate factor. It is possible that there is a 
reduction in the nature/extent of the anxiety/fear presented by the open arms with ledges, 
and as a consequence, head-dipping behaviour no longer relates to anxiety but to a directed 
exploratory behaviour assessing the height of the maze.
4.6 Conclusions
These results indicated that exposure to the presence and odour of a potential 
predator (rat) increased the plasma corticosterone concentrations and that this response was 
abolished 2 weeks after the removal of the predator, indicating that this natural threat was a 
source of stress in these male mice.
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CHAPTER 5. THE EFFECT OF ACUTE AND CHRONIC 
RESTRAINT STRESS IN RATS UPON THE HPA AXIS
5.1. Introduction
5.1.1. Restraint stress as a model for stress /  depression
The ability to respond to stress is a fundamental mechanism in mammals, one that 
involves the activation of the HPA axis (Sapolsky & Meaney, 1986), culminating in the 
release of corticosterone from the adrenal cortex.
In 1936, Selye reported that certain physiological changes occurred in experimental 
animals exposed to a wide variety of stressors. These changes represented some of the 
classic signs of the stress syndrome -  adrenal hypertrophy and thymicolymphatic 
involution. Selye observed that immobilising or restraining the rat led to the manifestation 
of his stress syndrome (Selye, 1936). Many different restraint procedures have 
subsequently been used. Historically, the restraint procedure was used as an experimental 
procedure for producing gastric lesions in the rat. In the 1960’s, Bonfrls and Lampling 
(1963) popularised the restraint procedure, and the technique was intensely studied in 
North America by Brodie and his co-workers (for a review see Brodie, 1971). Since then, 
many effective procedures have been developed for immobilising animals and the data 
generated has expanded to include central neurochemical consequences of stress, as well as 
drug effects upon these responses. Immobilisation is now used as a standard stress 
procedure for the purpose of observing the various physiological and biochemical 
responses to stress.
5.1.2» Endocrinological changes following restraint stress
Exposure of rats to stressful stimuli results in a marked elevation of plasma ACTH
and corticosterone concentrations (Cook et al, 1973; Suemaru et al 1985). It is generally
recognised that corticosteroid hormones exert a negative feedback signal, on both the
pituitary and the hypothalamus, capable of inhibiting HPA axis activity.
11
Repeated exposure to stress often leads to adaptation within stress response systems 
that is evident by a change in the magnitude of subsequent elicited stress responses. In 
some cases repeated stress leads to an enhanced or sensitised stress response and in other 
cases it leads to blunted or habituated stress response (Pitman et al, 1990; McCarty & 
Gold, 1996).
Repeated homotypic stress can result in habituation of corticosterone responses, 
and this has been described for restraint stress (Armario et al, 1988; Hashimoto et al, 
1988). The desensitisation of corticosterone responsiveness to repeated restraint may in 
part be associated with the desensitisation of the pituitary ACTH response and down- 
regulation of the anterior pituitary CRH receptors, but exposure of chronically stressed rats 
to a different (heterotypic) stressor induces greater and more rapid increases in plasma 
ACTH and corticosterone concentration (Hashimoto et al, 1988). This suggests that a 
centrally mediated mechanism can selectively modulate the response to different incoming 
signals. Studies of animals exposed to stress have demonstrated that differential regulation 
of negative feedback is possible, depending on the particular variables of stress exposure 
(Young et al, 1990; Liberzon et al, 1997).
Cook et al (1973) reported that there was no decrease in the ability to maintain an 
elevated ACTH concentration during 2 h of ether anaesthesia and assumed that the 
magnitude and duration of the increase in plasma ACTH concentration was related to the 
duration and intensity of the ACTH-releasing stimulus. On the other hand, it has been 
reported that adaptation of the pituitary-adrenal response occurs during more prolonged 
stress, e.g. continuous sound or immobilisation stress (Henkin & Knigge, 1963; Bohus, 
1969). Rivier and Vale (1987) reported that rats exposed to electroshocks for 3-5 h showed 
a marked increase in plasma ACTH concentrations 10 min after the beginning of the stress, 
followed by a decline despite continuous exposure to the stimulus, and they concluded that 
the inability to maintain elevated plasma ACTH concentrations appeared to be mediated 
through both the temporary decrease in a readily releasable pituitary ACTH pool and the
12
negative feedback exerted by corticosterone. On the other hand, Sakellaris and Vemikos- 
Dannellis (1975) reported that the pituitary-adrenal system was not inhibited by the 
circulating steroid level but actually sensitised to other stimuli. They and others 
(Dallman & Jones 1973; Armario et al, 1985) have postulated that repeated chronic stress, 
i.e., cold and restraint, might cause an “increased drive” to the ACTH-secreting 
mechanism, which compensates or overrides the corticosteroid feedback.
Although the importance of stress in life appears to be significant, the cellular and 
molecular mechanisms involved in the pathophysiology of stress remain largely unknown. 
Corticosteroids are known to mediate stress-related endocrine, behavioural, and autonomic 
responses. However, hardly any systematic work has studied the regulation of 
corticosteroid action during prolonged repeated stress. Immobilisation/restraint stress is the 
most commonly used paradigm to study the stress-related biological, biochemical, and 
physiological responses (Alexandrova, 1994). The available data on plasma concentrations 
of corticosteroids are mostly confined to a single acute or 7 day chronic 
immobilisation/restraint stress in rats (Meaney et al, 1991; Aguilera et al, 1996). It is 
reported that circulating corticosteroids reach a ceiling after a single acute 
immobilisation/restraint stress (Omrani et al, 1980; Meaney et al, 1991). However, it is not 
clear whether prolonged repeated stress results in ftirther elevations in circulating 
corticosteroid concentrations or if there is some kind of adaptation in the release of 
corticosteroids by rats to chronic stress. It is now abundantly clear that cell- and tissue- 
specific glucocorticoid actions are mediated through receptors (GR and MR), and there is 
good correlation between cellular concentrations of these receptors and biological 
responses (Vanderbilt et al, 1987). Unfortunately, at the present time, our understanding of 
the regulation of these receptors during acute and repeated stress remains limited.
Several chronic stress paradigms have been shown to reduce MR and GR mRNA 
concentration (Herman & Watson, 1995; Makino et al, 1995b) or receptor binding 
densities in the rat brain (Sapolsky et al, 1984). Following a chronic variable stress
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paradigm, GR mRNA expression has been shown to be negatively correlated with PVN 
CRH mRNA expression, suggesting a relationship between elevated CRH gene expression 
and down-regulation of GR at the level of the PVN (Herman et al, 1995). Many of these 
effects are dependent upon the sustained high concentrations of corticosterone that are 
produced during the stressor.
In the past five years, there have been important advances in understanding the 
physiology of the CRH system and its response to stress. The role of CRH receptor 
subtypes in emotional processes and its relation to depression and anxiety behaviours has 
been recently reviewed (Holsboer, 1999; Steckler & Holsboer, 1999).
Stress is known on the one hand to activate hypothalamic CRH pathways, which 
are involved in the regulation of the endocrine responses of the pituitary, and on the other 
hand to modulate the activity of extrahypothalamic CRH neuronal networks, which are 
responsible for the coordination of behavioural and autonomic reactions to stress 
(Fisher & Brown, 1983; Dallman, 1993). For example, chronic immobilisation stress has 
been shown to increase CRH immunoreactivity in the anterior hypothalamus, the 
paraventricular hypothalamus, and the locus coeruleus, and to decrease CRH 
immunoreactivity in the medial preoptic area and the dorsal vagal complex of the rat brain 
(Chappell et al, 1986).
An immune challenge or an immobilisation stress can induce a very selective and 
strong activation of the CRH type 1 receptor mRNA within hypothalamic nuclei involved 
in the regulation of neuroendocrine functions, particularly the parvocellular division of the 
PVN (Rivest et al, 1995). This fact, taken together with the ability of CRH to activate its 
own gene expression selectively within the PVN (Parkes et al, 1993), supports the 
existence of an ultra-short loop positive feedback mechanism through which CRH may 
modulate its own biosynthesis.
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There are several lines of evidence suggesting that neurotrophin function is altered 
in stress-related affective disorders, and that increased BDNF could be involved in the 
aetiology and treatment of these illnesses. First, chronic stress is reported to cause atrophy 
and, in some severe cases, death of vulnerable CA3 neurones in the hippocampus 
(Wooley et al, 1990). Atrophy of hippocampal neurones has also been observed after 
repeated chronic stress in rodents, and in response to psychosocial stress in nonhuman 
primates. Second, stress is reported to decrease the expression of BDNF in CA3 pyramidal 
and dentate gyrus granule cell layers in the hippocampus (Smith et al, 1995b). Down- 
regulation of BDNF could contribute to the atrophy of CA3 neurones, or render these 
neurones more susceptible to other factors, such as corticosteroids, that are induced in 
response to repeated stress. Third, brain imaging studies have shown that there is a small, 
but significant reduction in the volume of the hippocampus in patients with depression or 
posttraumatic stress disorder (Sheline et al, 1996; Sapolsky, 1996). Atrophy and decreased 
fimction of the hippocampus could explain the loss, in depressed patients, of negative 
feedback control that this brain region exerts on the FfPA axis (Young et al, 1991).
Sweet solutions, such as saccharin and sucrose, are palatable to rodents and are 
consumed in preference to water (Collier & Novell, 1967). In the CMUS model, 
responsivity of rats to reward is measured by preference for a palatable sucrose solution 
over tap water and by absolute sucrose consumption (Willner et al, 1987). The first 
publication describing the model (Willner et al, 1987) reported a reduction in sucrose 
preference after 3 weeks of CMUS, and later publications reported a deficit in consumption 
apparent after 2 or 3 weeks of CMUS (Papp et al, 1991; Willner et al, 1994). In these latter 
reports, preference data were either not obtained or not reported.
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The relationship between glucocorticoids and consumption of sweet drinks is 
unknown. Bhatnagar and colleagues (2000) showed that the voluntary intake of sweet 
saccharin (2 mM) is strongly and persistently determined by the circulating concentrations 
of corticosterone, suggesting that corticosterone strongly affects the reinforcing properties 
of pleasurable experiences.
Plaznik et al (1989) used a model of acute restraint stress (1 h), whereby they 
produced a short-term, but significant decrease of saccharin preference in a two-bottle test. 
As far as we are aware, sucrose preference and therefore anhedonia has not been tested 
after chronic restraint-stress in rats.
5.2. Aims
To study a stress paradigm in which rats are repeatedly exposed to restraint stress, 
which is considered an example of a psychological or processive stressor in which the 
triggering of a stress response results from the situation (of being trapped in the tube) 
rather than a result of direct noxious stimuli (Herman et al, 1996). The present chapter 
focused on the HPA axis as a stress response system to monitor 
(Dhabbar et al, 1997; Kalman et al, 1997), using plasma concentrations of corticosterone 
and ACTH as indicators of stress. Specifically examining the effect of restraint stress on 
GR density, GR mRNA, CRH type 1 receptor mRNA and BDNF mRNA concentrations in 
the brain. Sucrose preference was used as a behavioural measure of anhedonia.
5.3. Study Design
The following chapters (Chapters 5, 6 and 7) are part of one study that has been 
separated in order to approach and discuss each particular aspect of the study. Refer to 
Figure. 5.1. for a description of the study design for this specific chapter.
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5.4. Methods
5.4.1. Animals
Adult male Wistar rats weighing 250-300 g were housed in pairs and maintained in 
a controlled temperature (20-22°C), constant humidity ( -  60%) and a 12 hr light:dark cycle 
(lights on from 7:00 h to 19:00 h). Rats were bred in the Biological Research Facility at St. 
George’s Hospital Medical School. Food and tap water were available ad libitum. Rats 
were weighed weekly for the duration of the investigation. The use of these animals in the 
following scientific procedures were regulated by the Animals (Scientific Procedures) Act 
1986.
5.4.2. Restraint Stress Procedure
Rats were handled twice daily up until the time of testing in order to minimise 
procedural stress (approximately 7-10 days prior to experimentation). To minimise 
variation in plasma corticosterone and ACTH concentrations during the day, the restraint 
stress procedure was carried out between 8:00 and 11:00 h. As reviewed in the literature 
(Reul and DeKloet, 1985; Spencer et al, 1990), it is well established that the plasma 
corticosterone concentration is lowest during morning hours and, thus, the maximum 
concentration of corticosterone responses in animals should be provoked during the 
morning.
Restraint stress was conducted on a tabletop in a room adjacent to the holding 
room, in well-ventilated adjustable length cylindrical plexiglass tubes (6.3 cm diameter and
15.5 ± 2.5 cm length). Acute II and Chronic groups of rats also received 1 ml/kg p.o. of 
distilled water, 30 min prior to the first restraint stress.
All stress procedures were carried out in compliance with National Animal Welfare 
Laws and Home Office Guidelines of the Care & Use of Laboratory Animals.
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5.4.3. Sucrose Preference Tests
Sucrose preference tests were conducted before restraint stress and after day 1, day 
4 and day 22 of restraint stress (Figure. 5.1.). On these days, during restraint stress, rats 
were released from the restrainers after 30 min and placed back into their home cages, in 
their holding room. There they had access to a weighed amount of food, a pre-weighed 
bottle of tap water and a pre-weighed bottle containing a 1% sucrose solution for 22 h, 
overnight. At the end of the sucrose preference test, the sucrose, water and food were 
removed and weighed. Control rats were also subjected to a sucrose preference test at the 
same times.
5.4.4. Radioimmunoassay ofplasma corticosterone and ACTH concentrations
Plasma corticosterone and ACTH concentrations were measured by using 
radioimmunassay commercial kits (refer to Section 2.4.).
5.4.5. Other Assays
All sacrifice and dissection procedures were conducted as described in section
2.3.2, and took place in a room separate from both the holding room and the room in which 
the animals were stressed. Preparation of rat cytosolic fractions was carried out as 
described in section 2.3.5. Subsequent procedures and analysis were carried out as 
described in section 2.3.7.
Protein content was measured using Lowry’s method with bovine albumin as 
standard (Lowry et a/, 1951).
Preparation of rat tissue was carried out essentially as described in section 2.5.1.2. 
Subsequent RNA isolation, RT-PCR and agarose gel electrophoresis and analysis were 
carried out as described in section 2.5.
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5.5. Statistical Analysis
The data is presented as the arithmetic mean +/- s.e.mean. The effects of time 
(“days”) and restraint-stress on the biochemical and behavioural measures were analysed 
by two-factor completely randomised ANOVA (restraint-stress x time), followed by 
Newman-Keuls post-hoc comparisons. Statistical analyses were performed using the 
software package, “GBStat” v6.5 .
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5.6. Results
5.6.1. Plasma ACTH and Corticosterone Concentrations.
1. Corticosterone
Statistical analysis indicated that restraint stress exposure alone 
(Fi,29=272.5; p<0.0001), time alone (p2,29=14.34; p<0.0001) and the interaction between 
restraint stress and the length of exposure (F2,29=18.14; p<0.0001) significantly affected the 
plasma corticosterone concentration (Figure.5.2.). A single, 30 min restraint stress exposure 
increased plasma corticosterone concentration by just over 300% compared to controls. A 
second exposure produced a similar increase. Repeated exposure to restraint stress 
increased plasma corticosterone concentration by almost 700% compared to control.
F igu re.5 .2 .
Plasma corticosterone concentration following exposure to restraint-stress.
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Plasma corticosterone concentration in male Wistar rats, housed in pairs (n=8 per 
group), were measured in samples taken immediately following exposure to 
restraint stress. Data are expressed as mean ± sem. Comparison between 
vehicle-treated rats left in their home cages (control group) and rats restrained for 
30 mins/day (restraint-stress group) for 1 day, 2 days or 23 days before they were 
sacrificed. ##, p<0.01 compared to control; **, p<0.01 compared to one 30 min 
exposures to restraint stress.
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2. Adrenocorticotrophic Hormone (ACTH)
Statistical analysis indicated that restraint stress alone significantly afifected 
(F 1,27=63.63; p<0.0001) the plasma ACTH concentration (Figure.5.3.), A single, 30 min 
restraint stress exposure increased plasma ACTH concentration by 136% compared to 
controls. A second restraint stress produced similar results. Repeated exposure to restraint 
stress increased plasma ACTH concentration by just over 100% compared to control.
Figure.5.3.
Plasma ACTH concentration following exposure to restraint-stress.
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Plasma ACTH concentration in male Wistar rats, housed in pairs(n=8 per group), 
were measured m samples taken immediately following exposure to repeated 
daity restraint stress. Data are expressed as mean ± sem. Comparison between 
vehicle-treated rats left in their home cages (control group) and rats restrained 
for 30 mins/day (restraint-stress group) for 1 day, 2 days or 23 days before they 
were scarificed. #, p<0.05; ##, p<0.01 compared to control.
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5,6,2. Glucocorticoid Receptor (GR) Binding 
!• Bmax
Statistical analysis indicated that restraint stress alone significantly affected 
(Fi,3i = 67.0; p<0.0001) the Bmax values firom glucocorticoid receptor binding within the 
cortex (Figure.5.4A). A single, 30 min restraint stress exposure decreased cortical Bmax 
values by 24% compared to controls, which remained the same following a second 
exposure. Repeated exposure to restraint stress decreased cortical Bmax values by 34% 
compared to control. Control values varied between 110 and 140 finoFmg protein.
In the hippocampus, statistical analysis indicated that restraint stress alone 
(Fi,3o = 54.4; p<0.0001), length of time of the experiment (F2,3o= 12.14; p=0.0001), and the 
interaction of restraint stress with the length of exposure (F2,3o = 12.10; p=0.0001) 
significantly affected the Bmax values fi-om glucocorticoid receptor binding (Figure.5.4B). 
A single 30 min restraint stress exposure decreased Bmax levels by 40% compared to 
controls. Repeated exposure to restraint stress decreased hippocampal Bmax levels by 30% 
compared to control. Control values were more variable than in the cortex 
(ranging fi-om 80 and 120 finoFmg protein).
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Figures.5.4.
Glucocorticoid Receptor B^ax values from cortical (A) and 
hippocampal (B) cytosolic fractions following exposure to 
restraint stress
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GR values in cortex and hippocampus (taken from male Wistar rats, housed in 
pairs (n = 8 per group)) were measured in samples taken immediately following 
exposure to daily restraint stress. Data are expressed as mean ± sem. Comparison 
between vehicle-treated rats left in their home cages (control group) and rats 
restrained for 30 min/day (restraint-stress group) for either 1 day, 2 days or 23 days 
before they were scarificed, (A) B ^  in cortical tissue (B) B ^  in hippocampal 
tissue. #, p<0.05 and ##, p<0.01 compared to control; *, p<0.05and **, p<0.01 
compared to control after 1 day; **, p<0.01 compared to one or two 30 min 
exposures ro restraint stress.
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2. Kd
Statistical analysis indicated that restraint stress alone 
(Fi,37 = 66.04; p<0.0001) and the length of time of the experiment
(p2,37 = 5.078; p=0.0113) significantly affected the K<i levels fi-om glucocorticoid receptor
binding within the cortex (Figure.5.6A). A single, 30 min restraint stress exposure 
increased cortical Kd values by 180% compared to controls, which increased by a further 
40% following a second exposure. Repeated exposure to restraint stress increased cortical 
Kd levels by 140% compared to control. An example of a saturation curve is represented in 
Figure. 5.5.
In the hippocampus, statistical analysis indicated that restraint stress alone
(Fi,33 = 5.125; p=0.0303) and the length of time of the experiment
(F2 33 = 10.97; p=0.0002) significantly affected the Kd levels from glucocorticoid receptor 
binding (Figure.5.6B). A single 30 min restraint stress exposure increased Kd levels by 64% 
compared to controls. A second restraint stress produced similar results. Repeated 
exposure to restraint stress increased hippocampal Kd levels by 30% compared to controls. 
Control values were more variable than in the cortex (ranging from 1.00 and 1.88 nM).
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Figure 5.5.
Example of a saturation plot of ^ H-dexamethasone binding to GR in a rat cortical 
cytosolic fraction following exposure to restraint stress for 1 day
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Glucocorticoid Receptor values in cortical (A) and hippocampal (B) 
cytosolic fractions following exposure to restraint stress.
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GR K j values in cortex and hippocampus (taken from male Wistar rats, housed in 
pairs (n = 8 per group) were measured in samples taken immediately following 
exposure to daily restraint stress. Data are expressed as mean ± sem. Comparison 
between vehicle-treated rats left in their home cages (control group) and rats 
restrained for 30 min/day (restraint-stress group) for either 1 day, 2 days or 23 days 
before they were sacrificed, (A) in cortex (B) in hippocampus. ##, p<0.01 
compared to control; **, p<0.01 compared to one or two 30 min exposures to 
restraint stress.
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5.6.3. Glucocorticoid Receptor (GR) mRNA
Cortical GR mRNA levels did not change following a second exposure of restraint 
stress, compared to control. Repeated exposure to restraint stress had no effect compared to 
control (Figure.5.7.). Control values varied between 0.6 and 1.1 (arbitrary units).
5.6.4. Brain-DerivedNeutrophic Factor (BDNF) mRNA
Cortical BDNF mRNA levels increased by 30% following a second exposure of 
restraint stress, compared to the control. Repeated exposure to restraint stress decreased 
cortical BDNF mRNA levels by 36% compared to control (Figure.5.8.). Control values 
varied between 1.1 and 1.4.
5.6.5. Corticotropin-Releasing Hormone (CRH) Type 1 Receptor mRNA
Cortical CRH-Rl mRNA levels decreased by 30% following a second exposure of 
restraint stress, compared to the control, although this was not statistically significant 
(Figure.5.9.).
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Figure. 5.7.
Cortical GR mRNA and p-Actin mRNA following exposure to restraint stress.
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Cortieal GRmRNA and P-Aetin mRNA from male Wistar rats, housed in pairs 
(n=8 per group), were measured in samples taken immediately following exposure 
to restraint stress. (A ) RT-PCR and agarose gel electrophoresis analysis of GR 
mRNA expression. P-Actin mRNA expression was used as an internal control. 
Control samples were run on a gel with P-Actin mRNA and a lOObp ladder, the 
restraint samples were run on a separate gel with P-Aetin mRNA and a lOObp 
ladder. ( B) Ratio of cortical GR mRNA: P-Aetin mRNA (sum intensity of the 
bands). Data are expressed as mean ± sem. Comparison between vehicle-treated 
rats left in their home cages (control group) and rats restrained for 30 min/day 
(restraint-stress group) for either 2 days or 23 days before they were sacrificed. 
**, p<0.01 compared to controls after one or two days; **, p<0.01 compared to one 
or two 30 min exposures to restraint stress.
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Figure. 5.8.
Cortical BDNF mRNA and p-Actin mRNA following exposure to restraint
stress.
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Cortical BDNF mRNA and P-Actin mRNA from male Wistar rats, housed in pairs 
(n=8 per group), were measured in samples taken immediately following exposure to 
restraint stress. (A) RT-PCR and agarose gel electrophoresis analysis of BDNF mRNA 
expression. p-Actin mRNA expression was used as an internal control. Control samples 
and restraint samples were run on 1 gel with lOObp ladders and P-Actin mRNA was run 
on a separate gel with a lOObp ladder. (B ) Ratio of cortical BDNF mRNA: P-Actin 
mRNA (sum intensity of the bands). Data are expressed as mean ± sem. Comparison 
between vehicle-treated rats left in their home cages (control group) or restrained for 30 
min/day (restraint-stress group) for either 2 days or 23 days before they were sacrificed. 
##, p<0.01 compared to control; **, p<0.01 compared to one or two days of control; 
**, p<0.01 compared to one or two 30 min exposures to restraint stress.
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Figure.5.9.
Cortical CRH type 1 receptor mRNA and p-Actin mRNA following restraint
stress exposure for 2 days.
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Cortical CRH-Rl mRNA and P-Actin mRNA from male Wistar rats, 
housed in pairs (n=8 per group), were measured in samples taken 
immediately following exposure to restraint stress. (A) RT-PCR and 
agarose gel electrophoresis analysis of CRH-Rl mRNA expression. 
p-Actin mRNA expression was used as an internal control. Control 
samples were run on a gel with p-Actin mRNA and a lOObp ladder, 
restraint samples were run on a separate gel with p-Actin mRNA and a 
lOObp ladder. (B) Ratio of cortical CRH-Rl mRNA: p-Actin mRNA 
(sum intensity of the bands). Data are expressed as mean ± sem. 
Comparison between vehicle-treated rats left in their home cages 
(control group) and rats exposed to two 30 min exposures to restraint 
stress (restraint-stress group) before they were scarificed There were no 
significant differences between the groups.
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5.6.6. Behavioural Measurements
1. Sucrose Preference
Restraint-stress alone had no significant effect upon the sucrose preference after 1, 
4, or 22 days. (Table.5.1.).
Table. 5.1.
Sucrose preference (% of total fluid intake), following exposure to restraint stress.
GROUPS Mean ± sem N
BASAL 96.5 ± 0.7 13
ACUTE RESTRAINT-STRESS (1 x 30-minutes)
Control + 1 ml/kg p.o. distilled water (VEHICLE) 95.3 ±2.6 4
Restraint-Stress + Iml/kg p.o. distilled water 96.1 ±0.7 4
ACUTE RESTRAINT-STRESS (4 x 30-minutes)
Control + 1 ml/kg p.o. distilled water (VEHICLE) 89.8 ±6.1 3
Restraint-Stress + 1 nd/kg p.o. distilled water 96.2 ±1.7 3
CHRONIC RESTRAINT-STRESS (22 X 30-minutes)
Control + 1 ml/kg p.o. distilled water (VEHICLE) 91.9 ±5.5 3
Restraint-Stress + Iml/kg p.o. distilled water 97.3 ± 0.5 3
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2. Food Intake
Statistical analysis indicated that restraint stress alone significantly affected 
(Fi,i8 = 6.952; p=0.0168) the food intake over 22 h (Figure.5.10.). A single 30 min restraint 
stress exposure had no effect compared to basal levels or control, and this remained the 
same following a fourth exposure. Repeated exposure to restraint stress decreased food 
intake by 24% compared to control.
F igu re .5 .10 .
Food intake following exposure to restraint stress
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Food intake (g) by male Wistar rats, housed in pairs (n = 4 per group), measured 
over 22 h. Each pair of rats within a cage were placed in the same treatment group. 
All cages were kept on the same rack on one side of the holding-room to minimise 
variation. Data are expressed as mean ± sem. Comparison between vehicle-treated 
rats left in their home cages (control group) and rats restrained for 30 min/day 
(restraint-stress group) for either 1 day, 4 days or 22 days. ##, p<0.01 compared 
to control.
3 3
5.7. Discussion
The main findings of the present experiments can be summarised as follows; 
(1) acute and chronic restraint increased both corticosteroid and ACTH concentrations and 
decreased GR in the cortex and hippocampus; (2) acute restraint increased BDNF gene 
expression in the cortex, whereas chronic restraint decreased it within the same brain 
region; (3) chronic restraint decreased food intake.
The marked increase in the plasma concentrations of ACTH and corticosterone 
(Figure.5.2. and Figure.5.3.) confirm the activation of the HPA axis during restraint stress 
and indicates habituation has not occurred after 23 days of a repeated homotypic stress.
Several researchers studying HPA axis reactivity to a stress applied after a first 
stimulus have reported that prior stimulation does not cause any blunting of the response to 
the second superimposed stress and, in some cases, hyperresponsiveness has been noted 
(Dallman & Jones, 1973; Hanger et al, 1988). This has been seen in the plasma 
concentrations of both corticosterone and ACTH, in the present study. Suggesting that the 
repeated exposure to restraint stress was sufficient to override the glucocorticoid negative 
feedback.
Disproportional elevations in resting plasma corticosteroid concentrations with 
respect to ACTH are usually observed in chronically stressed rats, 
(Dallman et al, 1992; Aguilera, 1994) as was shown in the current results, and clinical 
conditions such as depression (Gold et al, 1988a,b). Study by Aguilera et al (1996) 
demonstrated that the mechanism responsible for increased plasma corticosterone 
concentrations included both increased steroidogenic capacity of the zona fasciculate of the 
adrenal, and decreased corticosterone metabolism.
The responsiveness of the adrenal cortex to regulatory hormones is critical in the 
control of plasma steroid concentrations during chronic stress. Episodic increases of 
plasma ACTH are largely responsible for the changes in steroidogenic enzymes in both
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zones of the adrenal cortex during repeated stress. On the other hand, regulation of 
glucocorticoid clearance is determined by factors other than ACTH.
It is well documented that exposure to stress for several days does not appear to
cause any loss of pituitary response or pituitary ACTH content
(Sakellaris & Vemikos-Danellis, 1975; Young & Akil, 1985) and on the contrary, results 
in a state of sustained activation of the mechanisms that mediate the pituitary response to 
stress. This suggests that rats exposed to stress may first undergo a period of transient loss 
of pituitary responsiveness which might protect the organism against excessive circulating 
amounts of ACTH; however, if the stress persists beyond this adaptation phase, pituitary 
sensitivity is restored, and ACTH stores increase again, thus preventing the animal fi'om 
staying in a prolonged period of (possibly detrimental) inability to adequately release 
ACTH. It is possible that CRH, which exerts a trophic effect on ACTH synthesis 
(Vale et al, 1983), represents a major mediator of this recovery phenomenon.
Stress alters the secretion of one or more of the hypothalamic factors, which 
interact at the pituitary to increase the secretion of ACTH. AVP and OT have been shown 
to modulate the effect of CRH on ACTH secretion and appear to play a key role in 
mediating the ACTH response to stress. Although AVP is a relatively weak secretagogue 
for ACTH, it markedly potentiates the activity of CRH both in vitro and in vivo. The role 
of OT is more complex. The type of stressor appears to determine the relative importance 
of these secretagogues in ACTH response. After restraint, ACTH release is primarily 
mediated by the active increase of OT, and AVP does not appear to play a role. When 
restraint is associated ^vith moderate levels of physical components and during
immobilisation, both secretagogues are involved in the ACTH response
(Scantamburlo et al, 2001).
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AVP plays an important role in the control of ACTH secretion during stress, mainly 
by modulating the regulatory effect of CRH in the pituitary corticotroph 
(Gillies & Lowry, 1979; DeGoeij et al, 1992). In control non-stressed rats, approximately 
50% of CRH-containing neurones in the parvocellular area of the PVN of the 
hypothalamus coexpress AVP, which is released into the pituitary portal circulation from 
nerve terminals located in the external zone of the median eminence 
(Whitnall et al, 1987; Plotsky, 1991). A number of studies have shown that the activity of 
the parvocellular vasopressinergic system is enhanced after adrenalectomy or chronic 
stress (Sawchenko et al, 1984; Harbuz & Lightman, 1992). Therefore examining AVP and 
OT levels during this study could have given us an insight into their role in the control of 
ACTH secretion during repeated stress.
Possible mechanisms to be considered for the failure of glucocorticoids to inhibit 
ACTH secretion during chronic stress are a decrease in GR in the pituitary or brain and 
changes in the fimctional activity of the GR. In the current study acute and chronic restraint 
stress led to a reduction in the density of GR in both cortex and hippocampus (Figure.5.4.). 
This data is compatible with previous findings that stress down-regulates hippocampal 
GRs (Sapolsky et al, 1984; Herman et al, 1995).
Decreased hippocampal GR concentrations are associated with reduced 
glucocorticoid negative feedback on ACTH release foUovdng the termination of stress 
(Sapolsky et al, 1986), which is consistent with the marked increase in the plasma 
concentrations of corticosterone and ACTH following the exposure to restraint stress, 
shown in section 5.6.1.
Studies have shown that exogenous administration of large doses of corticosteroids 
reduces cytosolic GR number in the hippocampus (Tomello et al, 1982). This finding 
suggests the possibility that chronic secretion of glucocorticoids stimulated by chronic 
stress may dovm-regulate GR in the brain. The principal finding of the study by Sapolsky
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et al (1984) was that repeated stress reduced the number of GR in the brain, a finding 
confirmed in the present experiment, and it seems likely that this is mediated by elevated 
corticosterone secretion during stress. They found that repeated stress caused a reduction in 
total available receptor number, rather than a simple redistribution, which is in agreement 
Avith the observations of Cidlowski and Cidlowski (1981). Mechanisms underlying these 
examples of down-regulation could include decreased synthesis of new receptors, 
increased degradation or preferential sequestering of receptors in inactive pools, or 
destruction of receptor-containing neurones.
Accumulating evidence suggests that GR activation suppresses the hippocampal 
output (Joels & DeKloet, 1992), theoretically resulting in the disinhibition of the HPA axis. 
Van Haarst et al (1997) demonstrated that an icv injection of GR antagonist increased 
plasma ACTH and corticosterone concentrations at the diurnal peak, whereas the 
intrahippocampal injection of GR antagonist produced an opposite, inhibitory effect, 
indicating a positive glucocorticoid feedback influence on the HPA axis through 
hippocampal GR. They proposed the importance of GR in the PVN itself in the 
glucocorticoid-mediated restraint of the activity of PVN CRH and AVP neurones, based on 
previous reports showing suppression of CRH biosynthesis by local administration of 
glucocorticoids (Kovacs & Mezey, 1987), and suggested that feedback inhibition through 
GR in the PVN may override a positive feedback effect through hippocampal GR. In this 
context, decreased GR mRNA levels in the PVN rather than in other brain regions are 
important for the attenuation of glucocorticoid-induced negative feedback on the activity 
of PVN CRH and AVP neurones during repeated restraint stress.
The current study indicates that a single 30 min restraint stress exposure and 
repeated exposure had no affect on GR mRNA in the cortex compared to control 
(Figure.5.7.). This is in contrast with the above results (Section 5.8.2.), showing a 
reduction in the density of GRs in both cortex and hippocampus. This contradiction could
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be due to increased receptor breakdown, which is quicker than the production of the 
mRNA.
Chronic exposure to stress has previously decreased GR mRNA in the 
hippocampus, which is in conflict with the current results (Sapolsky et al, 1984; Kitraki et 
al, 1999). There is a possibility that the stress-induced GR down-regulation was due to its 
increased receptor occupancy and internalisation rather than to a decrease in receptor 
synthesis. The increased secretion of corticosterone could also have mediated the delayed 
up-regulatory effect of restraint stress upon GR mRNA and could emphasise the region- 
specific sensitivity of GR mRNA to corticosterone. The majority of previous studies 
investigating the effects of chronic stress upon GR mRNA have been conducted in the 
hippocampus and very little is known about GR mRNA within other brain areas, therefore 
these effects could be region-specific.
Differential regulation of GR gene expression by different stressors has previously 
been reported (Watanabe et al, 1992; Herman & Spencer, 1998), and can be attributed to 
the nature, intensity and duration of a stressful stimulus, as well as to the time point after 
the stress at which GR mRNA concentrations are estimated. This is consistent with the 
present results and show that GR mRNA concentrations are not altered in the cortex 
shortly after an acute exposure to restraint, which is probably a result of the relatively short 
time interval between the stress procedure and the sacrifice of the animal and the nature of 
this stressor (Kitraki et al, 1999). Even in cells, the time of appearance of GR down- 
regulation can vary considerably (Dong et al, 1988; Vig et al, 1994).
The mechanism of down-regulation has been referred to be corticosterone 
dependent (Makino et al, 1995b) and is exerted primarily at the level of transcription of the 
GR gene (Rosewicz et al, 1988; Hoeck et al, 1989), although post-transcriptional actions 
cannot be excluded (Dong et al, 1988).
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Previous studies document varying degrees of GR mRNA down-regulation 
fbllovnng stress. The chronic intermittent stress paradigm usually produces minimal 
decreases in GR mRNA concentrations (Herman et al, 1995; Herman & Spencer, 1998), 
consistent with previous studies using other stress paradigms (Mamalaki et al, 1993; 
Herman et al, 1995). In contrast, chronic immobilisation can produce larger (40-50%) 
decreases in hippocampal GR expression, suggesting that the stability of GR expression 
may be modulated by stressor intensity or duration (Makino et al, 1995b).
This current study indicated that a single 30 min restraint stress exposure 
significantly increased BDNF mRNA concentrations within the cortex, but repeated 
restraint stress caused a significant reduction in BDNF mRNA concentrations within this 
brain region (Figure.5.8.). Previous studies have shown a down-regulation of BDNF 
mRNA concentration, mainly in the hippocampus, in response to acute and chronic stress 
(Zafi*a et al, 1991; Vaidya et al, 1999).
The role of corticosterone in mediating BDNF is not clear. According to Schaaf et 
al (2000), corticosterone suppresses the BDNF expression at the mRNA and protein level 
in a subfield-specific way. They propose a model for the mechanism of action, in which 
activated MR and GR repress transcriptional activity of the BDNF promoter site- 
specifically via interaction with other transcription factors (Schaaf et al, 2000). This could 
possibly be extended to other brain regions.
The stress-induced changes in BDNF expression have been found to be largely 
opposite to those produced by seizures and ischaemia. For instance, BDNF mRNA 
concentrations are increased throughout the brain up to 40 fold, by various seizure 
paradigms (Isackson et al, 1991; Rocamora et al, 1992). Likewise, ischaemia induces a 
transient increase in BDNF mRNA concentrations in the dentate gyrus 
(Takeda et al, 1993). The direction of these observed changes in BDNF mRNA 
concentrations induced by seizures or ischaemia is consistent with the notion that
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glutamate, which is released during seizures and ischaemia, positively regulates BDNF 
expression (Zafra et al, 1991). The fact that stress induced effects are opposite to those 
caused by seizures and ischaemia might imply that the underlying mechanisms driving 
growth factor expression are opposite too. Yet, restraint stress, like seizures and ischaemia, 
has been reported to increase glutamate turnover (Gilad et al, 1990; Moghaddam, 1993). 
Therefore, it is possible that our acute restraint stress positively regulated BDNF 
expression through increased glutamate or other neurotransmitters, such as norepinephrine, 
5-HT, or GAB A, but then the effects of these factors on BDNF expression decreased after 
chronic restraint stress, suggesting a desensitisation to or clearance of these factors over 
this time period.
Smith and colleagues (1995a) have shown that acute (2 h) or repeated 
immobilisation stress increases BDNF mRNA concentrations in the PVN, lateral 
hypothalamus, anterior and neurointermediate lobes of the pituitary. This is in distinct 
contrast to stress-induced decreases in extrahypothalamic areas, including basolateral 
amygdala, claustrum, and cingulated cortex as well as the hippocampus. Therefore, this 
current study confirms that acute stress increased BDNF mRNA concentrations in the 
cortex, an effect that may also enhance the BDNF-responsiveness of this brain region, and 
that BDNF-mediated responses may be either decreased or increased by chronic stress, 
depending on the brain region involved. In addition, these concentrations of BDNF mRNA 
in cortex are not regulated by chronic restraint stress, which could result fi-om habituation 
to the same stress on repeated exposure.
While corticosterone generally appears to decrease BDNF in previous studies, 
stress has been shown to decrease BDNF in the absence of corticosteroids, at least in the 
dentate gyrus (Smith et al, 1995b). This suggests that corticosterone feedback is not the 
only part of the stress response contributing to the observed decrease in BDNF mRNA 
concentrations. However, because the most robust and consistent decreases in BDNF occur
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in stressed animals which are adrenally intact, it is likely that basal concentrations of 
glucocorticoids are necessary for maximal inhibition of BDNF mRNA by stress, just as 
glucocorticoids are required for maximal stimulation of BDNF by kainic acid 
(Barbany&Persson, 1993).
Consequently, BDNF is a stress-responsive intercellular messenger that may be an 
important component of the stress-response. Therefore, changes in the expression of 
neutrophic factors are part of the brain’s response to stress. Whether changes in neutrophic 
factor availability actually contribute to the damage in the brain caused by stress or are an 
adaptive value for facing friture stressors remains to be explored.
In the current study acute restraint stress did not cause any significant changes in 
CRH type 1 receptor mRNA within the cortex (ïïgure.5.9.), although, there was a trend 
towards a decrease compared to control.
Numerous studies have examined the regulation of CRH; however, little is known 
about the mechanisms controlling the expression of CRH receptors in the brain. Some 
studies have found no alterations in levels of CRH receptor ligand binding in the brain by 
chronic stress or corticosterone administration (Wynn et al, 1984; Hanger et al, 1988), 
whereas others have demonstrated that levels of CRH receptors in the brain are decreased 
by repeated stress (Anderson et al, 1993) or intracistemal injection of CRH 
(Hanger et al, 1993).
Robust transcriptional activation of the gene encoding the CRH type 1 receptor 
(but not the type 2) has been previously observed in the rat endocrine hypothalamus, after 
different types of neurogenic and systemic stressors. A selective and transient increase of 
CRH type 1 receptor mRNA expression was found in the parvocellular PVN of acutely 
challenged rats (Rivest et al, 1995; Bonaz & Rivest, 1998), whereas little notable changes 
were detected in other regions of the brain. This suggests that sophisticated mechanisms
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take place in a site-dependent manner to regulate the CRH type 1 receptor in stressed 
animals.
Acute stress has been shown to cause biphasic changes in CRH receptor mRNA 
expression with an early decrease followed by an increase, which is consistent with these 
present results. However, in the absence of corticosteroids in adrenalectomised rats, stress 
results in prolonged CRH receptor mRNA loss, suggesting that interactions between 
corticosteroids and hypothalamic factors are critical for regulation of CRH receptor 
mRNA. The data from the study by Ochedalski and colleagues (1998) shows that 
interaction between CRH and glucocorticoids counteracts individual inhibitory effects of 
these regulators alone, and that such effects are likely to contribute to the regulatory 
pattern of pituitary CRH receptors during acute stress.
High concentrations of corticosterone or CRH have been shovm to synergistically 
decrease CRH receptor mRNA concentrations in the anterior pituitary, which was shovm 
by our decrease in CRH type 1 receptor mRNA in the cortex, although looking at the CRH 
concentrations could have confirmed this, and that high corticosterone has an inhibitory 
effect on PVN CRH receptor mRNA levels (Makino et al, 1995a). The extrahypothalamic 
regions, such as amygdala, bed nucleus of the stria terminalis and the cortex may have 
different sensitivities to corticosterone or CRH for the regulation of CRH receptor mRNA. 
Although stress stimulation of CRH mRNA in the PVN is glucocorticoid independent, 
basal levels are likely to be under dual, transcriptional and post-transcriptional, control by 
glucocorticoids (Luo et al, 1995).
There was no significant change in sucrose preference throughout restraint-stress 
exposure (Table.5.1.). Plaznik et al (1989) showed that a single 1 h immobilisation stress 
produced a short-term reduction of saccharin preference in rats. The effect was stable and 
lasted for 1-2 days, though there was some variability in the control group preference 
across all the experiments.
42
Possible reasons for the current lack of a reduction in sucrose preference after acute and
chronic restraint-stress may be due to a number of differences in our study compared to
previous studies:
1. Rats were housed in pairs, not single-housed, to limit any extraneous stress other than 
restraint;
2. They were not food or water deprived, although decreases in sucrose drinking can be 
seen in both food-deprived and non-deprived animals (Muscat & Willner, 1992), as 
well as in studies in which the CMUS procedure excluded periods of food and water 
deprivation (Muscat & Willner, 1992; Bertrand et al, 1997);
3. A two-bottle preference test was used, although the effects of CMUS have been 
reported in both single-bottle tests and in two-bottle preference tests 
(Willner et al, 1987; D’Aquila et al, 1997);
4. Sucrose preference was measured over 22 h rather than 1 h as used in previous studies. 
This was mainly to include the dark phase when the rats are most active, but also 
because previous tests conducted over 1 h produced small volumes to weigh and it 
proved difficult to ascertain any differences;
5. Restraint-stress was used rather than CMUS, which as far as we are aware has not been 
done before;
6 . Sucrose was used rather saccharin, although the calorie content of the sucrose appeared 
to be unimportant as the bodyweights remained unchanged and there was only a slight 
decrease in the intake of plain water;
7 . The control and stressed rats were handled daily, and previous CMUS studies have not 
reported if the animals were handled throughout their experiments;
8. Reversed lighting has previously been used, but we refrained from doing this to cause 
as little disruption as possible to the animals and to therefore make the study easier to 
conduct within the animal house facilities. There is a diurnal variation in sensitivity to
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chronic mild stress, at least in Wistar rats, which, according to D’Aquila et al (1997), 
show little or no response to chronic mild stress when tested during the light phase of 
the light-dark cycle, but show typical decreases in sucrose consumption and preference 
when tested at the start of the dark phase. Therefore, although we tried to counteract 
this by testing the Wistars over a 22 hr period, which encompassed the dark phase, it 
also included part of the light phase and so could have compromised the results;
9 . It has been shown that sensitivity to CMUS varies between strains 
(Griffiths et al, 1992; Pucilowski et al, 1993); therefore, although this procedure has 
been shown to be effective a variety of strains of rat, it might not be effective in 
Wistars;
10. Just as there are strain differences in sensitivity to inducing anhedonia, differences 
in sensitivity may also exist between rats of the same strain from different suppliers; 
such differences could arise either from genetic drift or from differences in rearing 
procedures. Our animals mainly came from the Biological Research Facility at SGHMS 
but some were obtained from suppliers. It has been observed that there is both strain 
and supplier differences in sensitivity to sucrose (Lush, 1989). According to Willner 
(1997), the 1% sucrose concentration that is routinely used in PVG or Lister hooded 
rats during his CMUS experiments, is only marginally preferred to water in some 
batches of Wistar rats, leading to unstable patterns of consumption in repeated tests, 
even in control animals. This trend is shown in the present study; therefore choosing a 
different concentration of sucrose could produce a more stable pattern of intake and 
therefore preference.
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Food intake decreased after repeated exposures to restraint-stress (Figure.5.10.), 
suggesting that stress slightly suppressed food intake in the current study, but this was 
further enhanced by the gradual increase in the controls. This measure was primarily used 
to establish changes in sucrose drinking were not due to a change in appetite, and that the 
animals preferred the sucrose without affecting the amount of food eaten. There was no 
change in the body weights of the animals in this present study. As sucrose preference was 
unchanged, we decided to look at this data to determine if eating behaviour had been 
modified by single and repeated exposures to restraint stress.
A study by Ely et al (1997) suggests that the severity and duration of exposure to 
stressors are capable of modifying eating behaviour. A chronic moderate stress, i.e., 
restraint, does not alter normal food consumption, but leads to changes in specific 
appetites, i.e., sweet food ingestion.
Exposure to stress causes a wide range of behavioural and physiological alterations 
in organisms, but only a few of them are sensitive to particular characteristics of the 
stressor, such as intensity and duration (Marti & Armario, 1998). Food intake is one of the 
variables sensitive to stress. Whereas exposure to short-term and mild stressors has been 
reported to transiently increase food intake (Morley et al, 1983), exposure to stressors of 
certain severity, including surgery, experimentally-induced inflammation, endotoxins, foot 
shock, crowding, and various types of restraint, always reduces food intake in the hours 
after stress (Stone & Platt, 1982; Berton et al, 1998), as shown in the current results.
Stress-induced reduction in food intake has been previously demonstrated both as a 
maintained decrease in 24 h food intake during and after repeated daily restraint stress 
(Kennett et al, 1986; Krahn et al, 1990), and as an acute response in the hours immediately 
after a single stress (Krahn et al, 1990).
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Central mechanisms involved in the stress-induced inhibition of food intake have 
not been hilly elucidated but certain peptides and neurotransmitters are thought to be 
involved in the response. It is well established that monoamines (Kennett et al, 1987) and 
CRH (Krahn et al, 1990) influence feeding behaviour and mediate behavioural and 
physiological responses to stress (Sutton et al, 1982; Krahn et al, 1988). Both CRH 
(Krahn et al, 1986) and/or serotonin (Kennett et al, 1986) are elevated in response to stress 
in a number of brain areas, including those that are involved in the regulation of feeding 
behaviour (Makino et al, 1995b). Intracerebroventricular administration of CRH produces 
behaviours typical of stress, including depression of appetite (Sutton et al, 1982; Krahn et 
al, 1986).
5.8 Conclusions
This series of experiments demonstrated that a repeated restraint stress paradigm 
significantly decreased the glucocorticoid negative feedback response of the HPA axis, for 
over 3 weeks. Emphasising that failure to adapt to a repeated daily restraint stress schedule 
is a useful animal model for depression, and this model has been shown to respond 
appropriately to antidepressant administration (Curzon, 1989).
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CHAPTER 6. THE EFFECT OF ACUTE AND CHRONIC 
PAROXETINE ADMINISTRATION IN RATS UPON THE HPA AXIS.
6.1. Introduction
Numerous anatomical, biochemical, and behavioural investigations have 
established the existence of functional interactions between central serotonin systems and 
the HPA axis. Serotonin activates all levels of the HPA axis (Delbende et al, 1992; Fuller, 
1996). For example, serotonin stimulates the release of CRH from hypothalamic slices. 
Corticosterone in turn influences serotonin synthesis, turnover and receptors via MR and 
GR (Chaouloff, 1993; Meijer & DeKloet, 1998). Serotonergic neurones are also involved 
in stress-induced activation of the HPA axis (De Souza & Van Loon, 1986) and in the 
circadian variations of ACTH and corticosteroid secretion (Szafarczyk et al, 1985). 
Furthermore, various types of drugs that increase serotonergic transmission (such as 
serotonin agonists, serotonin uptake inhibitors and serotonin releasers) stimulate the 
activity of the HPA axis (Bruni et al, 1982; Fuller & Snoddy, 1990).
Paroxetine is an SSRI (Tulloch & Johnson, 1992), a class of structurally unrelated 
drugs that enhance serotonergic transmission by blocking the presynaptic active membrane 
transport mechanism for the reuptake of serotonin (Frazer, 1997) and consequently 
increase serotonergic activity at the postsynaptic receptor (Johnson, 1992). The affinity of 
paroxetine for the serotonin reuptake site is 2 to 3 orders of magnitude greater than 
serotonin and as with the other members of the class, it effectively increases the 
concentration of endogenous serotonin in the synaptic cleft (Richelson, 1999). Paroxetine 
is the most potent inhibitor of serotonin reuptake of currently available antidepressants. It 
is a weak inhibitor of norepinephrine uptake but it is still more potent at this site than the 
other SSRIs and this may contribute to its clinical efficacy at higher doses 
(Tulloch & Johnson, 1992). The selectivity of paroxetine, i.e., the ratio of inhibition of
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uptake of noradrenaline to serotonin (NA/5-HT) is amongst the highest of the SSRIs 
(Hyttel, 1994). It has little affinity for catecholaminergic, dopaminergic or histaminergic 
receptors and by comparison with TCAs, has therefore, a reduced propensity to cause 
central and autonomic side effects (Tulloch & Johnson, 1992). Paroxetine exhibits some 
affinity for the muscarinic cholinergic receptor but much less than the TCAs 
(Tulloch & Johnson, 1992).
In addition, the secondary adaptive changes of somatodendritic (5-HTia) and 
terminal (5-HTib/id) autoreceptors observed with paroxetine are different to those observed 
with TCAs. Long-term administration of paroxetine in rats (over 2-3 weeks) decreases the 
responsiveness of these receptors, leading to greater serotonin release with each action 
potential, in contrast to the sensitisation of postsynaptic 5-HTia receptors, which occurs, 
with TCAs (Blier et al, 1990). Maximal antidepressant effects are observed only after 
weeks or even months of repeated treatment, suggesting that in addition to the inhibition of 
serotonin reuptake, these adaptive changes in synaptic serotonergic receptors are likely to 
be important for the therapeutic efficacy of paroxetine. Most long-term studies of 
antidepressants have focused on their effects on autoreceptors or postsynaptic receptors 
and the responses they elicit (Blier & Bouchard, 1994; Auerbach & Hjorth, 1995).
It is well established that noradrenergic neurones modulate the 5-HT system. 
Dorsal raphe 5-HT neurones receive noradrenergic projections from the locus coeruleus 
(Loizou, 1969; Baraban & Aghajanian, 1980), a nucleus that gives rise to more than 
40-45% of noradrenergic innervation of the brain. The noradrenergic neurones located in 
the locus coeruleus modulate the activity of 5-HT neurones in the dorsal raphe nucleus via 
excitatory ai-adrenoceptors (Baraban & Aghajanian, 1980). In turn, noradrenergic 
neurones of the locus coeruleus receive dense 5-HT projections, which have been shown to 
have an inhibitory effect (Léger & Descarriers, 1978; Vertes & Kocsis, 1994). Alterations 
in noradrenergic and serotonergic fimction have long been implicated in depression
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because clinically effective antidepressants directly interact with these systems and 
produce observable changes in depressive symptomatology (Schildkraut, 1965a; Owens & 
Nemeroff, 1994). The emergence of SSRIs as the treatment of choice for depression has 
shifted the recent emphasis of the monoamine theory toward serotonergic mechanisms 
rather than noradrenergic dysfimction (Baldwin & Rudge, 1995; Stanford, 1996).
Several pieces of data support the idea that serotonergic afferents modulate 
noradrenergic neuronal activity in the locus coeruleus. Serotonergic immunoreactive fibers 
provide a dense innervation of the locus coeruleus area (Palkovits et al, 1974; Léger & 
Descarriers, 1978). Serotonin attenuates sensory-evoked responses of locus coeruleus 
neurones (Segal, 1979) and decreases glutamate-induced excitation of these cells when 
applied locally (Bobker & Williams, 1989; Aston-Jones et al, 1991).
Previous studies have demonstrated that acute SSRIs have no effect on the 
spontaneous firing activity of locus coeruleus noradrenergic neurones (Béïque et al, 1999). 
A recent study indicates that the long-term (21 days), but not short-term (2 days) 
administration of paroxetine greatly reduced the spontaneous firing rate of the locus 
coeruleus noradrenergic neurones (Szabo et al, 1999). In contrast, the acute administration 
of an SSRI reduced the firing rate of 5-HT neurones of the dorsal raphé nucleus in the 
rodent brain (De Montigny et al, 1981; Quinaux et al, 1982). However, these neurones 
regain their normal firing rate after long-term administration (Blier & DeMontigny, 1983). 
This has been shown to be due to desensitisation of the somatodendritic 5-HTia 
autoreceptor, which modulates their firing activity (Blier & DeMontigny, 1983). The 
terminal 5-HT autoreceptor controlling 5-HT release also desensitises following long-term 
SSRI administration (Blier et al, 1988). These two modifications, in the presence of 
sustained 5-HT reuptake blockade, result in an increased amount of 5-HT released in the 
forebrain, per action potential.
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The efficacy of SSRIs, like paroxetine, are normally attributed to their ability to 
increase brain 5-HT function, although recent preclinical findings have shown that 
paroxetine also increases extracellular concentrations of noradrenaline, following repeated 
administration (Hajos-Korcsok et al, 2000; Owens et al, 2000). The recent study by Hajos- 
Korcsok et al (2000) found that repeated but not acute administration of paroxetine causes 
an increase in extracellular noradrenaline (and serotonin) concentration in the rat 
hippocampus. This facilitatory effect of paroxetine on noradrenaline may reflect a 
serotonin-noradrenaline interaction, in which case other SSRIs may have a similar effect. 
An increase in noradrenaline fimction may contribute to the antidepressant effect of 
paroxetine, and possibly other SSRIs.
6,LL Endocrinological changes following antidepressant administration
By virtue of their ability to inhibit the reuptake of 5-HT, SSRIs elevate the 
extracellular concentrations of 5-HT in the synapse. Consequently, the activation of post­
synaptic 5-HT receptors in the hypothalamus stimulates the secretion of several hormones. 
Therefore, increases in serum corticosterone, CRH and ACTH have been described with 
SSRIs in rats (Bourin et al, 2001). Indeed, several studies using rats have indicated that a 
single injection of fluoxetine increases plasma concentrations of ACTH and corticosterone 
(Fuller et al, 1976). Acute administration of fluoxetine and paroxetine also increase plasma 
cortisol concentration in humans (Reist et al, 1996). SSRIs are substantially less 
efficacious in increasing plasma concentrations of hormones than 5-HT releasing drugs 
such as d-fenfluramine (Lucey et al, 1992; Coccaro et al, 1996). One explanation for this 
weak neuroendocrine response to an acute administration of SSRIs is that by blocking 
5-HT reuptake in the cell body region in the raphé, they subsequently activate 
somatodendritic 5-HTia autoreceptors. These 5-HTia autoreceptors in the raphe nuclei 
provide negative feedback inhibition of serotonergic firing. Therefore, the tendency of
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SSRIs to increase the concentrations of 5-HT in the synapse are negated by activation of 
the negative feedback, leading to reduced release of 5-HT. Consequently, less activation 
of post-synaptic 5-HT receptors occurs and a less robust neuroendocrine response to acute 
administration of SSRIs is observed.
A number of studies have described that the function of GR is reduced in depressed 
patients (GR resistance) and that antidepressants act by reversing these putative GR 
changes (Pariante & Miller, 2001). Specifically, studies in depressed patients, animals, and 
cellular models have demonstrated that antidepressants increase GR expression, enhance 
GR function and promote GR nuclear translocation; this, in turn, is associated vÂth 
enhanced GR-mediated negative feedback by endogenous corticosteroids, and thus with 
reduced resting and stimulated HPA axis activity (Pariante & Miller, 2001).
Previous investigations first performed on primary cultures of rat brain 
(Pepin et al, 1989) and later in different brain regions and the pituitary of the rat in vivo 
(Brady et al, 1991; Reul et al, 1994), have demonstrated that antidepressants have varying 
affects on GR mRNA concentrations. They have shown a decrease and increase in anterior 
pituitary (Brady et al, 1991; Reul et al, 1994), increase in the hypothalamus 
(Peiffer et al, 1991; Reul et al, 1994), increase or not altered in the hippocampus 
(Peiffer et al, 1991; Reul et al, 1994), and not altered in the neocortex and amygdala 
(Reul et al, 1994). Other studies have demonstrated that administration of antidepressants 
increase the activity of the GR-gene promoter (Pepin et al, 1992) and induce the steroid- 
independent translocation of the GR in mouse fibroblast cells (Pariante et al, 1997). The 
hypothesis of a primary effect of antidepressants on steroid receptor function were further 
corroborated by the findings that the antidepressant administration in rats resulted in 
changes of various brain HPA parameters such as increases in steroid receptor mRNA 
concentrations and protein concentrations as well as a decrease of HPA hormone secretion 
(Brady et al, 1991; Reul et al, 1994). These observations led to the assumption that the
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common mechanism of action of the different classes of antidepressants is the restoration 
of neuroendocrine feedback functions due to their action on GR function and GR-mediated 
cellular effects (Holsboer & Barden, 1996). It was concluded that this mode of action 
finally causes a normalisation of HPA-regulated hormone secretion with subsequent 
clinical improvement (Reul et al, 1994; Holsboer & Barden, 1996).
A number of animal studies have shown that long-term (10-28 days) administration 
of antidepressants increases GR and/or MR binding (Reul et al, 1993; Budziszewska et al, 
1994) and GR and/or MR mRNA expression (Peiffer et al, 1991; Seckl & Fink, 1992) in 
the hippocampus, and GR binding in the hypothalamus (Reul et al, 1993). Such time 
courses coincide closely with those of antidepressant therapy: long-term
(10 days-several weeks) administration of antidepressants is necessary to see the first signs 
of clinical efficacy. Thus, the up-regulation of brain GR and/or MR appears to be pivotal 
for the therapeutic action of antidepressants.
The hypothesis that antidepressants exert their clinical effects through direct 
modulation of the GR is one of the most striking and innovative models of the mechanism 
of action of this class of drugs (Barden, 1999; Pariante & Miller, 2001).
It has been previously shown that mixed 5-HT/noradrenaline antidepressant drugs 
could increase the number of GR and thereby normalise the feedback inhibition of 
corticosterone secretion (Seckl & Fink, 1992; Reul et al, 1993). It is therefore hypothesised 
that an increase in serotonergic transmission might regulate the HPA axis functioning 
through a regulation of corticosteroid receptors. The effects of a short-term increase in 
serotonin transmission on corticosteroid receptors are not yet clear. Conflicting results 
might come from (i) the use of drugs that have differential short-term effects on 5-HT 
metabolism (Seckl & Fink, 1992; Yau et al, 1997), and (ii) the difficulty to correlate the 
effects on MR and GR mRNA concentrations and the effects on binding sites.
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Antidepressant administration influences the expression of genes encoding for 
hypothalamic-pituitary-adrenal axis constituents. Thus, chronic treatment with some 
tricyclic antidepressants downregulates the CRH mRNA concentration in the PVN 
(Brady et al, 1991) and upregulates the hippocampal MR (Brady et al, 1991) and the GR 
mRNA concentration (Peiffer et al, 1991; Rossby et al, 1995). However, the latter effect is 
not a common mechanism of antidepressants, as fluoxetine does not cause such an effect 
(Rossby et al, 1995). Therefore, the molecular mechanism underlying the effects of 
antidepressants on GR fimction remains unclear.
One mechanism through which CRH may modulate a broad spectrum of 
physiological and behavioural responses is via actions on ascending neuromodulatory 
systems, such as serotonergic systems. Several lines of evidence support the hypothesis 
that CRH plays a role in regulating serotonergic neurotransmission. First, moderate to high 
densities of CRH-immunoreactive neuronal cell bodies and fibers are associated 'with 
serotonergic neurones in brainstem raphe structures (Cummings et al, 1983; Ruggiero et al,
1999). Second, CRHi and CRHi receptor binding sites, receptor mRNA expression, and 
CRHi receptor-immunoreactive neurones have been identified in raphé nuclei 
(De Souza et al, 1985; Chen et al, 2000), raising the possibility that CRH or CRH-like 
peptides may have direct receptor-mediated actions on serotonergic neurones. Third, 
exogenous CRH or CRH-like peptides alter serotonin metabolism or neurotransmission in 
studies using ex vivo tryptophan hydroxylase activity assays and in vivo microdialysis 
(Singh gr 1992).
According to a recent study by Isogawa et al (2000), the CRH type 1 receptor 
antagonist, CP-154,526, produced a decrease in dialysate concentration of noradrenaline 
and serotonin, but not dopamine, in the hippocampus of rats. This suggests that the CRH 
type 1 receptor is linked with the release of noradrenaline and 5-HT in the hippocampus.
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The possible existence of an interaction between the central serotonin and BDNF 
systems has recently attracted wide interest. BDNF, for example, has been shown to 
influence the survival and function of serotonin neurones in the rat brain 
(Mamounas et al, 1995). Previous studies have also shown that the chronic administration 
of SSRIs increases BDNF mRNA expression in the hippocampus, suggesting that 
increased serotonergic function influences BDNF gene expression 
(Zetterstrom et al, 1998). In contrast, a more recent study has shown that acute 5 -HT2 
receptor stimulation results in decreased BDNF mRNA in the rat dentate gyrus, while there 
was an increase in neocortical areas (Vaidya et al, 1997).
The possibility that BDNF is involved in the actions of antidepressant treatment is 
also supported by results from behavioural, neurochemical, and morphological studies. 
Chronic infusion of BDNF is reported to have antidepressant effects in two behavioural 
models of depression, the forced swim and learned helplessness paradigms 
(Siuciak et al, 1996). BDNF has been demonstrated to have potent neutrophic effects on 
serotonin neurones when infused into midbrain (Siuciak et al, 1994). In addition, infusion 
of BDNF into forebrain results in a dramatic elevation of serotonin neuronal fiber density, 
and protection of neurones from neurotoxic damage (Mamounas et al, 1995). Upregulation 
of BDNF in response to antidepressant administration could have similar behavioural 
effects, and could enhance serotonergic neurotransmitter function. These findings also 
indicate that there is a positive, reciprocal interaction between 5-HT and BDNF; chronic 
SSRI administration increases levels of BDNF, and upregulated BDNF would be expected 
to increase serotonin neuronal function.
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6.2. Aims
To study the effects of acute and chronic antidepressant administration on the HPA 
axis. Paroxetine was selected for several reasons: (i) it is the most potent inhibitor of the 
5-HT transporter currently available, (ii) in the rat it has a long half-life (8h; Owens et al,
2000) which makes it particularly usefiil for repeated administration.
Animal studies have shown that long-term in vivo administration of antidepressants 
up-regulates hippocampal GR and/or MR (Brady et al, 1991; Budziszewska et al, 1994), 
but it is not clear whether this up-regulation is evoked through a direct action of 
antidepressants on these receptors. Therefore the direct effects of short- and long-term 
paroxetine administration on GR density, GR mRNA, CRH type 1 receptor mRNA and 
BDNF mRNA concentrations were examined in the rat brain. Sucrose preference was used 
as a behavioural measure of anhedonia.
6.3. Study Design
This chapter is part of one study, alongside Chapters 5 and 7. Refer to Figure. 6.1. 
for a description of the study design for this specific chapter. Rats were handled twice daily 
up until the time of testing in order to minimise procedural stress (approximately 7-10 days 
prior to experimentation), and during this time they were given two bottles of water per 
cage, to minimise place preference (refer to Section.5.3.2.).
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6.4. Methods
6.4.7. Animals
Adult male Wistar rats -  as per Section 5.4.1. The use of these animals in the 
following scientific procedures were regulated by the Animals (Scientific Procedures) Act 
1986.
6.4.2, Paroxetine Administration
Previous experiments in our laboratory used 5mg/kg p.o. paroxetine but this had no 
effect when administered with restraint stress, whereas preliminary experiments had shown 
an effect with lOmg/kg p.o. Also other investigations used oral doses of lOmg/kg p.o. 
Therefore this dose was chosed for the following studies. Rats received daily 
administration of paroxetine (lOmg/kg p.o.) or distilled water (ImPkg p.o.). The later were 
the same control animals (Acute II and Chronic) that were studied in the previous chapter 
(refer to section.5.3).
6.4.3, Sucrose Preference Test
The sucrose preference tests were conducted at the same time each day, as 
described in section 5.4.3.
6.4.4, Radioimmunoassay ofplasma corticosterone and ACTH concentrations
Plasma corticosterone and ACTH concentrations were measured by using 
radioimmunassay commercial kits (refer to Section 2.4.).
6.4.5, Other Assays
GR binding, protein measurements and mRNA were carried out as in section 5.4.5
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6.5. Statistical Analysis
The data is presented as the arithmetic mean +/- s.e.mean. The effects of time 
(“days”) and paroxetine on all the biochemical and behavioural measures v^ere analysed by 
two-factor completely randomised ANOVA (paroxetine x time), followed by Newman- 
Keuls post-hoc comparisons. All statistical analyses were performed using the software 
package, “GBStat” v6.5.
6.6. Results
6,6,1 Plasma Corticosterone and ACTH Concentrations,
1, Corticosterone
Statistical analysis indicated that paroxetine adminstration alone 
(Fi,2i=40.47; p<0.0001), time alone (Fi,2i=44.41; p<0.0001) and the interaction between 
paroxetine and the length of administration (Fi 2i=41.44; p<0.0001) significantly affected 
the plasma corticosterone concentrations (Figure.6.2.). A single paroxetine administration 
increased plasma corticosterone concentrations by 166%, compared to vehicle. Plasma 
corticosterone concentrations in rats given paroxetine for 21 days were the same as in 
vehicle-treated rats.
2, Adrenocorticotrophic Hormone (ACTH)
A single paroxetine administration had no significant effect upon plasma ACTH 
concentrations compared to vehicle. Plasma ACTH concentrations in rats given paroxetine 
for 21 days were not significantly different from the vehicle-treated rats (Figure.6.3.).
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Figure.6.2.
Plasma Corticosterone Concentration following Paroxetine
Administration.
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Plasma corticosterone concentrations in male Wistar rats, housed in pairs 
(n=8 per group), were measured in samples taken following administration of 
paroxetine. Data are expressed as mean ± sem. Comparison between 
vehicle-treated rats (vehicle group) and paroxetine-treated rats 
(paroxetine group) left in their homecages for 1 day or 21 days before they 
were scarificed. ##, p<0.01 compared to vehkle; **, p<0.01 compared to one 
administration of paroxetine.
Figure.6.3.
Plasma ACTH concentration following paroxetine 
administration.
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Plasma ACTH concentrations in male Wistar rats, housed in pairs 
(n=8 per group), were measured in samples taken following 
administration of paroxetine. Data are expressed as mean ± sem. 
Comparison between vehicle-treated rats (vehicle group) and 
paroxetine-treated rats ( paroxetine group) left in their homecages for 
1 day or 21 days before they were scarificed. **, p<0.01 compared to 
one administration of paroxetine.
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6.6.2, Glucocorticoid Receptor Binding
1» Btnax
Statistical analysis indicated that paroxetine alone (Fi,23-4.613; p=0.0409) and the 
length of time of the experiment (Fi,23=5.846; p=0.0226) significantly affected the Bmax 
values from glucocorticoid receptor binding within the cortex (Figure.6.4A). A single 
paroxetine administration decreased cortical GR Bmax by 20% compared to vehicle. 
Repeated paroxetine administration had no significant effect on cortical GR Bmax compared 
to vehicle.
In the hippocampus, statistical analysis indicated that the length of time of the 
experiment significantly affected (Fi,23=31.02; p<0.0001) the Bmax values from
glucocorticoid receptor binding (Figure.6.4B), as shown by the control values varying 
between 95 and 130 finoFmg protein. A single paroxetine administration or repeated 
paroxetine administrations had no significant effect on hippocampal GR Bmax compared to 
vehicle.
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Figure.6.4.
Glucocorticoid Receptor Bmax values from cortical (A) and hippocampal (B) 
cytosolic fractions following administration of paroxetine.
(A)
160-1
* *1 4 0 -
%  120 -  9
100 -
r  s
O «
l i
8 0 -
6 0 -
4 0 -
20 -
211
Time (days)
Vehicle
Paroxetine
(B)
160-,
140-"S 3
® 120-1  
CL 5
M  W 1 0 0 -
S È
Z: a  80-
2 SP -M 60- 
-  2 
eS g 40-
* ** *
2 0 -
1 21
Time (days)
GR Bmax values in cortex and hippocampus (taken from male Wistar rats, housed in 
pairs (n = 8 per group)) were measured in samples taken following administration 
of paroxetine. Data are expressed as mean ± sem. Comparison between 
vehicle-treated rats (vehicle group) and rats administered with paroxetine 1 Omg/kg 
p.o. per day ( paroxetine group) for either 1 day or 21 days before they were 
sacrificed, (A) Bmax in cortical tissue (B) Bmax in hippocampal tissue. 
#, p<0.05 compared to vehicle; **, p<0.01 compared to vehicle after 1 day; 
**, p<0.01 compared to one administration of paroxetine.
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In the cortex, statistical analysis indicated that length of time of the experiment 
significantly affected (Fi,27=8.412; p=0.0081) the Kd values from glucocorticoid receptor 
binding (Figure.6.5A). A single paroxetine administration or repeated paroxetine 
administrations had no significant effect upon cortical GR Kd compared to vehicle.
In the hippocampus, statistical analysis indicated that length of time of the 
experiment significantly affected (Fi 26=20.19; p=0.0002) the Kd values from 
glucocorticoid receptor binding (Figure.6.5B), as shown by the control values varying 
between 1.00 and 1.88 nM. A single paroxetine administration or repeated paroxetine 
administrations had no significant effect upon hippocampal GR Kd compared to vehicle.
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F i g u r e . 6 . 5 .
G l u c o c o r t i c o i d  R e c e p t o r  Kd v a l u e s  f rom c o r t i c a l  (A)  
and h i p p o c a m p a l  ( B)  c y t o s o l i c  f r a c t i o n s  f o l l o w i n g  
a d m i n i s t r a t i o n  o f p a r o x e t i n e .
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GR Kd va lues  in cor tex  and h ippocampus ,  taken from male Wistar rats,  
h ou se d  in pairs (n = 8 per group) w e r e  m e a s u r e d  in sa m p l es  taken  
fol lowing administration o f  paroxet ine.  D a t a  are e x p r e s s e d  as  m e a n  ± 
se m .  Compar i son  b e t w e e n  veh ic le - treated  rats (vehicle  group) and  
paroxet ine- treated  rats ( paroxet ine group)  left  in their h o m e c a g e s  for 
either 1 day or 21 days before  they w e r e  sacri f iced,  ( A  ) Kd in cort ica l  
t issue ( B )  Kd  in h ippocampal  t i s sue .** ,  p<0.01  c o m p a r e d  to 1 day o f  
vehicle;  * * , p < 0 . 0 1  com pa red  to one administration o f  paroxet ine.
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6.6.3» GlucocorticoidReceptormRNA
Statistical analysis indicated that paroxetine administration
(Fi,23=11.8; p = 0.0022) and length of time of the experiment (Fi,23=15.37; p = 0.0007) 
significantly affected the GR mRNA concentrations in the cortex (Figure.6.6.). A single 
paroxetine administration had no significant effect upon cortical GR mRNA concentrations 
compared to vehicle. Repeated paroxetine administrations decreased cortical GR mRNA 
concentrations by 45% compared to vehicle but this is appears to be due to an increase in 
controls rather than an effect of drug administration. Control values varied between 0.6 and 
1.2 arbitrary units.
6.6.4. Brain-Derived Neutrophic Factor (BDNF) mRNA:
Statistical analysis indicated that paroxetine administration
(Fi,25=32.74; p<0.0001) and length of time of the experiment
(Fi,25=57.43; p<0.0001) significantly affected the BDNF mRNA concentrations in the 
cortex (Figure.6.7.). A single paroxetine administration had no significant effect upon 
cortical BDNF mRNA concentrations compared to vehicle. Repeated paroxetine 
administration decreased cortical BDNF mRNA concentrations by 70% compared to 
vehicle. Control values varied between 1.1 and 1.4 arbitrary units.
6.6.5. Corticotropin-Releasing Hormone (CRH) Type 1 Receptor mRNA
Statistical analysis indicated that a single paroxetine administration had no 
significant effect upon the CRH type 1 receptor mRNA after 2 days (Figure.6.8.).
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Figure. 6.6.
Cortical GR mRNA and p-Actin mRNA following paroxetine administration.
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Cortical GR mRNA and p-Actin mRNA concentrations from male 
Wistar rats, housed in pairs (n=8 per group). (A) RT-PCR and agarose 
gel electrophoresis analysis of GR mRNA expression. P-Actin mRNA 
expression was used as an internai control. Vehicle samples were run on 
a gel with p-Actin mRNA and a lOObp ladder, paroxetine samples were 
run on a separate gel with P-Actin mRNA and a lOObp ladder.
(B) Ratio of cortical GR mRNA: P-Actin mRNA (sum intensity of the 
bands). Data are expressed as mean ± sem. Comparison between 
vehicle-treated rats (vehicle group) and paroxetine-treated rats 
(paroxetine group) left in their homecages for either 1 day or 21 days 
before they were sacrificed. ##, p<0.01 compared to vehicle; **, p<0.01 
compared to 1 day of vehicle.
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Figure. 6.7.
Cortical BDNF mRNA and p-Actin mRNA following paroxetine
administration.
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Cortical BDNF mRNA and P-Actin mRNA from male Wistar rats, housed in 
pairs (n=8 per group), were measured in samples taken immediately following 
paroxetine administration. (A ) RT-PCR and agarose gel electrophoresis analysis 
of BDNF mRNA expression. P-Actin mRNA expression was used as an internal 
control. Vehicle samples were run on a gel with a lOObp ladder, the paroxetine 
samples were run on another gel with a lOObp ladder, and the P-Actin mRNA was 
run on a separate gel with a lOObp ladder. (B) Ratio of cortical BDNF mRNA: 
p-Actin mRNA (sum intensity of the bands). Data are expressed as mean ± sem. 
Comparison between vehicle-treated rats (vehicle group) and paroxetine-treated 
rats (paroxetine group) left in their homecages for either 1 day or 21 days before 
they were sacrificed. ##, p<0.01 compared to vehicle; *, p<0.05 compared to 
1 day of vehicle; **, p<0.01 compared to one administration of paroxetine.
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Figure.6.8.
Cortical CRH type 1 receptor mRNA and ft-Actin mRNA following a single
paroxetine administration.
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Cortical CRH type 1 receptor:P-Actin mRNA from male Wistar rats, housed in 
pairs (n = 8 per group), were measured in samples taken immediately following 
paroxetine administration. (A) RT-PCR and agarose gel electrophoresis analysis 
of CRH type 1 receptor mRNA expression. p-Actin mRNA expression was used 
as an internal control. Vehicle samples and paroxetine samples were run on 1 gel 
with lOObp ladders and p-Actin mRNA was run on a separate gel with a lOObp 
ladder. (B) Ratio of cortical CRH type 1 receptoriP-Actin mRNA (sum intensity 
of the bands). Data are expressed as mean ± sem. Comparison between 
vehicle-treated rats (vehicle group) and paroxetine-treated rats (paroxetine group) 
left in their homecages for 1 day before they were sacrificed.
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6.6.6, Behavioural Measurements 
1. Sucrose Preference
Single or repeated paroxetine administration had no significant effect upon sucrose 
preference compared to vehicle or basal levels. (Table.6.1.).
Table.6.1.
Sucrose preference (% of total fluid intake) following paroxetine administration.
GROUPS Mean ± N
BASAL 96.5 ± 0.7 13
IDAY
1 ml/kg p.o. distilled water 95.3+2.6 4
1 Omg/kg p.o. Paroxetine 96.1+0.7 4
2 DAYS
1 ml/kg p.o. distilled water 89.8 + 6.1 3
1 Omg/kg p.o. Paroxetine 95.1+0.6 3
20 DAYS
1 ml/kg p.o. distilled water 91.9 + 5.5 3
1 Omg/kg p.o. Paroxetine 95.1+0.7 3
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2. Food Intake
Statistical analysis indicated that paroxetine significantly affected
(Fi,i8 = 12.77; p=0.0022) the food intake over 22 h (Figure.6.9.). A single paroxetine 
administration decreased food intake by about 20% compared to basal levels but this was 
not significantly different compared to vehicle. A second paroxetine administration (day 2) 
significantly decreased food intake by about 25% compared to vehicle and repeated 
paroxetine administration significantly decreased food intake by about 30% compared to 
vehicle.
Figure.6.9.
Food intake follow ing adm inistration o f paroxetine.
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Food intake (g) from male W istar rats, housed in pairs 
(n = 4 per group), measured over 22 h. Data are expressed as mean 
± sem. Comparison between vehicle-treated rats (vehicle group) 
and paroxetine-treated rats (paroxetine group) left in their home 
cages for either 1 day, 2 days or 20 days. ##, p<0.01 compared to 
vehicle; *, p<0.05 compared to one administration o f paroxetine.
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6.7. Discussion
The main findings of the present experiments can be summarised as follows: 
(1) acute paroxetine increased plasma corticosterone but had no effect upon plasma ACTH 
concentration; (2) acute paroxetine decreased GR in the cortex; (3) chronic paroxetine 
decreased BDNF gene expression in the cortex; (4) acute and chronic paroxetine decreased 
food intake.
The current data indicated that plasma corticosterone concentrations were 
significantly elevated by acute paroxetine administration, but this decreased after chronic 
administration (Figure.6.2.), suggesting that there was a time-lag in the effectiveness of 
paroxetine in reducing plasma corticosterone concentrations. Acute administration had no 
significant effect on plasma ACTH concentrations but after chronic administration of 
paroxetine ACTH concentration decreased below the controls (Figure.6.3.). These results 
confirm previous investigations that have shown long-term antidepressant administration 
(>2 weeks) decreases plasma corticosterone concentrations and attenuate HPA activity in 
comparison to acute administration (Reul et al, 1993; Rowe et al, 1997).
Reports in the literature have stated that acute administration of SSRIs increases the 
secretion of several hormones, i.e. ACTH, corticosterone and cortisol, GH, prolactin and 
AVP, but chronic administration with SSRIs does not alter basal blood concentrations of 
hormones, a finding confirmed by the present results. However, adaptive changes are 
induced by long-term administration with SSRIs in serotonergic, noradrenergic and 
peptidergic neural fimction. Neuroendocrine challenge tests both in experimental animals 
and in humans indicate that chronic SSRIs produce an increase in serotonergic terminal 
fimction, accompanied by desensitisation of post-synaptic 5-HTia receptor-mediated 
cortisol, GH and OT responses, and by supersensitivity of post-synaptic 5-HT2a 
(and/or 5-HT2c) receptor-mediated secretion of hormones. Chronic exposure to SSRIs 
does not alter the neuroendocrine stress-response and produces inconsistent changes in a 2
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adrenoceptor-mediated GH secretion. Overall, the effects of SSRIs on neuroendocrine 
function are dependent on adaptive changes in specific neurotransmitter systems that 
regulate the secretion of specific hormones (for a review see Raap & Van de Kar, 1999).
These findings are interesting when taken in the context of the time course needed 
for SSRIs to exert their therapeutic efficacy in major depression. The increase in 5-HT 
release resulting fi*om long-term SSRI treatment would theoretically lead to an increased 
activation of 5-HT2a receptors on noradrenergic locus coeruleus neurones 
(Haddjeri et al, 1997). This would yield an increased inhibitory response and ultimately a 
decrease in firing activity of locus coeruleus noradrenergic neurones, as observed by Szabo 
et al (1999). SSRIs thus decrease the locus coeruleus firing rate, which may ultimately also 
attenuate noradrenaline release in projection areas. This in turn may have a profound 
impact on the a 2-adrenergic heteroreceptors on the 5-HT terminals, thus dinunishing the 
inhibitory influence of these noradrenergic receptors and contributing to the increase of 
5-HT neurotransmission by the SSRI (Szabo et al, 1999). Therefore examining serotonin 
and noradrenaline concentrations during this study could have given us an insight into their 
role in the control of the HPA axis.
The current study indicated that the effect of paroxetine on the densities of GR 
differed according to the brain region. In the cortex, there was a 20% reduction in receptor 
number after acute administration (Figure.6.4A). In the hippocampus, there was no change 
in GR binding (Figure.6.4B). Previous studies in our laboratory have shown paroxetine 
induced decreases in corticosteroid receptors in the cortex and thymus following 14 and 28 
days of administration, respectively (Maurya M, 2001).
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AU previous investigations into the effects of chronic antidepressant administration 
on brain corticosteroid receptor concentration have been carried out in animals that were 
adrenalectomised prior to the measurement of corticosteroid receptor binding activity. This 
procedure has the effect of removing residual endogenous Ugand from binding sites thus 
enabling the measurement of changes in (available) corticosteroid receptor concentration 
under conditions of minimal nuclear occupancy. However;
i) the procedure of adrenalectomy itself is found to interfere with the 
regulation of corticosteroid receptors (Reul et al, 1989; Karst et al, 1997).
ii) in depression, corticosteroid receptor regulation by stress and/or 
antidepressant treatment occurs in the presence of the endogenous Ugand.
It is essential therefore to investigate corticosteroid receptor binding activity in the 
presence of endogenous Ugand in laboratory animals to determine whether the up- 
regulation of corticosteroid receptors observed foUowing long-term antidepressant 
administration is an effect observed in the adrenaUy-intact animal. This study has shown 
that this effect is not observed in the cortex or hippocampus of adrenaUy-intact rats after 21 
days of paroxetine administration, suggesting that the presence of endogenous Ugand does 
alter the corticosteroid receptor binding activity foUowing long-term antidepressant 
administration.
The neuroanatomical specificity of these effects also supports the hypothesis of 
altered corticosteroid receptor plasticity foUowing stress and antidepressant administration. 
Many changes in corticosteroid receptor concentrations are observed in the hippocampus 
(the location of most brain MR and some GR) and the hypothalamus, both regions that are 
heavUy involved with corticosteroid receptor regulation. Since many of the changes in 
receptor plasticity are observed in GR (which are more widely distributed), the
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investigation of these receptors in various other brain regions (and peripheral tissues) 
would also be of interest.
A study by Sémont et al (2000) showed that the expression of hippocampal and 
hypothalamic corticosteroid receptors were regulated by short-term stimulation of 
serotonin neurotransmission through a corticosterone-independent mechanism. However, 
the regulation of corticosteroid receptors by serotonin were different according to the 
method used to stimulate serotonin neurotransmission, i.e. stimulation of serotonin 
synthesis and release by 5-HTP, or inhibition of serotonin reuptake by an SSRI. 
Antidepressant drugs have also been shown to directly increase GR binding sites in 
primary hippocampal neurones, which are devoid of pre-synaptic serotonergic innervations 
(Hery et al, 2000). This suggests that the effects of antidepressants on hippocampal 
corticosteroid receptor mRNA expression could be independent of its actions on serotonin.
In this present study, acute administration of paroxetine had no effect on GR 
mRNA concentrations within the cortex after acute paroxetine administration, and this 
remained during chronic administration (Figure.6.6.). Therefore, in the cortex the densities 
of GR binding sites did not correlate well with their respective mRNA. A possible 
explanation for the lack of change in cortical GR mRNA expression after paroxetine 
administration, would be that paroxetine might have produced regionally selective 
changes, which were not detected using the methods in this study. Indeed, Yau et al (1997) 
pointed out the subregional specificity of the effects of 5-HT upon hippocampal 
corticosteroid receptors. Nevertheless, the involvement of a post-transcriptional effect of 
serotonin on GR binding sites cannot be excluded. The phosphorylation status of GR may 
play an important role in the regulation of GR densities (Webster et al, 1997); and, since 
serotonergic binding to most of its receptors activates kinases, serotonin could regulate GR 
densities directly, by acting on their phosphorylation status. In the cortex, the discrepant
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findings between the decrease in GR protein and no change in the mRNA expression could 
be due to the different half fives of GR mRNA and protein (Dong et al, 1988).
Several groups have shown increased MR and GR mRNA expression in the 
hippocampus following long-tem antidepressant administration (Brady et al, 1991; Yau er 
al, 1995), and therefore reduce HPA axis activity. However, very little has been reported 
using SSRI antidepressants upon corticosteroid receptor mRNA expression. Brady et al 
(1992) reported no change in hippocampal MR and GR mRNA expression following 2- 
weeks of fluoxetine administration while another study showed no change in hippocampal 
GR mRNA concentrations after 10-days of fluoxetine administration (Rossby et al, 1995).
Some antidepressants, e.g., desipramine, also induce increases in GR gene 
promoter activity, GR mRNA concentrations (Pepin et al, 1992a; Rossby et al, 1995), and 
in the receptor density (Przegafinski & Budziszewska, 1993). However, other 
antidepressants, such as oxaprotifine, citalopram and mianserin do not affect the receptor 
density (Budziszewska et al, 1994), suggesting that the effect upon GR mRNA and binding 
varies between antidepressant drugs.
The hippocampus is densely innervated by serotonergic fibers originating firom the 
raphe nuclei. Serotonin is a potent regulator of hippocampal MR and GR, with neurotoxic 
lesions to central serotonergic innervations decreasing mRNA concentrations 
(Yau et al, 1994) and serotonin directly increasing GR mRNA expression in hippocampal 
neurones in culture (Mitchell et al, 1990). However, less is known about the effects of 
antidepressants on cortical corticosteroid receptor mRNA expression.
In a recent study, fluoxetine administered to rats for 7 days reduced the mean firing 
rate of serotonin neurones in the dorsal raphe (Czachura & Rasmussen, 2000), thus 
limiting the amount of serotonin released into the synapse. Hence a delayed substantial 
increase in extracellular serotonin concentrations in the hippocampus after fluoxetine
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administration may in part explain the delayed therapeutic effects of antidepressants on 
corticosteroid receptors and thus normalisation of the HPA axis.
GR is a hormone-activated transcription factor, which binds to a specific DNA 
sequence (GRE) and acts as a regulator of gene expression. The GR-mediated gene 
transcription can be modulated by cAMP/PKA-PLC/PKC- and CAM-mediated signal 
transduction pathways (Maroderm et al, 1993; Ning & Sanchez, 1995) whose activities are 
affected by antidepressant drugs (Silver et al, 1986; Nibuya et al, 1996). To date, only the 
effect of desipramine on GR-mediated transcription has been determined, and this is 
dependent on experimental conditions, i.e., on the concentration and time of its and 
dexamethasone presence in the medium, and on the presence/absence of steroids in the 
serum added to an incubation medium (Pariante et al, 1997; Pepin et al, 1992a). Pariante et 
al (1997) found that desipramine induced GR translocation from the cytoplasm to the 
nucleus in the absence of steroids (with no effect alone on GR-mediated gene 
transcription) and potentiated dexamethasone-induced GR translocation and 
dexamethasone-induced GR-mediated gene transcription. They suggested that one 
important aspect of the effects of antidepressants in vivo may be to facihtate GR-mediated 
feedback inhibition on the HPA axis, by facilitating GR translocation and function, and 
thereby reverse glucocorticoid hypersecretion in depression.
A wide variety of neurotransmitters, which are regulated differentially by distinct 
stressors, may be involved in the regulation of hippocampal or cortical GR mRNA and/or 
binding (Herman, 1993). A recent study has shown the regulation of hippocampal GR or 
GR mRNA by catecholamines (through a p-adrenergic receptor), NMD A, or GABA-A 
receptors (Tritos et al, 1999).
After acute administration of paroxetine, there was a slight decrease in BDNF 
expression in the cortex, but after chronic administration this was further decreased 
(Figure.6.7.).
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Very few investigations have been conducted on the effects of antidepressant drugs 
on BDNF mRNA concentrations, yet they all indicate that antidepressants increase BDNF 
mRNA, which is opposite to the current results. For example, according to Nibuya et al 
(1996), chronic, but not acute, administration of several different antidepressant drugs 
including tranylcypromine, desipramine, sertraline, and mianserin, significantly increased 
BDNF mRNA concentrations in the hippocampus, but only tranylcypromine significantly 
increased expression of BDNF in fi*ontal cortex.
Zetterstrom et al (1999) demonstrated that paroxetine reduced BDNF mRNA 
concentrations in the dentate gyrus but was without effect in the fi-ontal cortex in rats, 
suggesting that serotonin modulated BDNF mRNA concentrations in a different way 
according to the brain region. This is compatible with microdialysis studies demonstrating 
that acute paroxetine administration increased extracellular serotonin concentration in 
hippocampus (Sharp, 1992) but lacked a significant effect in fi-ontal cortex 
(Sharp et al, 1997).
The present results indicated that a single paroxetine administration had no 
significant effect upon CRH type 1 receptor expression in cortical tissue (Figure.6.8.), 
although there was a trend towards a decrease.
There is very little literature on the effects of antidepressants, particularly SSRIs, 
upon CRH receptor expression in the brain. Fluoxetine administration (lOmg/kg i.p.) has 
been shown to cause a significant increase in CRH-Rl receptor mRNA levels in the PVN 
but with a slow synthesis of the receptor mRNA, as high concentrations were only 
discernible 360 minutes after fluoxetine administration (Torres et al, 1998). As this was 
conducted in the PVN with fluoxetine, there is a possibility that differences may occur due 
to the brain region examined as well as the antidepressant used.
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In this present study, acute and chronic paroxetine administrations had no 
significant effect upon sucrose preference (Table.6.1.), but suppressed food intake 
(Figure.6.9.), suggesting that this antidepressant does not have an effect upon sucrose 
preference, in this current study.
Chronic treatments with tricyclic or atypical antidepressants have been shown to 
reverse chronic mild stress-induced anhedonia, but at doses which have no effect on 
rewarded behaviours in non-stressed animals (for a review see Willner, 1995). Both 5-HTP 
and fluoxetine, as well as other SSRIs, are well known to reduce food intake in rats 
(for a review see Dourish, 1992).
6.8 Conclusions
This series of experiments demonstrated that paroxetine significantly affected 
components of the HPA axis under baseline conditions, resulting in similar responses 
elicited by stress (Table.6.2.).
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Table.6.2.
Similar responses elicited by either 30 min restraint stress or 
lOmg/kg p.o. paroxetine administration.
Measurement Treatment 1 day 21/23 days
Corticosterone (ng/ml) lOmg/kg p.o. Paroxetine 166% t -
30 min Restraint Stress 200% t -
Cortical GR Bmax lOmg/kg p.o. Paroxetine 20% i -
(finol/mg protein)
30 min Restraint Stress 24% i _
Cortical GR mRNA lOmg/kg p.o. Paroxetine No Change -
(sum intensity of the bands)
30 min Restraint Stress No Change _
Cortical BDNF mRNA lOmg/kg p.o. Paroxetine - 70% i
(sum intensity of the bands)
30 min Restraint Stress 36% i
Cortical CRH-Rl mRNA lOmg/kg p.o. Paroxetine No Change -
(sum intensity of the bands)
30 min Restraint Stress No Change
Food Intake (g) in 22h lOmg/kg p.o. Paroxetine - 25% i
30 min Restraint Stress - 24% i
Refer to Sections 5.6.1.1., 5.6.2., 5.6.3., 5.6.4., 5.6.5., and 5.6.6.2. respectively, for the 
restraint stress data.
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CHAPTER 7. THE EFFECT OF PAROXETINE ADMINISTRATION, 
IN RATS, ON THE STRESS-INDUCED RESPONSES OF THE HPA 
AXIS.
7.1. Introduction
The normalisation of the hyperactive HPA axis and the mood-stabihsing effects 
seem to occur simultaneously during antidepressant administration, indicating that the two 
effects are either directly or indirectly interdependent (Holsboer et al, 1982; Holsboer & 
Barden, 1996). Thus, the effects of long-term antidepressant administration on the HPA 
axis and the feedback inhibition of glucocorticoids are therefore important in 
understanding the mechanisms by which antidepressants exert their therapeutic effects.
Stress-related behavioural paradigms, particularly those associated with increased 
anxiety or conditioned fear, may activate topographically organised mesolimbocortical 
serotonergic systems. For example, behavioural paradigms associated with increased 
anxiety or conditioned fear increase serotonin metabohsm or release in the medial 
prefrontal cortex (Adell et al, 1997; Dunn, 1988), cingulated cortex (Palkovits et al, 1976), 
entorhinal cortex (Blanchard et al, 1991; Ge et al, 1997), nucleus accumbens 
(Inoue et al, 1993; Ge et al, 1997), amygdala (Blanchard et al, 1991; Amat et al, 1998), 
and dorsal hippocampus (Joseph & Kennett, 1983; Ge et al, 1997). This topographically 
selective activation of serotonergic neurotransmission suggests that the serotonergic 
neurones activated by these stress-related stimuli may reside in the median raphe nucleus 
(Vertes & Martin, 1988; Vertes et al, 1999) and ventral and interfascicular regions of the 
caudal dorsal raphe nucleus (Pierce et al, 1976).
Previous exposure to stressful stimuli has been shown to result in an upregulation 
of tryptophan hydroxylase mRNA concentrations (coding for the rate limiting enzyme in 
serotonin synthesis) in the dorsal and median raphe nuclei (Chamas et al, 1999) and
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enhance the responsiveness of mesolimbocortical serotonergic neurotransmission to a 
subsequent stress (De Souza & Van Loon, 1986; Adell et al, 1988a). Intense 
psychophysical stress is believed to sensitise the animal so that subsequent behavioural 
responses to stress (including behavioural anxiety and fear) are exaggerated 24 or 48 h 
later (Graeff et al, 1996). This behavioural sensitisation is believed to be a result of 
prolonged, enhanced sensitivity of serotonergic neurones located in the caudal portion of 
the dorsal raphe nucleus, possibly involving a functional desensitisation of somatodendritic 
5-HTia receptors (Laaris et al, 1997; Grahn et al, 1999).
In addition to the behavioural and neurochemical consequences of exposure to 
stress there is an abundance of literature dealing with the attenuating effect of 
antidepressant treatments on stress-induced HPA axis activation 
(Reul et al, 1993; Holsboer & Barden, 1996). While it has been reported that both TCAs 
and MAOIs attenuate stress-related increases in HPA axis activity (Reul et al, 1994), less 
attention has been given to the effect of SSRIs on stressor-induced HPA axis activation.
In spite of a large number of studies on the neurochemical changes in stress, an 
equivocal case is yet to be made for the role of a specific neurotransmitter in this important 
neurobiological disorder. The difficulty arises fi*om the fact that there is no single 
neurotransmitter system that appears to be responsible for the stress-induced damage to the 
hippocampal neurones. A recent study by Sunanda et al (2000) evaluated the effect of 
restraint stress on the alterations in the concentrations of biogenic amines, amino acids and 
acetylcholinesterase activity in the hippocampus of male Wistar rats. They showed a 
significant decrease in the concentrations of noradrenaline, dopamine, 5-HT and 
acetylcholinesterase activity in the stressed rats compared to controls. However, 
concentrations of glutamate were significantly increased in stressed rats. These results 
indicate that chronic restraint stress (6 h per day for 21 days) decreases aminergic and
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cholinergic neurotransmission, and increases the glutamatergic transmission in the 
hippocampus.
As with other effective antidepressants, although the primary pharmacological 
action is understood, httle is known regarding the ultimate mechanism(s) of action of the 
SSRIs that serve to confer therapeutic efficacy. One possibihty is that affective disorders 
are the result of a disruption of some appropriate level of balance among central 
monoaminergic systems (Schatzberg & Schildkraut, 1995).
Failure to adapt to a daily restraint stress schedule repeated over 5-7 days has been 
used as an animal model for depression, and this model has been shown to respond 
appropriately to antidepressant pre-treatment (Curzon, 1989).
7, LI. Endocrinological changes following exposure to restraint stress with 
antidepressant administration.
While SSRIs are prescribed for anxiety and panic disorders, little information is 
available regarding their effects on stress-induced release of hormones. Daily injections of 
rats with fluoxetine (5mg/kg/day) for 21 days did not alter the corticosterone response to 
forced swim stress (Duncan et al, 1998). Daily injections of fluoxetine (lOmg/kg/day) to 
rats for 14 days did not alter the effect of conditioned fear stress on the secretion of ACTH, 
corticosterone, OT, prolactin or renin. These data suggest that the neuroendocrine stress 
responses are not altered by chronic SSRI treatment. The importance of hormones such as 
cortico sterone/cortisol and the enzyme renin for survival probably requires multiple 
neurotransmitter mechanisms to mediate the effects of stress on their secretion. It is 
unlikely that all these neural mechanisms would be altered in a similar manner by SSRIs.
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In addition to the behavioural and neurochemical consequences of exposure to 
stress there is an abundance of literature dealing with the attenuating effect of 
antidepressant treatments on stress-induced HPA axis activation (Reul et al, 1993; 
Holsboer & Barden, 1996).
Farisse et al (1999) have shown that there is a tonic activation of serotonin turnover 
by corticosterone through GR in the mouse hippocampus, and that stress-induced 
stimulation of serotonin metabolism in the brain stem and hippocampus (but not the cortex, 
striatum or hypothalamus) appeared to be delayed in transgenic mice deficient in GR 
compared to control mice. These results are particularly relevant for mood disorders where 
alterations of serotonergic transmission might be secondary to an impairment of GR 
functions. Recent studies have also indicated that life-long GR impairment has profound 
consequences for behavioural and neuroendocrine responses to a psychological stressor, 
and that long-term impaired fiinctioning of GR evolves in hyper-responsiveness of the 
raphe-hippocampal serotonergic system (Linthorst et al, 2000).
Lopez et al (1998) studied the effect of CMUS and antidepressant treatment on 
5-HTia, GR and MR densities in rat hippocampus. They found that rats subjected to 
CMUS showed a significant elevation of basal plasma corticosterone, a decrease in 5-HTia 
mRNA and binding, as well as alterations in the MR/GR ratio. These were prevented by 
imipramine or desipramine (but not zimelidine) administration, suggesting that alterations 
in 5-HTiA receptor levels and in the MR/GR balance may be one of the mechanisms by 
which stress may trigger and/or maintain depressive episodes.
Therefore very little work has been conducted on the effect of stress, particularly 
restraint, and antidepressant treatment on GR mRNA and binding in the rat brain.
Major depression is a condition that has been associated with a predisposing 
influence of major stressors, particularly early in life, and with neurochemical and 
neuroendocrine findings of CRH hypersecretion (Arborelius et al, 1999). On the basis of
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these observations, it has been hypothesised that antidepressants may act in part by 
reducing CRH synthesis or secretion, either tonically or in response to stress 
(Stout et al, 2002).
Stress-related stimuh, particularly behavioural paradigms associated with increased 
anxiety or conditioned fear (Pezzone et al, 1993; Chung et al, 2000) including opiate 
withdrawal (Chieng et al, 1995; Chahl et al, 1996) and intracerebroventricular infusion of 
CRH or CRH-like peptides (Vaughan et al, 1995; Bittencourt & Sawchenko, 2000), 
activate immediate-early gene expression within the dorsal raphe nucleus. Based on these 
findings and evidence that stress-related stimuh increase serotonergic neurotransmission in 
the MRN and DRN (Adell et al, 1997; Maswood et al, 1998) and limbic forebrain regions, 
especially in response to intense, uncontrollable, or unpredictable stimuh 
(Adeh et al, 1988b; Amat et al, 1998), one hypothesis is that stress increases serotonergic 
neurotransmission via the actions of CRH on subpopulations of serotonergic neurones that 
contribute to the mesolimbocortical serotonergic innervation of the forebrain.
7.L2. Neurotrophin changes following exposure to restraint-stress with antidepressant 
administration.
The finding that stress decreases the expression of BDNF within the hippocampus 
suggests that regulation of neurotrophins could also contribute to the effects of stress on 
neuronal survival and fimction (Smith et al, 1995b). In adrenalectomised rats the influence 
of stress on the down-regulation of BDNF concentration was not significantly altered 
suggesting that glucocorticoids alone could not fuhy explain the regulation of BDNF by 
stress (Smith et al, 1995b). There are several neurotransmitter systems, including 
monoamine systems, that are influenced by stress and that could regulate the expression of 
BDNF (Kutchel, 1991; Chaouloff, 1993). One of these is the serotonergic system, which is 
profoundly influenced by stress (Joseph & Kennett, 1983; Vahabzadeh & Fihenz, 1994).
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Moreover, recent work has shown that activation of 5-HT2a receptors decreases 
concentrations of BDNF mRNA in the hippocampus in a manner similar to that observed 
after stress. This finding raises the possibility that the stress-induced down-regulation of 
BDNF concentrations may be mediated by release of 5-HT and activation of 5 -HT2A 
receptors.
7,1.3. Behavioural changes following exposure to restraint-stress with antidepressant 
administration.^
A series of previous studies showed that the CMUS-induced anhedonia could be 
effectively reversed by chronic administration of antidepressant drugs including tricyclics, 
atypical antidepressants and monoamine oxidase inhibitors, but not with drugs devoid of 
an antidepressant activity (Willner et al, 1987; Papp et al, 1996).
A growing number of studies have revealed that like the antidepressive effect on 
depressed patients, prolonged but not acute administration of antidepressant reverses 
stress-induced behavioural disturbances. Noradrenergic and serotonergic projections have 
long been thought to be involved in the pathophysiology of mood disorders and in the 
mechanism of action of antidepressant drugs. However, and in addition to these 
neurotransmitters, a role for dopamine as part of the biochemical basis of depression has 
also been suggested (Willner, 1983; Kapur & Mann, 1992). Moreover, and despite the fact 
that antidepressant drugs have traditionally been reported to exert their primary action on 
noradrenergic and serotonergic neurones, a role for dopaminergic processes in the central 
effects of such drugs has also been suggested. For instance, acute and chronic 
antidepressants can influence dopaminergic activity on fi-ontocortical areas 
(Tandae/a/, 1996).
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D’Aquila et al (1994) have previously demonstrated that acute administration of 
dopamine receptor agonists reduces the consumption of a sweet solution in chronically 
stressed rats successfully administered with tricychc or atypical antidepressants, at doses 
that did not reduce consumption in non-stressed animals or in untreated stressed animals. 
These data suggest that an increase in dopamine receptor responsiveness is responsible for 
the action of antidepressant drugs in this model (Muscat et al, 1990; Cheeta et al, 1994).
Central mechanisms involved in the stress-induced inhibition of food intake have 
not been fully elucidated, but certain peptides and neurotransmitters are thought to be 
involved in the response. It is well established that monoamines (Kennett et al, 1987) and 
CRH (Krahn et al, 1990) influence feeding behaviour and mediate behavioural and 
physiological responses to stress (Sutton et al, 1982; Krahn et al, 1988). Several 
investigators have attributed stress-induced anorexia to activation of CRH 
(Krahn et al, 1986) and/or serotonin pathways (Kennett et al, 1986; Shimizu et al, 1989). 
Both of these transmitters are elevated in response to stress in a number of brain areas, 
including those that are involved in the regulation of feeding behaviour 
(Shimizu et al, 1992; Makino et al, 1995b). Intracerebro ventricular administration of CRH 
produces behaviours typical of stress, including depression of appetite (Sutton et al, 1982; 
Krahn ef a/, 1986).
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7.2. Aims
To study a stress paradigm in which rats are repeatedly exposed to restraint stress in 
combination with acute and chronic administration of the SSRI, paroxetine. Furthermore, 
to examine if chronic paroxetine alone can affect an acute restraint, and if this differs from 
the acute results. The present studies focused on the HPA axis as a stress response system 
to monitor (Dhabbar et al, 1997; Kalman et al, 1997), using plasma concentrations of 
corticosterone and ACTH as indicators of stress. Specifically to examine the effect of 
restraint stress, in combination with acute and chronic administrations of paroxetine, on 
corticosterone and ACTH as indicators of stress. Specifically to examine the effect on GR 
density, GR mRNA, CRH type 1 receptor mRNA and BDNF mRNA concentrations in the 
brain. Sucrose preference was used as a behavioural measure of anhedonia.
7.3. Study design
This chapter is part of one study, alongside Chapters 5 and 6. Refer to Figure. 7.1. 
for a description of the study design for this specific chapter. In Chapters 5 and 6 restraint 
stress or paroxetine administration, respectively, were considered on their own, upon the 
HPA axis. Therefore data from these have a direct relevance upon this chapter, and the 
results from “stress” animals in Chapter 5 have been included as a direct comparison 
within the results section 7.6.
Rats were handled twice daily up until the time of testing in order to minimise 
procedural stress (approximately 7-10 days prior to experimentation), and during this time 
they were given two bottles of water per cage, to minimise place preference (refer to 
Section.5.4.3.).
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7.4. Methods
7.4.L Animals
Adult male Wistar rats -  as per Section 5.4.1. The use of these animals in the 
following scientific procedures were regulated by the Animals (Scientific Procedures) Act 
1986.
7.4.2. Restraint Stress Procedure
This was conducted as described in section 5.4.2. In the Chronic I group, the stress 
rats were subjected to 30 min/day restraint stress exposure, for 2 days (refer to Figure. 7.1.). 
This was to achieve a stress-response (as established in the previous section 5.7) before the 
administration of drugs.
7.4.5. Paroxetine Administration
Rats were handled twice daily up until the time of testing in order to minimise 
procedural stress (approximately 7-10 days prior to experimentation), and during this time 
they were given two bottles of water per cage, to minimise place preference (refer to 
Section.5.4.3.). Previous experiments in our laboratory used 5mg/kg p.o. paroxetine but 
this had no effect when administered with restraint stress, whereas preliminary experiments 
had shown an effect with lOmg/kg p.o. Also other investigations used oral doses of 
lOmg/kg p.o. Therefore this dose was chosen for the following studies. Rats received daily 
administrations of paroxetine (lOmg/kg p.o.) or distilled water (Iml/kg p.o.). The latter 
were the same control animals (Acute II and Chronic) that were studied in the previous 
chapters (refer to sections.5.4 and 6.4.).
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7.4.4. Sucrose Preference Test
The sucrose preference tests were conducted at the same time each day, as 
described in section 5.4.3.
7.4.5. Radioimmunoassay ofplasma corticosterone and ACTH concentrations
Plasma corticosterone and ACTH concentrations were measured by using 
radioimmunassay commercial kits (refer to Section 2.4.).
7.4.6. Other Assays
GR binding, protein measurements and mRNA, were carried out as in section 5.4.5.
7.5. Statistical Analysis
The data is presented as the arithmetic mean +/- s.e.mean. The effects of time 
(“days”), restraint-stress and paroxetine on biochemical and behavioural measures were 
analysed by three-factor completely randomised ANOVA (restraint-stress x paroxetine x 
time), followed by Newman-Keuls post-hoc comparisons. All statistical analyses were 
performed using the software package, “GBStat” v6.5 .
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7.6. Results
7.6.1 Plasma Corticosterone and ACTH Concentration.
1. Corticosterone
Statistical analysis indicated that restraint stress exposure with paroxetine 
administration (Fi,2i=4L38; p<0.0001), length of time of the experiment
(Fi^i=13.20; p=0.0016) and the interaction between restraint stress exposure with 
paroxetine administration and the length of time (Fi,2i=ll-82; p=0.0025) significantly 
affected the plasma corticosterone concentration (Figure.7.2.).
Two days of paroxetine administration decreased stress-induced plasma 
corticosterone concentrations by 45%, which was still an increase of 166% compared to 
controls. Repeated paroxetine administration decreased stress-induced plasma 
corticosterone concentrations by 80%, which was still an increase of 45% compared to 
controls.
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Figure.7.2.
Plasma corticosterone concentrations following exposure to 
restraint stress with or without paroxetine administration.
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Plasma corticosterone concentrations in male Wistar rats, housed in pairs 
(n=8 per group), were measured in samples taken immediately following 
exposure to restraint stress. Data are expressed as mean ± sem. 
Conparison between vehicle-treated rats left in their home cages 
(control group), rats dosed with lOmg/kg p.o paroxetine and restrained for 
30 min/day (paroxetine + restraint stress) and rats restrained for 30 min/day 
(restraint stress from Section 5.6.1.1) for 2 days or 21 days before they 
were sacrificed. ##, p<0.01 compared to control; **, p<0.01 compared to 
2 days of exposures to restraint stress with paroxetine administration ; 
**, p<0.01 compared to 2 days of exposures to restraint stress; *** p<0.001 
effect of paroxetine on restraint stress.
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2. Adrenocorticotrophic Hormone (ACTH)
Statistical analysis indicated that restraint stress exposure with paroxetine 
administration (Fijg=54.73; p<0.0001), time alone (Fi,ig=22.82; p=0.0002) and the 
interaction between restraint stress exposure with paroxetine administration and the length 
of time (Fi,18=28.56; p<0.0001) significantly affected the plasma ACTH concentrations 
(Figure.7.3.). Two days of paroxetine had no significant effect upon the stress-induced 
increase in plasma ACTH, although this was still a 36% increase compared to controls. 
Repeated paroxetine administration enhanced stress-induced increase in plasma ACTH 
concentrations by 78%, and by 240% compared to control.
Figure.7.3.
Plasma ACTH concentrations following exposure to restraint 
stress with or without paroxetine administration.
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Plasma ACTH concentrations in male Wistar rats, housed in pairs 
(n=8 per group), were measured in samples taken immediate^ following 
exposure to restraint stress. Data are expressed as mean ± sem. 
Comparison between vehicle-treated rats left in their home cages 
(control group), rats dosed with lOmg/kg p.o paroxetine and restrained for 
30 min/day ( paroxetine + restraint stress) and rats restrained for 
30 min/day (restraint stress from Section 5.6.1.2.) for 2 days or 23 days 
before they were sacrificed. #, p<0.05 and ##, p<0.01 compared to 
control; **, p<0.01 compared to 2 days of exposures to restraint stress 
with paroxetine administration; **, p<0.01 effect of paroxetine on 
restraint stress.
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7,6,2,GlucocorticoidReceptor Binding 
!• Bmax
Statistical analysis indicated that administration of paroxetine with restraint stress 
exposure (Fi,21=17.86; p=0.0004) significantly effected the Bmax values firom GR binding 
within the cortex (Figure.7.4A). Two days of paroxetine administration reduced the stress- 
induced decrease of cortical Bmax values by 34%, and similarly compared to control. 
Repeated paroxetine administration had no significant effect upon the stress-induced 
decrease of cortical Bmax values, although this was decreased by nearly 30% compared to 
control.
Statistical analysis indicated that administration of paroxetine with restraint stress 
exposure (Fi,22=65.17; p<0.0001) and the interaction between the paroxetine 
administration with restraint stress exposure and the length of time 
(Fi,22=19.84; p=0.0002), but not the length of time of the experiment alone significantly 
effected the Bmax values firom GR binding within the cortex (Figure.7.4B). Two days of 
paroxetine administration had no significant effect upon the stress-induced decrease of 
hippocampal Bmax values, although this was stül a decrease of just over 50% compared to 
controls. Repeated paroxetine administrations had no significant effect upon the stress- 
induced decrease of hippocampal Bmax values, although this was still a decrease of just 
over 20% compared to control. Control values varied between 90 and 130 finoFmg protein.
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Statistical analysis indicated that administration of paroxetine with restraint stress 
exposure (Fi,25=83.31; p<0.0001), length of time of the experiment
(Fi,25=31.09; p<0.0001) , and the interaction between the paroxetine administration with 
restraint stress exposure and the length of time (Fi,25=13.57; p^O.OOll) significantly 
effected the Kd values firom GR binding within the cortex (Figure.7.5A). A single 
administration of paroxetine with two 30 min exposures of restraint stress, increased 
cortical K<i values by nearly 160% compared to controls. Repeated exposure to restraint 
stress in combination with paroxetine administrations, increased cortical Kd values by 50% 
compared to control but with no significant effect in comparison to restraint stress alone.
Statistical analysis indicated that the length of time of the experiment alone 
(Fi,24=39.07; p<0.0001) significantly effected the Kd values fi*om GR binding within the 
hippocampus (Figure.7.5B). Acute or chronic administration of paroxetine with restraint 
stress had no significant effect upon the Kd values firom GR binding within the 
hippocampus, in comparison to restraint stress alone. Control values fi*om the hippocampus 
varied between 1.00 and 1.88 nM.
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F igu re.7 .4 .
Glucocorticoid receptor values in cortical (A) and hippocampal (B) 
cytosolic fractions following exposure to restraint stress with or without 
paroxetine administration.
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GR values in cortex and hippocampus, taken from male Wistar rats, housed 
in pairs (n = 8 per group), were measured in samples taken immediately following 
exposure to restraint stress. Data are expressed as mean ± sem. Comparison 
between vehicle-treated rats left in their home cages (control group), rats dosed 
with lOmg/kg p.o paroxetine and restrained for 30 min/day (paroxetine + restraint 
stress) and rats restrained for 30 min/day (restraint stress from Section 5.6.2.1.) 
for 2 days or 23 days before they were sacrificed, (A) B in cortical tissue 
(B) B in hippocampal tissue. #, p<0.05; ##, p<0.01 compared to control; 
**, p<0.01 compared to 2 days of exposure to restraint stress with paroxetine 
administration; **, p<0.01 compared to 2 days of exposure to restraint stress; 
*, p<0.05 effect of paroxetine on restraint stress.
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Figure.7 .5 .
Glucocorticoid receptor values in cortical (A) and 
hippocampal (B) cytosolic fractions following exposure to 
restraint stress with or without paroxetine administration.
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GR K j  values in cortex  and hippocam pus, taken from m ale W istar rats 
housed in pairs (n =  8 per group), w ere m easured in sam ples taken  
immediately following exposure to daily restraint stress. D ata are exp ressed  as 
m ean ±  sem . Comparison b etw een  veh icle-treated  rats left in their hom e  
ca g es  (control group), rats dosed with lOmg/kg p .o  paroxetine and restrained  
for 30 min/day ( paroxetine +  restraint stress) and rats restrained for 
30 min/day (restraint stress from Section 5 .6.2b) for 2 days or 23 days before  
they w ere sacrificed, (A ) K j in cortical tissue (B ) K j  in hippocampal tissue. 
# # , p<0.01 com pared to control; **, p<0.01 com pared to 2 days o f  control; **, 
p<0.01 com pared to 2 days exposure o f  restraint stress with a  single 
paroxetine administration; **, p<0.01 com pared to 2 days exposure o f  restraint 
stress
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7.6.3, Glucocorticoid Receptor mRNA
Statistical analysis indicated that administration of paroxetine with restraint stress 
exposure (Fi,2i=7.731; p=0.0112), and length of time of the experiment alone 
(Fi,2i=18.15; p=0.0003) significantly effected cortical GR mRNA concentrations 
(Figure.7.6.). Two days of paroxetine administration had no significant effect upon cortical 
GR mRNA concentrations compared to controls or restraint stress. Repeated paroxetine 
administration enhanced stress-induced decrease in cortical GR mRNA concentrations by 
58%, and decreased by nearly 40% compared to control.
7.6.4, Brain-DerivedNeutrophic Factor (BDNF) mRNA:
Statistical analysis indicated that length of time of the experiment alone 
(Fi;23=14.38; p=0.0009) significantly effected cortical BDNF mRNA concentrations 
(Figure.7.7.). Two days of paroxetine administration reversed the stress-induced increase of 
cortical BDNF mRNA concentrations by over 30% to controls levels. Repeated paroxetine 
administration had no significant effect upon stress-induced decrease in cortical BDNF 
mRNA, but was reduced by nearly 30% compared to control.
7,6,5 Corticotrophin-Releasing Hormone (CRH) Type 1 Receptor mRNA
Acute administration of paroxetine with restraint stress had no significant effect 
upon the stress-induced decrease of cortical CRH-Rl mRNA concentration (Figure.7.8.), 
but it was decreased by just over 20% compared to control.
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Figure. 7.6.
Cortical GR mRNA and p-Actin mRNA following exposure to restraint stress
with or without paroxetine administration.
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23
Cortical GR mRNA and P-Actin mRNA from male Wistar rats, housed in pairs 
(n=8 per group), were measured in samples taken immediately following exposure to 
restraint stress. (A) RT-PCR and agrose gel electrophoresis analysis of GR mRNA 
expression. P-Actin mRNA expression was used as an internal control. C ontrol 
samples with P-Actin mRNA and a lOObp ladder were run on a gel, the paroxetine + 
restraint stress samples were run on a separate gel with P-Actin mRNA and a lOObp 
ladder. ( B) Ratio of cortical GR mRNA: P-Actin mRNA (sum intensity of the 
bands). Data are expressed as mean ± sem. Comparison between vehicle-treated 
rats left in their home cages (control group), rats dosed with lOmg/kg p.o paroxetine 
and restrained for 30 min/day (paroxetine + restraint stress) and rats restrained for 30 
min/day (restraint stress from Section 5.6.3) for 2 days or 23 days before they were 
sacrificed.**, p<0.01 compared to 2 days of control; **, p<0.01 compared to 2 days 
exposure of restraint stress; ***, p<0.001 effect of paroxetine on restraint stress.
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Figure. 7.7.
Cortical BDNF mRNA and (3-Actin mRNA following exposure to restraint
stress with or without paroxetine administration.
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Cortical BDNF mRNA and P-Actin from male Wistar rats housed in pairs (n=8 per group), 
were measured in samples taken immediately following exposure to daity restraint stress. 
(A) RT-PCR and agarose gel electrophoresis analysis of BDNF mRNA expression. 
P-Actin mRNA expression was used as an internal control. Control samples and paroxetine + 
restraint sampleswere run on a gel with a lOObp ladder and P-Actin mRNA was run on a 
separate gel with a lOObp ladder. ( B) Ratio of cortical BDNF mRNA: P-Actin mRNA 
(sum intensity of the bands). Data are expressed as mean ± sem. Comparison between 
vehicle-treated rats left in their home cages (control group), rats dosed with lOmg/kg p.o 
paroxetine and restrained for 30 min/day ( paroxetine + restraint-stress) and rats restrained 
for 30 min/day (restraint stress from Section 5.6.4) for 2 days or 23 days before they were 
sacrificed. #, p<0.05 and ##, p<0.01 compared to control; **, p<0.01 compared to 2 days of 
control; *, p<0.05 effect of paroxetine on restraint stress.
1 0 0
Figure. 7.8.
Cortical CRH type 1 receptor and p-Actin mRNA following two 30 min
exposures to restraint stress with or without a single paroxetine administration.
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Cortical CRH type 1 receptor : p-Actin mRNA from male Wistar 
rats, housed in pairs (n=8 per group), were measured in samples 
taken immediately following exposure to restraint stress. 
(A) RT-PCR and agarose gel electrophoresis analysis of CRH 
type 1 receptor mRNA expression. p-Actin mRNA expression was 
used as an internal control. Control samples were run on a gel with a 
lOObp ladder, paroxetine + restraint stress samples were run on a 
separate gel with a lOObp ladder, and p-Actin mRNA samples were 
run on another gel with a lOObp ladder. (B) Ratio of cortical CRH 
type 1 receptor : p-Actin mRNA (sum intensity of the bands). Data 
are expressed as mean ± sem. Comparison between vehicle-treated 
rats left in their home cages (control group), rats dosed with lOmg/kg 
p.o paroxetine and restrained for 30 min/day 
(paroxetine + restraint-stress) and rats restrained for 30 min/day 
(restraint stress from Section 5.6.5) for 2 days before they were 
sacrificed.. #, p<0.05 compared to control.
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7.6,6. Behavioural Measurements
1. Sucrose Preference
Single or repeated exposure to restraint stress with paroxetine administration had 
no significant efiect upon sucrose preference compared to vehicle, basal or restraint stress 
alone (Table.7.1.).
Table.7.1.
Sucrose preference (% of total fluid intake) following exposure to restraint stress with 
or without paroxetine administration.
GROUPS Mean ± s.e.mean N
BASAL 96.5 ± 0.7 13
ACUTE RESTRAINT-STRESS (1 x 30 min) + PAROXETINE (1 x lOmg/% p.o.)
Control + 1 ml/kg p.o. distilled water (VEHICLE) 95.3 ±2.6 4
Restraint Stress+ 1 ml/kg p.o. distilled water (VEHICLE) 96.1 ±0.7 4
Restraint Stress + lOmg/kg p.o. paroxetine 95.6 ± 0.9 4
ACUTE RESTRAINT-STRESS (4 x 30 min) + PAROXETINE (2 x lOmg/kg p.o.)
Control + 1 nd/kg p.o. distilled water (VEHICLE) 89.8 ±6.1 3
Restraint Stress+ 1 ml/kg p.o. distilled water (VEHICLE) 96.2 ±1.7 3
Restraint Stress + lOmg/kg p.o. paroxetine 95.2 ± 0.7 3
CHRONIC RESTRAINT-STRESS (22 x 30 min) + PAROXETINE (21 x lOmg/1% p.o.)
Control + Iml/kg p.o. distilled water (VEHICLE) 91.9 ±5.5 3
Restraint Stress+ 1 ml/kg p.o. distilled water (VEHICLE) 97.3 ± 0.5 3
Restraint Stress + lOmg/kg p.o. paroxetine 95.2 ±1.7 3
Restraint Stress with Vehicle data fi*om Section 5.6.6.1,
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2. Food Intake
Statistical analysis indicated that length of time of the experiment alone 
(F2,i7=3.754; p=0.0446) significantly effected food intake (Figure.7.9.). A single 
administration of paroxetine had no significant effect upon the stress-induced decrease in 
food intake, but this was decreased by nearly 25% compared to basal levels, and by 20% 
compared to control Two days of paroxetine administration had no significant effect upon 
the stress-induced decrease in food intake, as well as basal and control levels. Repeated 
paroxetine administration reversed the stress-induced decrease in food intake by 22% with 
no significant effect compared to control.
F ig u r e .7 .9 .
Food intake following exposure to restraint stress with or without 
paroxetine administration.
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Food intake (g) measured over 22 h, from male Wistar rats, housed 
in pairs. Data expressed as mean ± sem. Comparison between 
vehicle-treated rats left in their home cages (control group), rats 
dosed with lOmg/kg p.o paroxetine and restrained for 3 0 min/day 
(paroxetine + restraint-stress) and rats restrained for 30 min/day 
(restraint stress from Section 5.6.6.2.) for 1 day, 2 days or 23 days 
before they were sacrificed. ##, p<0.01 compared to control; 
**, p<0.01 compared to 2 days of exposure to restraint stress with 
paroxetine administration; *, p<0.05 effect of paroxetine on restraint 
stress.
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7.7.Chronic Paroxetine Administration Followed by a Single 30min Restraint Stress 
Exposure
7.7.1. Plasma Corticosterone
Unfortunately, these samples were compromised due to a problem with the RIA 
and it was unable to be repeated due to insufihcient remaining plasma.
7.7.2. Plasma ACTH
Twenty-one days of paroxetine administration, followed by a single 30 min 
restraint stress exposure, had no significant effect upon plasma ACTH concentration 
compared to the vehicle-treated rats (Figure.7.10.).
F i g u r e . 7 .10 .
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samples  taken im m edia te ly  fo l low ing  rest raint  s t ress  
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C o m p a r i s o n  be tw een  veh ic le - t rea ted  rats (vehic le)  
and rats dosed  daily with lOm g/k g  p.o.  pa roxe t ine  fo r  
21 days ( paroxe t ine  group) ,  fo l lo w e d  by a s ingle  
30 min  res tra in t  s t re ss  exposure  be fo re  they were 
sacr i f i ced .  There were no s ta t is t ica l ly  s ign i f ican t  
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7.7.3.GlucocorticoidReceptor (GR) Binding
1- Bniax
Statistical analysis indicated that chronic paroxetine administration, followed by a 
single 30 min restraint stress exposure significantly affected (Fs,9 = 1.862; p = 0.0482) the 
cortical GR Bmax levels. Twenty-one days of paroxetine administration, followed by a 
single 30 min restraint stress exposure, increased cortical GR Bmax values by 40% 
compared to the vehicle-treated rats (Figure.7.11A).
Twenty-one days of paroxetine administration, followed by a single 30 min 
restraint stress exposure, had no significant effect upon hippocampal GR Bmax levels 
compared to the vehicle-treated rats (Figure. 7.11B).
2.Kd
Twenty-one days of paroxetine administration, followed by a single 30 min 
restraint stress exposure, increased cortical GR Kd values by nearly 50% compared to the 
vehicle-treated rats (Figure.7.12A).
Twenty-one days of paroxetine administration, followed by a single 30 min 
restraint stress exposure, had no significant effect upon hippocampal GR Kd values 
compared to the vehicle-treated rats (Figure.7.12B).
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Figure.7.11.
Glucocorticoid receptor values in cortical (A) and 
hippocampal (B) cytosolic fractions, after chronic paroxetine 
administration followed by a single 30 min restraint stress
exposure.
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in cortex and hippocampus, from male Wistar rats housed 
in pairs (n = 8 per group, were measured in samples taken immediately 
following restraint stress exposure. Data are expressed as mean ± sem. 
Comparison between vehicle-treated rats (vehicle group) and rats dosed 
daily with lOmg/kg p.o. paroxetine for 21 days ( paroxetine group), 
followed by a single 30 min restraint stress exposure before they were 
sacrificed.(A) B^^  ^ from cortical tissue, (B) B^ ^^ x from hippocampal 
tissue. #, p<0.05 compared to vehicle.
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Figure.7.12.
Glucocorticoid receptor Revalues in cortex (A) and 
hippocampus (B) cytosolic fractions, after chronic paroxetine 
administration followed by a single 30 min restraint stress
exposure.
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GR Kd values in cortex and hippocampus, from male Wistar rats, housed 
in pairs (n = 8 per group), were measured in samples taken immediately 
following restraint stress exposure. Data are expressed as mean ± sem. 
Comparison between vehicle-treated rats (vehicle group) and rats dosed 
daily with lOmg/kg p.o. paroxetine for 21 days ( paroxetine group), 
followed by a single 30 min restraint stress exposure before they were 
sacrificed. (A) Kj from cortical tissue, (B) Kj from hippocampal tissue. 
There were no statistically significant differences between the groups.
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7.7.4. GR mRNA
Statistical analysis indicated that chronic paroxetine administration, followed by a 
single 30-min restraint stress exposure significantly affected (Fs,? = 3.686; p=0.0441) 
cortical GR mRNA concentration. Twenty-one days of paroxetine administration, followed 
by a single 30 min restraint stress exposure, decreased cortical GR mRNA concentrations 
by nearly 20% compared to the vehicle-treated rats (F1gure.7.13.).
7.7.5. BDNF mRNA
Statistical analysis indicated that chronic paroxetine administration, followed by a 
single 30-min restraint stress exposure significantly affected (F4J = 16.62; p=0.0001) 
cortical BDNF mRNA concentration. Twenty-one days of paroxetine administration, 
followed by a single 30 min restraint stress exposure, increased cortical BDNF mRNA 
concentrations by 733% compared to the vehicle-treated rats (Figure.7.14.).
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Figure. 7.13.
Cortical GRmRNA: p-Actin mRNA after chronic paroxetine administration 
followed by a single 30 min restraint stress exposure.
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Cortical GR mRNA and p-Actin mRNA in male Wistar rats, housed 
in pairs (n=8 per group), were measured in samples taken 
immediately following restraint stress exposure. (A) RT-PCR and 
agarose gel electrophoresis analysis of GR mRNA expression. 
P-Actin mRNA expression was used as an internal control. Vehicle 
samples were run on a gel with with p-Actin mRNA and a lOObp 
ladder, paroxetine samples were run on a separate gel with p-Ac tin 
mRNA and a lOObp ladder. (B) Ratio of cortical GR mRNA:p-Actin 
mRNA (sum intensity of the bands). Data are expressed as 
mean ± sem. Comparison between vehicle-treated rats 
(vehicle group) and rats dosed daily with lOmg/kg p.o. paroxetine for 
21 days ( paroxetine group), followed by a single 30 min restraint 
stress exposure before they were sacrificed. #, p<0.05 compared to 
vehicle.
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Figure.7.14.
Cortical BDNF mRNA and p-Actin mRNA after chronic paroxetine
administration followed by a single 30 min restraint stress exposure.
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Cortical BDNF mRNA and p-Actin mRNA from male Wistar rats, housed 
in pairs (n = 8 per group), were measured in samples taken immediately 
following restraint stress exposure. ( A) RT-PCR and agarose gel 
electrophoresis analysis of BDNF mRNA expression. P-Actin mRNA 
expression was used as an internal control. Vehicle samples and paroxetine 
samples were run on a gel with a lOObp ladder and p-Actin mRNA was run 
on a separate gel with a 1 OObp ladder. ( B) Ratio of cortical 
BDNF mRNA: p-Actin (sum intensity of the bands). Data are expressed as 
mean ± sem. Comparison between vehicle-treated rats (vehicle group) and 
rats dosed daily with lOmg/kg p.o. paroxetine for 21 days 
(paroxetine group), followed by a single 30 min restraint stress exposure 
before they were sacrificed. ###, p<0.001 compared to vehicle.
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7.8. Discussion
The main findings of the present experiments can be summarised as follows; 
(1 ) paroxetine reversed the stress-induced increase in plasma corticosterone but enhanced 
plasma ACTH concentration; (2) chronic paroxetine administered prior to a single restraint 
stress did not prevent the ACTH response to stress; (3) paroxetine reduced the stress- 
induced downregulation of GR in the cortex but not the hippocampus; (4) chronic 
paroxetine administered prior to a single restraint stress enhanced GR levels in the cortex 
but not the hippocampus; (5) chronic paroxetine with restraint stress enhanced the stress- 
induced downregulation of GR gene expression in the cortex; (6 ) chronic paroxetine 
administered prior to a single restraint stress had no effect upon GR gene expression in the 
cortex; (7) paroxetine reversed the stress-induced upregulation of BDNF gene expression 
in the cortex; (8 ) chronic paroxetine administered prior to a single restraint stress enhanced 
BDNF gene expression in the cortex; (9) acute paroxetine had no effect upon 
stress-induced downregulation of CRH type 1 receptor gene expression in the cortex; 
(1 0 ) chronic paroxetine reversed the stress-induced decrease in food intake.
The complete reversal of the stress-induced increase of plasma corticosterone by 
paroxetine, after 21 days (Figure.7.2.), suggests that feedback inhibition by corticosterone 
was facilitated by treatment with this antidepressant, which acts predominantly on the 
serotonergic system. Specific SSRIs (zimelidine and fluoxetine) have previously been 
unable to prevent the stress-induced rise in plasma corticosterone (Lopez et al, 1998), and 
this failure to block the rise in corticosterone was associated with an inability to fully 
prevent down regulation of 5-HTia receptor gene expression. The discrepancy between 
studies may be due to the different stressor used (CMUS), the length of the study 
(28 days), as well as the route of administration of the drugs (i.p. vs p.o.).
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Although the measurement of plasma ACTH concentration by RIA in general 
accurately reflects the physiological status, it is clear that the RIA may in some 
circumstances give values different from those determined by bioassay. For example, 
bioactive ACTH disappears from the circulation faster than immunoreactive ACTH 
(Besser et al, 1971).
Purification of pituitary peptides and identification by RIAs has detected several 
peptides with ACTH immunoreactivity. Characterisation of peptides with ACTH 
immunoreactivity have been most extensively performed in a mouse cell line (AtT-20) 
derived from an ACTH-secreting tumour of the anterior pituitary and subsequently 
characterised in other species including rats and man (Yalow, 1976; Orth & Nicholson, 
1977). These peptides were classified according to their molecular weights and referred to 
as ‘big’ ACTH which includes both 3IK and 22K ACTH, ‘intermediate’ ACTH 
(13K ACTH) and ‘little’ ACTH (4.5K ACTH). The different forms of ACTH are thought 
to represent different steps in the processing of POMC. Thus, ‘little’ ACTH is authentic 
ACTHi-39, ‘intermediate’ ACTH is a glycosylated form of ACTH1.39 while ‘big’ ACTH 
presumably represents POMC and the 22K biosynthetic intermediate (Eipper & Mains, 
1980). While all forms of ACTH may be detected by immunoassays, they do not all 
possess fiill biological activity. ‘Intermediate’ ACTH is equipotent with authentic ACTH, 
while ‘big’ ACTH has less than 1% the potency of ACTH1.39 in terms of steroidogenic 
activity (Gasson, 1979). In normal rat pituitary tissue only 1% of the POMC precursor is 
secreted into the general circulation, the majority being proteolytically processed before 
release (Eipper & Mains, 1980). Therefore, the commercial RIA kit used to determine the 
concentrations of ACTH could have detected forms of ACTH that were non-biologically 
active as well as biologically active. These different forms of ACTH could have reacted 
with the paroxetine to give an enhanced response. Therefore, to ensure that only
112
biologically-active ACTH would be detected in any future studies, an immunoradiometric 
assay (IRMA) kit would replace the RIA used here.
Paroxetine administered for 21 days prior to a restraint stress had no effect upon 
plasma ACTH concentration (Figure.7.3.), suggesting that this particular antidepressant did 
not appear to have a protective effect, in this study, on the HPA axis in response to an 
acute psychological stressor. It would have been helpfiil if this could have been confirmed 
by assessing the plasma corticosterone concentrations under these conditions.
Previously, rats treated daily for 24 days with paroxetine (7.5mg/kg i.p.) did not 
alter the stress associated elevation in serum corticosterone provoked by the FST, and 
therefore failed to alter the HPA axis response to this stress (Connor et al, 2000). The 
variability in results may be attributable in part to the dose used and route of drug 
administration (7.5mg/kg i.p. rather than lOmg/kg p.o.), as well as that paroxetine may 
have a different effect according to the stressor used (FST instead of restraint stress).
According to the literature, glucocorticoid hormones have major effects on 
behaviour, hippocampal morphology, and serotonergic neurotransmission 
(Nausieda et al, 1982; Mendelson & McEwen, 1992), downregulating hippocampal 
5-HTiA receptors at the level of receptor mRNA expression (Chalmers et al, 1993). This 
latter effect has also been observed after chronic unpredictable stress and prevented by 
concomitant imipramine administration.
In another study, however, Papp et al (1994) found that chronic exposure to mild 
stress increased 5-HTia binding in the hippocampus, an effect also observed after chronic 
imipramine administration. In addition, a neuroendocrine functional study showed the 
development of a supersensitivity of 5-HTia receptors in animals submitted to stressful 
situations where escape responses could not be accomplished (Korte et al, 1992). 
Therefore, adrenal steroids may have biphasic effects on serotonin systems. By facilitating 
5-HTia -mediated neurotransmission that may be necessary for development of stress
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tolerance, chronic exposure to high concentrations of corticosteroids, however, may lead to 
a downregulation of 5-HTia receptors and consequent failure of the system 
(Chalmers et al, 1994).
According to Joseph and Kennett (1983), at least part of the corticosteroid response 
to restraint stress is mediated by an increase in serotonergic activity that is dependent on an 
increased supply of the precursor, tryptophan, and that this can be antagonised by other 
amino acids that compete with tryptophan for access to the brain. After repeated restraint- 
stress, the concentrations of brain noradrenaline have also been shown to decrease in rats 
(ŸQriclc et al, 1987).
Harbuz et al (1993), showed that p-chlorophenyl-alanine (PCPA) pre-treatment, 
which resulted in a 95% depletion in hypothalamic serotonin, had no effect on basal 
concentrations of ACTH or the increase in response to a physical stress. Plasma ACTH 
concentrations were also not affected by serotonin depletion in response to the 
predominantly psychological stress of restraint. Both basal and restraint stress-induced 
circulating corticosterone concentrations were however ftirther stimulated in the PCPA- 
pre-treated rats suggesting a possible inhibitory serotonergic tone at the adrenal level.
Jorgensen et al (1998) concluded that 5-HTia, 5-HTzA and S-HTic receptors, but 
not 5 -HT3 receptor were involved in the stress-induced ACTH secretion following 
restraint-, ether-, cold swim or endotoxins in rats. Further that serotonergic neurones in the 
raphe nuclei were activated during restraint stress, and that these neurones and neurones in 
the PVN of the hypothalamus, were important for the mediation of the restraint stress- 
induced ACTH response.
114
Paroxetine partially reversed the stress-induced downregulation of cortical but not 
hippocampal GR levels (Figure.7.4A. and B.), and this was reflected when paroxetine was 
administered for 21 days prior to a restraint stress (Figure.7.11A. and B), suggesting that 
paroxetine has a protective and regulatory role in GR levels within the brain, but that this 
appears to be region-specific.
The precise cellular mechanisms underlying the desensitisation in the corticotroph 
and the brain regions affected are at present unclear. Regarding the brain regions affected, 
one possibility is that GRs increase in several noradrenergic and serotonergic nuclei 
following long-term antidepressant treatment as reported by Kitayama et al (1988). This 
would increase the negative feedback inhibition of the HPA axis and reduce the stress 
response. Another possibility is a desensitisation of 5-HTia receptors in the PVN 
(Li et al, 1997), but this effect cannot account for all antidepressants, since chronic 
treatment with desipramine, a noradrenaline reuptake inhibitor, did not attenuate 
8 -OH-DPAT induced hormone release, indicating that other mediators must contribute to 
the action (Li et al, 1997).
Chronic stress, using the GUMS model, has been shown to be associated with an 
alteration in the MR/GR ratio in the hippocampus; the changes in MR/GR ratio were 
prevented if chronically stressed rats were treated with desipramine or zimelidine 
(Lôpez et al, 1998). Therefore, it would be beneficial to examine MR under these 
conditions, to assess their influence on GR.
The present data shows that chronic paroxetine further decreased the stress-induced 
downregulation of GR gene expression in the cortex (Figure.7.5.), but that chronic 
paroxetine administered before a restraint stress increased it (Figure.7.13.).
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Some studies have found increases in MR and /or GR mRNA after 2 weeks of 
antidepressant treatment (Peiffer et al, 1991; Seckl & Fink, 1992), but others have not 
found changes in this time fi*ame (Brady et al, 1991). Lopez and colleagues (1998) found 
no changes in GR and MR mRNA in hippocampus after 4 weeks of desipramine treatment; 
however, they found that desipramine administration restored the abnormal MR/GR ratio 
in stressed animals to control levels. This may represent one of the multiple mechanisms 
by which antidepressants may enhance feedback and maintain low corticosterone 
concentrations, even in the presence of stress. Zimelidine had some effect on MR/GR ratio, 
but not enough to offset the “drive” of the HPA axis, at least within 4 weeks.
The present data shows that acute paroxetine administration reversed the stress- 
induced increase in cortical BDNF mRNA levels. Chronic paroxetine administration with 
restraint stress partially reversed the stress-induced decrease in cortical BDNF mRNA 
levels, although the latter was not significant (Figure.7.6.). Yet, chronic paroxetine 
administered before a restraint stress dramatically increased the stress-induced cortical 
BDNF mRNA levels (Figure.7.14.).
According to Nibuya et al (1996), chronic (21 days), but not acute (1 day), 
administration of several antidepressant drugs including tranylcypromine, desipramine, 
sertraline, and mianserin completely blocked down-regulation of BDNF mRNA 
concentrations in the hippocampus in response to restraint stress, in agreement with the 
present results, although there was not a complete blockade, on chronic exposure. 
Discrepancies between studies may be attributable to the different brain regions examined 
(i.e. hippocampus, cortex), the use of different antidepressants, the methods and/or 
sensitivity of mRNA analyses used (i.e. in situ, RT-PCR), as well as species differences 
(i.e. mice, rat).
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Recently, the cAMP signalling pathway has been implicated in antidepressant 
action after chronic treatment. CRE-mediated gene transcription is upregulated in the 
cortex and hippocampus after chronic antidepressant administration in the rat 
(Thome et al, 2000). CREB expression and ftmction are upregulated by chronic 
antidepressant treatment in both rodents and humans (Nibuya et al, 1996; Dowlatshahi et 
al, 1998). CREB upregulation may activate downstream targets such as BDNF after 
antidepressant treatment by binding to CRE elements located in the promoter region of the 
BDNF gene (Nibuya et al, 1995; Tao et al, 1998). Therefore, temporal and regional 
upregulation of BDNF mRNA and its receptor, TrkB, parallels CREB mRNA activation 
after chronic antidepressant administration (Nibuya et al, 1996).
With the use of selective serotonin receptor antagonists, Vaidya al (1999) 
determined that serotonin release during stress and activation of the 5 -HT2a receptor may 
be one of the mechanisms via which stress influences BDNF expression. They showed 
only partial blockade of the stress response by the 5 -HT2a receptor, which implies that 
other neurotransmitter systems are involved. The noradrenergic neuronal pathways are 
powerfully influenced by stress and noradrenaline is reported to regulate the expression of 
BDNF (Thoenen et al, 1991; Vahabzadeh & Fillenz, 1994). Although in their study, pre­
treatment with prazosin, an aradrenergic receptor antagonist, or propanolol, a Pi/2- 
adrenergic receptor antagonist, did not influence the stress regulation of BDNF expression 
(Vaidya et al, 1999). Also the CRH neuropeptide system and the CRH type 1 receptor 
subtype are known to mediate many central effects of stress (Herman & CuUinan, 1997). 
Yet pre-treatment with the CRH type 1 receptor antagonist, CP 154,526, did not block the 
stress-induced decrease in BDNF mRNA concentrations, indicating that this receptor 
subtype is not involved in the stress effect under their conditions (Vaidya et al, 1999). It is 
possible that the CRH type 2 receptor subtype could play a role in the regulation of BDNF
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concentrations by stress, although there are currently no selective antagonists for this 
receptor.
Serotonergic inputs from the DRN are thought to exert a global control over the 
hippocampus, via modulation of local inhibitory intemeurones (Freund et al, 1990). 
Serotonin released into the hippocampus during immobilisation stress could activate 
5 -HT2A receptors expressed on GABAergic intemeurones and increase GAB A release. 
Activation of 5-HT2a receptors is reported to increase the firing of GABAergic neurones 
and to thereby induce IPSPs in granule cells (Piguet & Galvan, 1994). Such an effect on 
the firing rate of granule cells could explain the finding that G ABA decreases BDNF 
expression in the hippocampus (Zafra et al, 1991).
The present data shows that acute paroxetine had no effect upon the stress-induced 
downregulation of CRH type 1 receptor mRNA levels in the cortex (Figure.7.7.). It would 
have been constmctive to have considered chronic effects upon this particular aspect of the 
HPA axis in order to determine whether this antidepressant would have had an opposing 
effect on the stress-induced response.
According to Lowry et al (2000) serotonergic responses to CRH were enhanced 
after exposure of rats to isolation housing and repeated restraint stress for 5 days. They 
concluded that these observations suggested that CRH actions on serotonergic neurones 
might play an important role in behavioural responses associated with anxiety and 
conditioned fear, extending previous hypothetical models for the complex neurobiological 
mechanisms underlying these behavioural states (Gray, 1982; Davis, 1998),
The study by Lowry et al (2000) supports the hypothesis that CRH acts on a 
topographically organised subpopulation of serotonergic neurones to activate 
mesolimbocortical serotonergic pathways during intense, prolonged, uncontrollable or 
unpredictable stress. They also showed that mesolimbocortical and mesostriatal 
serotonergic systems are differentially regulated by CRH; this in turn may contribute to the
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dissociation of mesolimbocortical and mesostriatal serotonergic activity during stress 
(Clement et al, 1998).
Exposure of rats to chronic, unpredictable, and diverse stressors were found to 
reduce rat preference for saccharin and sucrose for more than 2  weeks after termination of 
the stress regime: the effect being attenuated by chronic pre-treatment of rats with 
antidepressant drugs (Katz, 1982; Willner et al, 1987). Nevertheless, the current data 
showed no stress-induced reductions and therefore the administration of paroxetine had 
little effect upon sucrose preference compared to controls (Table.7.3.).
This current study demonstrated that chronic paroxetine administration reversed the 
stress-induced decrease in food intake (Figure.7.9.). A study by Harleem and Parveen 
(1994) showed that a single 2 h episode of restraint stress decreased food intake and the 
growth rate of rats, as confirmed by the stress-induced reduction shown in section 5.6.6.2. 
although the body weights remained unchanged They also demonstrated that an acute 
challenge with 2  h restraint increased serotonin synthesis in the cortex, hypothalamus, 
midbrain and hindbrain of previously unrestrained rats, but not those adapted to 5 days of 
2  h daily restraint.
7.9. Conclusion
A considerable body of literature supports an inhibitory influence of brain serotonin 
on the HPA axis response to stress. This has been confirmed by the use of paroxetine, 
subsequently increasing brain serotonin, within these experiments. However, the effects of 
chronic administration of paroxetine prior to restraint stress need to be investigated ftirther, 
due to the inconclusive results obtained.
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CHAPTER 8. GENERAL DISCUSSION
The overall aim of the studies described in this thesis was to investigate the 
response of the HPA axis to different stressors, namely predator stress and restraint stress, 
and the subsequent adaptations following administration of paroxetine. Particular emphasis 
was placed on chronic stress and its impact on corticosteroids and their interaction with 
various receptors within the brain; despite extensive literature on the HPA axis and its link 
with stress and depression, most animal studies investigating antidepressant effects are 
performed under baseline conditions; however, in humans with depression, antidepressants 
are given to them under an “altered” (one could argue “stressed”) condition. Therefore, 
investigating the effect of antidepressants on the HPA axis under conditions of chronic 
stress may be closer to the clinical situation, as a significant number of patients with 
depression show evidence of HPA overactivity. Two studies were carried out and the 
findings of each have been presented and discussed in detail within each of the separate 
chapters. This chapter will summarise the major findings, consider their biological 
significance, and discuss some of their implications.
The initial study (Chapters 3 and 4) involved the development and use of a predator 
stress paradigm in mice. Plasma corticosterone concentrations showed that a stressful 
response had been achieved using the presence and odour of rats, over 8  weeks, and that 
this effect was decreased when the mice were removed from the “stress” room. This was 
partially substantiated by the significant decrease in food consumption but this stressful 
procedure did not appear to affect sucrose preference or cortical GR binding. The EPM 
data is questionable due to the overwhelmingly high presence of the mice in the closed 
arms throughout the study, suggesting that the apparatus and experimental conditions were 
too “stressful”, and any anxiogenic effects by the stress procedures were masked by this. 
So this data cannot be relied upon, in this study.
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Therefore, this model was shown to be stressful, through increased plasma 
corticosterone concentration, but the behavioural tests used (sucrose preference and EPM) 
need more preliminary experiments to substantiate them in our laboratory. Results from 
these behavioural tests were conflicting with previous experiments, suggestii% that they 
just complicated the issue rather than corroborated the plasma corticosterone 
concentrations (the basic indicator of stress). So this model could work as a natinal 
predator model of stress, but the behavioural tests used to verify this need careful 
consideration and must be able to stand alone in the laboratory before being involved with 
this model.
Several of the classic alterations associated with animal models of depression have 
not yet been observed in the predator stress paradigm. Investigations being conducted in 
this area are still in tlie early stages and the hypothesis tliat tliis belmviouial paradigm may 
constitute to some degree, an animal model of stress/depression/anxiety is recent. Overall 
responses of rats and mice to predator e^osure indicate that this stimulus is a stressfiil one 
(see section 4.1). Responses to this stressor also indicate liigh levels of anxiety-like 
behaviour in animals exposed to predator stress. Some of tliese changes observed in this 
paradigm can be compared to those observed in human stress situations and also in a 
number of various other putative models of depression and anxiety.
The second study was separated into three distinct chapters (Chapters 5, 6 and 7) in 
order to approach and discuss each particular aspect of the study. The first of tliese 
chapters (Chapter 5) looked at acute and chronic restraint stress in rats, and assessed the 
HPA axis under these conditions. This section of the study demonstrated that this particular 
stressor provoked HPA axis responses for 3 weeks without adaptation or habituation, 
through increased plasma corticosteroid concentration, decreased GR in both cortex and 
hippocampus, decreased BDNF mRNA within the cortex, as well as a decrease in food 
intake. Such findings endorse this as a chronic animal model of depression.
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The second chapter of this study (Chapter 6) looked at acute and chronic paroxetine 
administration in rats, on the baseline conditions of the HPA axis. This section of the study 
demonstrated that paroxetine elicited “stress-like” responses of the HPA axis under normal 
conditions. For instance, acutely administered paroxetine increased plasma corticosterone 
concentration which were reduced after chronic administration, but it decreased GR, GR 
mRNA and BDNF mRNA in the cortex, as well as decreased food intake even after 
chronic administration. These confirm previous results in the literature (apart from GR 
mRNA whereby we have shown a decrease when others have shown an increase). Chronic 
administration of antidepressant drugs on GR and GR mRNA have been shown to vary 
between different antidepressants and brain regions assessed.
Previous studies have reported increases in hippocampal GR/GR mRNA following 
long-term administration of TCAs or moclobemide -  these studies were conducted in 
adrenalectomised animals thus possibly rendering GR in this region more sensitive to 
fluctuations induced by antidepressant administration. The observed neuroanatomical 
specificities of the antidepressant effects in the current studies could possibly also relate to 
differing monoaminergic innervations of theses areas which may indirectly be a&cting 
GR in these regions. In the current studies, changes have been observed primarily in the 
cortex and not in the hippocampus, suggesting a different mechanism may be active in the 
presence of endogenous ligand. The data obtained may have been confounded by the 
presence of endogenous corticosterone in the system at the time of assay as previous 
investigations used adrenalectomised animals only. However, the procedure of 
adrenalectomy itself can also interfere with the status of the HPA axis and though, in these 
studies, we may have been measuring only -70-90% of the total GR population, this was 
sufficient to enable reflections of any changes in numbers of receptors following various 
procedures.
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The final chapter of this study (Chapter 7) examined acute and chronic paroxetine 
administration on the HPA axis under the influence of restraint stress, as well as being 
administered chronically prior to an acute restraint stress. This section of the study 
demonstrated that this particular antidepressant had a variable impact on the HPA axis 
under chronic stress, whether given prior to restraint or during restraint. Paroxetine 
reversed the stress-induced effects upon plasma corticosterone concentration, GR and 
BDNF mRNA in the cortex, as well as food intake, confirrning that part of its action is to 
attenuate the HPA axis under long-term stressfiil conditions. Whereas, when given for 3 
weeks prior to acute restraint, paroxetine failed to alter the ACTH response to this stress 
and cortical GR mRNA, but protected GR in the cortex, and enhanced BDNF mRNA in 
the cortex.
The GR binding assay may be subject to the criticism that it is a rather sensitive 
assay that has the potential to be affected by numerous external factors. In our laboratory 
however, this assay has proven to be reliable over the years and the results of the studies 
conducted over the duration of this thesis have not been subject to large fluctuations.
Our data was generated using adrenally-intact animals, which contained 
endogenous circulating corticosterone at the time of death. Therefore, many precautions 
were taken in order to ensure that basal corticosterone concentrations remained witliin the 
normal range with minimal fluctuations.
Previous investigations have not always used the same radioligand to measure 
corticosteroid receptors; Budziszweska et al (1994) used ^H-corticosterone whereas Reul et 
a! (1994) have used ^H-dexamethasone and ^H-aldosterone in their experiments -  these 
variations in corticosteroid receptor measurement methods may also contribute to observed 
differences in results.
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The lack of a consistent up- or down regulation of GR in our studies may also be 
attributed to the doses of antidepressants used as these differed between previous studies 
and our own, as did the route/method of administration. Future experiments may benefit 
fi-om establishing dose-response effects of antidepressants and also the measurement of 
MR in these samples.
In order to obtain valid data pertaining to plasma corticosterone and ACTH 
concentrations, it was important to use controlled conditions throughout. Any deviations 
fi'om normal light/dark cycles, noise, light intensity and ten^erature may have generated 
the possibility of altering basal hormone concentrations, as well as inducing shifts in 
normal circadian rhythms. The circadian pattern of corticosteroid secretion also required 
sanq>les to be collected at the same time each day. Animals were minimally disturbed at all 
times to reduce the risk of stress-induced corticosteroid secretion, unless otherwise stated. 
The levels of circulating corticosterone at the time of sacrifice corresponded with a 
70-90% occupation of MR indicating that most of the receptors being measured in our 
investigations were GR. This conclusion was supported by the demonstration of a GR-hke 
competition profile and similar binding parameters were obtained in saturation experiments 
using the selective GR agonist RU28362 to define specific binding.
The subjective nature of these and the lack of standardised behawoural testing 
procedures across laboratories makes it difiBcult to compare data fi*om various studies. 
Optimisation of testing procedures (as described in Chapter 3) for our own studies ensured 
that protocols were consistently observed. The species of animals used also appears to 
greatly impact any behavioural measurements (Capeless & Whitney, 1995). As the use of 
behavioural models and transgenic animals in the development of psychiatric disorders 
increases so does the importance of choosing animals with the appropriate genetic 
background, again, an issue raised by the lack of standardisation of protocols.
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Discrepancies between studies may be attributed to numerous possible variations in animal 
species used, the testing protocols and the receptor binding assays.
Depressed patients exhibit an altered timing of rest/activity. It may be useM, in 
future studies, to constantly monitor activity in animal model investigations instead of 
obtaining ‘snapshot measures’, as animals with HPA disorders are more likely to display 
altered circadian rhythmicity.
Based on previous data (Lopez et al, 1998), it is apparent that specific 5HT 
receptors may be directly regulated in response to alterations of corticosteroid 
concentrations, which can result firom repeated stress. Although it is clear that 
corticosteroids can regulate 5-HT receptors, it is also important to remember that 
regulation can exist in the other direction. Acute administration of 5-HT 1A and 5-HT2 
agonists can cause release of ACTH and corticosterone, and destruction of central 5-HT 
neurones decreases hippocampal GR and MR gene expression (Seckl & Fink, 1992). 
Therefore the relationship between corticosteroids and 5-HT in the brain is conq)lex and 
tightly controlled. As has been previously shown, stress-induced corticosteroid release 
affects 5-HT receptor function (Lopez et al, 1998) but stress can also affect other receptors 
through non-corticosteroid-mediated pathways (Post, 1992). The interplay of these factors 
may lead to the emergenee, or maintenanee, of affeetive symptoms. Similarly, 
antidepressants can counteract this phenomenon by affecting 5-HT receptor function 
directly (Weiner et al, 1989; Blier & de Montigny, 1994) and by simultaneously regulating 
stress-induced eorticosteroid secretion. This does not exelude the possibility that steroids 
ean be acting simultaneously through other systems (e.g. noradrenaline), thereby 
synergistieally affeeting mood and behaviour.
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The HPA response to a severe chronic stressor is likely to involve several 
neurotransmitter systems. Therefore, a compound that modulates a single neurotransmitter 
may not be able to prevent, or may even potentiate, the HPA axis activation in response to 
a chronic stress. The failure of an antidepressant to restore peripheral corticosteroids to 
baseline concentrations may therefore impair its ability to correct a “central” 
monoaminergic deficit.
In conclusion, the studies in this thesis have centred on the HPA axis and attempted 
to break down the effects of chronic stress to try and provide a fuller picture of the effect of 
stress in relation to depression, and to elucidate how antidepressants alleviate these 
symptoms through this axis. Overall, these studies show that basal activity of the HPA axis 
in the male mouse and rat undergoes marked change in response to chronic stress, 
depending on the stressor used. Also, it illustrates the general principle that the efficacy of 
antidepressant treatment may be dictated, in part, by its ability to alter the activity of the 
HPA axis (Lopez et al, 1998; Holsboer & Barden, 1996).
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8.1. Future Work
The Predator Stress model requires more thorough preliminary investigations to 
attribute the neurochemical and behavioural changes to the nature of the stimulus, by 
examining rat odour (acute and chronic exposure) and the visual presence of the rats 
(acute and chronic exposure) separately, as well as the contribution of novelty and any 
handling stress. Assessments also need to be made to study the effects of rat exposure on 
general activity and location with respect to the rat (proxemic avoidance) and the 
behavioural response to rat odour. Also to give a more complete analysis of the long-term 
effect of this model, neurochemical and endocrine assays need to be conducted at more 
regular intervals, as well as looking at the effects of acute exposure.
Factors worthy of investigation in the second study (Chapters 5-7) include: 
(a) endocrine assays of corticosterone and ACTH conducted at more regular intervals to 
give a more comlete analysis of the long-term effects; (b) examination of GR mRNA 
within other brain regions; (c) examination of BDNF mRNA within other brain regions, as 
well as its receptor, TrkB, under chronic as well as acute conditions. The neurotrophins 
have far-reaching effects on cell function and all known cellular effects mediated by these 
factors result from the tyrosinu kinase activities of the receptors; (d) examination of CRH 
concentration, possibly through microdialysis, as well as CRH type 1 receptor mRNA 
within other brain regions, under chronic as well as acute conditions. Numerous studies 
have examined the regulation of CRH; however, little is known about the mechanism 
controlling the expression of CRH receptors in the brain under basal or stress conditions; 
(e) examination of serotonin concentration, possibly through microdialysis, to try and 
understand the effects of paroxetine upon the HPA axis under basal and stress conditions.
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